

Spread of Artemisinin Resistance in *Plasmodium falciparum*

New England Journal of Medicine

371, 411-423

DOI: [10.1056/nejmoa1314981](https://doi.org/10.1056/nejmoa1314981)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Modelling the contribution of the hypnozoite reservoir to Plasmodium vivax transmission. ELife, 2014, 3, .	2.8	88
2	Efficacy of Mobile Phone Short Message Service (SMS) Reminders on Malaria Treatment Adherence and Day 3 Post-Treatment Reviews (SMS-RES-MAL) in Kenya: A Study Protocol. Journal of Clinical Trials, 2014, 05, 217.	0.1	1
3	Characterization of the Anopheles gambiae octopamine receptor and discovery of potential agonists and antagonists using a combined computational-experimental approach. Malaria Journal, 2014, 13, 434.	0.8	35
4	Isoprenoid Metabolism in Apicomplexan Parasites. Current Clinical Microbiology Reports, 2014, 1, 37-50.	1.8	63
5	Novel approaches to identify protective malaria vaccine candidates. Frontiers in Microbiology, 2014, 5, 586.	1.5	31
6	Antimalarial resistance: is vivax left behind?. Lancet Infectious Diseases, The, 2014, 14, 908-909.	4.6	1
7	Spread of Artemisinin Resistance in Malaria. New England Journal of Medicine, 2014, 371, 1944-1945.	13.9	12
8	Treatment of Malaria – A Continuing Challenge. New England Journal of Medicine, 2014, 371, 474-475.	13.9	24
9	Diverse chemotypes disrupt iron homeostasis in the malaria parasite. Molecular Microbiology, 2014, 94, 327-339.	1.2	79
10	Nanomimics of Host Cell Membranes Block Invasion and Expose Invasive Malaria Parasites. ACS Nano, 2014, 8, 12560-12571.	7.3	60
11	Plasmodium falciparum Founder Populations in Western Cambodia Have Reduced Artemisinin Sensitivity <i>In Vitro</i> . Antimicrobial Agents and Chemotherapy, 2014, 58, 4935-4937.	1.4	47
12	Mutations in Plasmodium falciparum K13 propeller gene from Bangladesh (2009–2013). Malaria Journal, 2014, 13, 431.	0.8	78
13	Diversity-oriented synthesis and activity evaluation of substituted bicyclic lactams as anti-malarial against Plasmodium falciparum. Malaria Journal, 2014, 13, 467.	0.8	7
14	Limited polymorphisms in k13 gene in Plasmodium falciparum isolates from Dakar, Senegal in 2012–2013. Malaria Journal, 2014, 13, 472.	0.8	79
15	Drug resistance genomics of the antimalarial drug artemisinin. Genome Biology, 2014, 15, 544.	3.8	66
16	Chloroquine Remains Effective for Treating Plasmodium vivax Malaria in Pursat Province, Western Cambodia. Antimicrobial Agents and Chemotherapy, 2014, 58, 6270-6272.	1.4	13
17	K13-Propeller Polymorphisms in Plasmodium falciparum Parasites From Sub-Saharan Africa. Journal of Infectious Diseases, 2015, 211, 1352-5.	1.9	203
18	Delayed Parasite Clearance after Treatment with Dihydroartemisinin-Piperaquine in Plasmodium falciparum Malaria Patients in Central Vietnam. Antimicrobial Agents and Chemotherapy, 2014, 58, 7049-7055.	1.4	88

#	ARTICLE	IF	CITATIONS
19	Genomics illuminates parasite biology. <i>Nature Reviews Microbiology</i> , 2014, 12, 727-727.	13.6	2
20	The interaction between artemether-lumefantrine and lopinavir/ritonavir-based antiretroviral therapy in HIV-1 infected patients. <i>BMC Infectious Diseases</i> , 2015, 16, 30.	1.3	24
21	Plasmodium falciparum SERA5 plays a non-enzymatic role in the malarial asexual blood-stage lifecycle. <i>Molecular Microbiology</i> , 2015, 96, 368-387.	1.2	59
22	Global Emergency Medicine: A Review of the Literature From 2014. <i>Academic Emergency Medicine</i> , 2015, 22, 976-984.	0.8	13
23	Chemogenomic profiling of Plasmodium falciparum as a tool to aid antimalarial drug discovery. <i>Scientific Reports</i> , 2015, 5, 15930.	1.6	34
24	Genome-wide transcriptome profiling reveals functional networks involving the Plasmodium falciparum drug resistance transporters PfCRT and PfMDR1. <i>BMC Genomics</i> , 2015, 16, 1090.	1.2	20
25	Therapeutic efficacy of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Enfranze, north-west Ethiopia. <i>Malaria Journal</i> , 2015, 14, 258.	0.8	21
26	Falciparum malaria molecular drug resistance in the Democratic Republic of Congo: a systematic review. <i>Malaria Journal</i> , 2015, 14, 354.	0.8	26
27	Artemether-lumefantrine treatment of uncomplicated Plasmodium falciparum malaria: a systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient data. <i>BMC Medicine</i> , 2015, 13, 227.	2.3	92
28	Past and new challenges for malaria control and elimination: the role of operational research for innovation in designing interventions. <i>Malaria Journal</i> , 2015, 14, 279.	0.8	46
29	Elimination of Plasmodium falciparum in an area of multi-drug resistance. <i>Malaria Journal</i> , 2015, 14, 319.	0.8	39
30	Baseline data of parasite clearance in patients with falciparum malaria treated with an artemisinin derivative: an individual patient data meta-analysis. <i>Malaria Journal</i> , 2015, 14, 359.	0.8	47
31	Design, Synthesis, and Evaluation of Novel Ferroquine and Phenylequine Analogues as Potential Antiplasmodial Agents. <i>ChemMedChem</i> , 2015, 10, 2099-2110.	1.6	5
32	Clinical determinants of early parasitological response to ACTs in African patients with uncomplicated falciparum malaria: a literature review and meta-analysis of individual patient data. <i>BMC Medicine</i> , 2015, 13, 212.	2.3	61
33	Plasmodium falciparum dihydroartemisinin-piperaquine failures in Cambodia are associated with mutant K13 parasites presenting high survival rates in novel piperaquine in vitro assays: retrospective and prospective investigations. <i>BMC Medicine</i> , 2015, 13, 305.	2.3	143
34	From METS to malaria: RRx-001, a multi-faceted anticancer agent with activity in cerebral malaria. <i>Malaria Journal</i> , 2015, 14, 218.	0.8	15
35	Availability and quality of anti-malarials among private sector outlets in Myanmar in 2012: results from a large, community-based, cross-sectional survey before a large-scale intervention. <i>Malaria Journal</i> , 2015, 14, 269.	0.8	9
36	Significant geographical differences in prevalence of mutations associated with Plasmodium falciparum and Plasmodium vivax drug resistance in two regions from Papua New Guinea. <i>Malaria Journal</i> , 2015, 14, 399.	0.8	18

#	ARTICLE	IF	CITATIONS
37	Cost effectiveness and resource allocation of Plasmodium falciparum malaria control in Myanmar: a modelling analysis of bed nets and community health workers. <i>Malaria Journal</i> , 2015, 14, 376.	0.8	15
38	The epidemiology of subclinical malaria infections in South-East Asia: findings from cross-sectional surveys in Thailand–Myanmar border areas, Cambodia, and Vietnam. <i>Malaria Journal</i> , 2015, 14, 381.	0.8	163
39	Polymorphisms of the artemisinin resistant marker (K13) in Plasmodium falciparum parasite populations of Grande Comore Island 10 years after artemisinin combination therapy. <i>Parasites and Vectors</i> , 2015, 8, 634.	1.0	29
40	Synthesis and Antiplasmodial Activity of Novel Chloroquine Analogues with Bulky Basic Side Chains. <i>ChemMedChem</i> , 2015, 10, 1570-1583.	1.6	15
41	Cheminformatics Based Machine Learning Models for AMA1–RON2 Abrogators for Inhibiting Plasmodium falciparum Erythrocyte Invasion. <i>Molecular Informatics</i> , 2015, 34, 655-664.	1.4	5
42	Understanding artemisinin-resistant malaria. <i>Current Opinion in Infectious Diseases</i> , 2015, 28, 417-425.	1.3	78
43	Bayesian hierarchical regression on clearance rates in the presence of asexual and asexual phases with an application to malaria parasites. <i>Biometrics</i> , 2015, 71, 751-759.	0.8	4
44	Synthesis and Evaluation of Novel Acyclic Nucleoside Phosphonates as Inhibitors of Plasmodium falciparum and Human Oxopurine Phosphoribosyltransferases. <i>ChemMedChem</i> , 2015, 10, 1707-1723.	1.6	21
45	High Antimalarial Efficacy of Dihydroartemisinin–Piperaquine on the China–Myanmar Border: The Calm Before the Storm. <i>American Journal of Tropical Medicine and Hygiene</i> , 2015, 93, 436-437.	0.6	5
46	3.4 Synthetic Vs. Natural Bioactive Compounds Against Tropical Disease. , 2015, , 275-289.		0
47	Effect of Nelumbo nucifera Stamen Extract on Phagocytosis and Malaria Parasite Growth Against Plasmodium Berghei Infected Mice. <i>Malaria Control & Elimination</i> , 2015, s1, .	1.0	0
48	Synthèse et criblage antiplasmodial de quelques benzimidazolyl-chalcones. <i>International Journal of Biological and Chemical Sciences</i> , 2015, 9, 1697.	0.1	5
49	Praziquantel and Arachidonic Acid Combination – An Innovative Approach to the Treatment of Schistosomiasis. , 2015, , .		1
50	Artesunate Treatment of Severe Pediatric Malaria: A Review of Parasite Clearance Kinetics and Clinical Implications. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2015, 26, 237-240.	0.7	4
51	Slow Clearance of Plasmodium falciparum in Severe Pediatric Malaria, Uganda, 2011–2013. <i>Emerging Infectious Diseases</i> , 2015, 21, 1237-1239.	2.0	43
52	Induction of Multidrug Tolerance in Plasmodium falciparum by Extended Artemisinin Pressure. <i>Emerging Infectious Diseases</i> , 2015, 21, 1733-1741.	2.0	40
53	Are Children Always Vulnerable Research Participants?. <i>Asian Bioethics Review</i> , 2015, 7, 151-163.	0.9	4
54	Pathogenesis of cerebral malaria: new diagnostic tools, biomarkers, and therapeutic approaches. <i>Frontiers in Cellular and Infection Microbiology</i> , 2015, 5, 75.	1.8	48

#	ARTICLE	IF	CITATIONS
55	Malaria vaccines: identifying Plasmodium falciparum liver-stage targets. <i>Frontiers in Microbiology</i> , 2015, 6, 965.	1.5	21
56	Antiplasmodial activity of iron(II) and ruthenium(II) organometallic complexes against Plasmodium falciparum blood parasites. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2015, 110, 981-988.	0.8	12
57	Quality of Artemisinin-Based Combination Formulations for Malaria Treatment: Prevalence and Risk Factors for Poor Quality Medicines in Public Facilities and Private Sector Drug Outlets in Enugu, Nigeria. <i>PLoS ONE</i> , 2015, 10, e0125577.	1.1	34
58	Progress in Medicine: Experts Take Stock. <i>PLoS Medicine</i> , 2015, 12, e1001933.	3.9	2
59	The Stapled AKAP Disruptor Peptide STAD-2 Displays Antimalarial Activity through a PKA-Independent Mechanism. <i>PLoS ONE</i> , 2015, 10, e0129239.	1.1	13
60	Prevalence and Molecular Characterization of Glucose-6-Phosphate Dehydrogenase Deficiency at the China-Myanmar Border. <i>PLoS ONE</i> , 2015, 10, e0134593.	1.1	39
61	Molecular Evolution of PvMSP3 β Block II in Plasmodium vivax from Diverse Geographic Origins. <i>PLoS ONE</i> , 2015, 10, e0135396.	1.1	13
62	Genetic Analysis and Species Specific Amplification of the Artemisinin Resistance-Associated Kelch Propeller Domain in P. falciparum and P. vivax. <i>PLoS ONE</i> , 2015, 10, e0136099.	1.1	37
63	No Polymorphism in Plasmodium falciparum K13 Propeller Gene in Clinical Isolates from Kolkata, India. <i>Journal of Pathogens</i> , 2015, 2015, 1-4.	0.9	13
64	Severe Malaria Not Responsive to Artemisinin Derivatives in Man Returning from Angola to Vietnam. <i>Emerging Infectious Diseases</i> , 2015, 21, 1264-1265.	2.0	7
65	Artemisinin Resistance: The More We Know, the More Complicated It Appears. <i>Journal of Infectious Diseases</i> , 2015, 211, 667-669.	1.9	3
66	Impact of Antimalarial Treatment and Chemoprevention on the Drug Sensitivity of Malaria Parasites Isolated from Ugandan Children. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 3018-3030.	1.4	48
67	Malaria medicines: a glass half full?. <i>Nature Reviews Drug Discovery</i> , 2015, 14, 424-442.	21.5	367
68	Study of the antimalarial properties of hydroxyethylamine derivatives using green fluorescent protein transformed Plasmodium berghei. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2015, 110, 560-565.	0.8	5
69	Phase 3 trial with the RTS,S/AS01 malaria vaccine shows protection against clinical and severe malaria in infants and children in Africa. <i>Evidence-Based Medicine</i> , 2015, 20, 9-9.	0.6	4
70	Prevalence of K13-propeller polymorphisms in Plasmodium falciparum from China-Myanmar border in 2007-2012. <i>Malaria Journal</i> , 2015, 14, 168.	0.8	71
71	In Vitro Antimalarial Activity of Novel Semisynthetic Nocathiacin I Antibiotics. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 3174-3179.	1.4	16
72	Ex Vivo Drug Susceptibility Testing and Molecular Profiling of Clinical Plasmodium falciparum Isolates from Cambodia from 2008 to 2013 Suggest Emerging Piperaquine Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 4631-4643.	1.4	63

#	ARTICLE	IF	CITATIONS
73	Artemisinin Resistance-Associated Polymorphisms at the K13-Propeller Locus are Absent in Plasmodium falciparum Isolates from Haiti. American Journal of Tropical Medicine and Hygiene, 2015, 92, 552-554.	0.6	14
74	The X-ray structure of Plasmodium falciparum dihydroorotate dehydrogenase bound to a potent and selective N-phenylbenzamide inhibitor reveals novel binding-site interactions. Acta Crystallographica Section F, Structural Biology Communications, 2015, 71, 553-559.	0.4	22
75	Lack of Artemisinin Resistance in Plasmodium falciparum in Uganda Based on Parasitological and Molecular Assays. Antimicrobial Agents and Chemotherapy, 2015, 59, 5061-5064.	1.4	55
76	Evaluating the Pharmacodynamic Effect of Antimalarial Drugs in Clinical Trials by Quantitative PCR. Antimicrobial Agents and Chemotherapy, 2015, 59, 4249-4259.	1.4	37
77	A Review of Plasmodium coatneyi Macaque Models of Severe Malaria. Veterinary Pathology, 2015, 52, 998-1011.	0.8	12
78	Perceived Benefits, Harms, and Views About How to Share Data Responsibly. Journal of Empirical Research on Human Research Ethics, 2015, 10, 278-289.	0.6	45
79	Artemisinin resistance in Myanmar. Lancet Infectious Diseases, The, 2015, 15, 1001-1002.	4.6	2
81	Parasite clearance after malaria therapy: staying a step ahead of drug resistance. BMC Medicine, 2015, 13, 251.	2.3	13
82	Haem-activated promiscuous targeting of artemisinin in Plasmodium falciparum. Nature Communications, 2015, 6, 10111.	5.8	486
83	Clinical Efficacy of Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Plasmodium falciparum Malaria at the China-Myanmar Border. American Journal of Tropical Medicine and Hygiene, 2015, 93, 577-583.	0.6	29
84	Optimum population-level use of artemisinin combination therapies: a modelling study. The Lancet Global Health, 2015, 3, e758-e766.	2.9	62
85	Advances in genetics and genomics: use and limitations in achieving malaria elimination goals. Pathogens and Global Health, 2015, 109, 123-141.	1.0	5
86	The discovery of artemisinin and the Nobel Prize in Physiology or Medicine. Science China Life Sciences, 2015, 58, 1175-1179.	2.3	189
87	Molecular Assessment of Artemisinin Resistance Markers, Polymorphisms in the K13 Propeller, and a Multidrug-Resistance Gene in the Eastern and Western Border Areas of Myanmar. Clinical Infectious Diseases, 2015, 60, 1208-1215.	2.9	71
88	Host-based Prophylaxis Successfully Targets Liver Stage Malaria Parasites. Molecular Therapy, 2015, 23, 857-865.	3.7	33
89	Quinine conjugates and quinine analogues as potential antimalarial agents. European Journal of Medicinal Chemistry, 2015, 97, 335-355.	2.6	76
90	The Other Face of Artesunate: Southern Drug to Treat Northern Diseases. EBioMedicine, 2015, 2, 17-18.	2.7	2
91	Pooled Sequencing and Rare Variant Association Tests for Identifying the Determinants of Emerging Drug Resistance in Malaria Parasites. Molecular Biology and Evolution, 2015, 32, 1080-1090.	3.5	34

#	ARTICLE	IF	CITATIONS
92	Understanding artemisinin resistance. <i>Science</i> , 2015, 347, 373-374.	6.0	30
93	Genetic architecture of artemisinin-resistant <i>Plasmodium falciparum</i> . <i>Nature Genetics</i> , 2015, 47, 226-234.	9.4	515
94	<i>Plasmodium falciparum</i> susceptibility to standard and potential anti-malarial drugs in Dakar, Senegal, during the 2013–2014 malaria season. <i>Malaria Journal</i> , 2015, 14, 60.	0.8	26
95	<i>Plasmodium falciparum</i> subtilisin-like protease 1: discovery of potent difluorostatone-based inhibitors. <i>RSC Advances</i> , 2015, 5, 22431-22448.	1.7	15
96	Towards real-time monitoring of artemisinin resistance. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 367-368.	4.6	19
97	The emerging threat of artemisinin resistance in malaria: focus on artemether-lumefantrine. <i>Expert Review of Anti-Infective Therapy</i> , 2015, 13, 1031-1045.	2.0	13
98	Malaria resistance to non-artemisinin partner drugs: how to reACT. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 621-623.	4.6	16
99	Temporal trends in prevalence of <i>Plasmodium falciparum</i> molecular markers selected for by artemether–lumefantrine treatment in pre-ACT and post-ACT parasites in western Kenya. <i>International Journal for Parasitology: Drugs and Drug Resistance</i> , 2015, 5, 92-99.	1.4	35
100	The Mu Subunit of <i>Plasmodium falciparum</i> Clathrin-Associated Adaptor Protein 2 Modulates <i>In Vitro</i> Parasite Response to Artemisinin and Quinine. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2540-2547.	1.4	42
101	Altering Antimalarial Drug Regimens May Dramatically Enhance and Restore Drug Effectiveness. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 6419-6427.	1.4	29
102	Fitness of artemisinin-resistant <i>Plasmodium falciparum</i> <i>in vitro</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2787-2796.	1.3	26
103	Analysis of Major Genome Loci Underlying Artemisinin Resistance and <i>pfmdr1</i> Copy Number in pre- and post-ACTs in Western Kenya. <i>Scientific Reports</i> , 2015, 5, 8308.	1.6	26
104	Screening and Treating UN Peacekeepers to Prevent the Introduction of Artemisinin-Resistant Malaria into Africa. <i>PLoS Medicine</i> , 2015, 12, e1001822.	3.9	7
105	Enhancing malaria diagnosis through microfluidic cell enrichment and magnetic resonance relaxometry detection. <i>Scientific Reports</i> , 2015, 5, 11425.	1.6	63
106	Valproic Acid as a Potential Inhibitor of <i>Plasmodium falciparum</i> Histone Deacetylase 1 (PfHDAC1): An <i>In Silico</i> Approach. <i>International Journal of Molecular Sciences</i> , 2015, 16, 3915-3931.	1.8	12
107	Quality of Artemisinin-Containing Antimalarials in Tanzania's Private Sector—Results from a Nationally Representative Outlet Survey. <i>American Journal of Tropical Medicine and Hygiene</i> , 2015, 92, 75-86.	0.6	20
108	A Repeat Random Survey of the Prevalence of Falsified and Substandard Antimalarials in the Lao PDR: A Change for the Better. <i>American Journal of Tropical Medicine and Hygiene</i> , 2015, 92, 95-104.	0.6	35
109	A crucial piece in the puzzle of the artemisinin resistance mechanism in <i>Plasmodium falciparum</i> . <i>Trends in Parasitology</i> , 2015, 31, 345-346.	1.5	6

#	ARTICLE	IF	CITATIONS
110	Analysis of Malaria Epidemiological Characteristics in the People's Republic of China, 2004â€“2013. <i>American Journal of Tropical Medicine and Hygiene</i> , 2015, 93, 293-299.	0.6	59
111	Mitochondrial population genomic analyses reveal population structure and demography of Indian <i>Plasmodium falciparum</i> . <i>Mitochondrion</i> , 2015, 24, 9-21.	1.6	7
112	Identification and Deconvolution of Cross-Resistance Signals from Antimalarial Compounds Using Multidrug-Resistant <i>Plasmodium falciparum</i> Strains. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1110-1118.	1.4	34
113	Machines vs Malaria: A Flow-Based Preparation of the Drug Candidate OZ439. <i>Organic Letters</i> , 2015, 17, 3218-3221.	2.4	47
114	Supporting malaria elimination with 21st century antimalarial agent drug discovery. <i>Drug Discovery Today</i> , 2015, 20, 1265-1270.	3.2	48
115	ELQ-300 Prodrugs for Enhanced Delivery and Single-Dose Cure of Malaria. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 5555-5560.	1.4	62
116	Targeting the Cell Stress Response of <i>Plasmodium falciparum</i> to Overcome Artemisinin Resistance. <i>PLoS Biology</i> , 2015, 13, e1002132.	2.6	254
117	Selection and Spread of Artemisinin-Resistant Alleles in Thailand Prior to the Global Artemisinin Resistance Containment Campaign. <i>PLoS Pathogens</i> , 2015, 11, e1004789.	2.1	85
118	<i>Plasmodium</i> IspD (2-C-Methyl-erythritol 4-Phosphate Cytidyltransferase), an Essential and Druggable Antimalarial Target. <i>ACS Infectious Diseases</i> , 2015, 1, 157-167.	1.8	42
119	Synthesis of isocryptolepine analogues and their structureâ€“activity relationship studies as antiplasmodial and antiproliferative agents. <i>European Journal of Medicinal Chemistry</i> , 2015, 94, 56-62.	2.6	52
120	Comparing the Impact of Artemisinin-Based Combination Therapies on Malaria Transmission in Sub-Saharan Africa. <i>American Journal of Tropical Medicine and Hygiene</i> , 2015, 92, 555-560.	0.6	13
121	Dihydroartemisinin-piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 683-691.	4.6	213
122	Malaria genomics: tracking a diverse and evolving parasite population. <i>International Health</i> , 2015, 7, 82-84.	0.8	18
123	Amplification of pfm _{dr1} , pfcrt, pvmdr1, and K13 Propeller Polymorphisms Associated with <i>Plasmodium falciparum</i> and <i>Plasmodium vivax</i> Isolates from the China-Myanmar Border. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2554-2559.	1.4	40
124	Common Pesticide, Dichlorodiphenyltrichloroethane (DDT), Increases Amyloid-Î² Levels by Impairing the Function of ABCA1 and IDE: Implication for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 46, 109-122.	1.2	25
125	A molecular mechanism of artemisinin resistance in <i>Plasmodium falciparum</i> malaria. <i>Nature</i> , 2015, 520, 683-687.	13.7	485
126	Evaluation of spiropiperidine hydantoins as a novel class of antimalarial agents. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 5144-5150.	1.4	21
127	Malaria Vaccines: Moving Forward After Encouraging First Steps. <i>Current Tropical Medicine Reports</i> , 2015, 2, 1-3.	1.6	21

#	ARTICLE	IF	CITATIONS
128	Observing in real time the evolution of artemisinin resistance in <i>Plasmodium falciparum</i> . <i>BMC Medicine</i> , 2015, 13, 67.	2.3	8
129	The prognostic utility of bedside assessment of adults hospitalized with malaria in Myanmar: a retrospective analysis. <i>Malaria Journal</i> , 2015, 14, 63.	0.8	7
130	Efficacy of sulphadoxine-pyrimethamine + artesunate, sulphadoxine-pyrimethamine + amodiaquine, and sulphadoxine-pyrimethamine alone in uncomplicated <i>falciparum</i> malaria in Mali. <i>Malaria Journal</i> , 2015, 14, 64.	0.8	12
131	Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated malaria in the setting of three different chemopreventive regimens. <i>Malaria Journal</i> , 2015, 14, 53.	0.8	5
132	Improving uptake and use of malaria rapid diagnostic tests in the context of artemisinin drug resistance containment in eastern Myanmar: an evaluation of incentive schemes among informal private healthcare providers. <i>Malaria Journal</i> , 2015, 14, 105.	0.8	26
133	Malaria rapid diagnostic test as point-of-care test: study protocol for evaluating the VIKIA [®] Malaria Ag Pf/Pan. <i>Malaria Journal</i> , 2015, 14, 114.	0.8	14
134	Assessing anti-malarial drug effects ex vivo using the haemozoin detection assay. <i>Malaria Journal</i> , 2015, 14, 140.	0.8	5
135	Anti-malarial prescribing practices in Sudan eight years after introduction of artemisinin-based combination therapies and implications for development of drug resistance. <i>BMC Pharmacology & Toxicology</i> , 2015, 16, 3.	1.0	9
136	Spread of artemisinin-resistant <i>Plasmodium falciparum</i> in Myanmar: a cross-sectional survey of the K13 molecular marker. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 415-421.	4.6	363
137	Synthesis and Potent Antimalarial Activity of Kalihinol B. <i>Journal of the American Chemical Society</i> , 2015, 137, 4912-4915.	6.6	42
138	Artemisinin-Resistant <i>Plasmodium falciparum</i> Parasites Exhibit Altered Patterns of Development in Infected Erythrocytes. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 3156-3167.	1.4	97
139	Surveillance of Artemisinin Resistance in <i>Plasmodium falciparum</i> in India Using the kelch13 Molecular Marker. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2548-2553.	1.4	65
140	Decreasing <i>pfmdr1</i> Copy Number Suggests that <i>Plasmodium falciparum</i> in Western Cambodia Is Regaining <i>In Vitro</i> Susceptibility to Mefloquine. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2934-2937.	1.4	29
141	Polymorphisms in the K13-Propeller Gene in Artemisinin-Susceptible <i>Plasmodium falciparum</i> Parasites from Bougoula-Hameau and Bandiagara, Mali. <i>American Journal of Tropical Medicine and Hygiene</i> , 2015, 92, 1202-1206.	0.6	89
142	Resistance to antimalarial drugs: An endless world war against <i>Plasmodium</i> that we risk losing. <i>Journal of Global Antimicrobial Resistance</i> , 2015, 3, 58-63.	0.9	24
143	Triaminopyrimidine is a fast-killing and long-acting antimalarial clinical candidate. <i>Nature Communications</i> , 2015, 6, 6715.	5.8	55
144	Subtle Changes in Endochin-Like Quinolone Structure Alter the Site of Inhibition within the Cytochrome <i>bc₁</i> Complex of <i>Plasmodium falciparum</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1977-1982.	1.4	61
145	Fighting fire with fire: mass antimalarial drug administrations in an era of antimalarial resistance. <i>Expert Review of Anti-Infective Therapy</i> , 2015, 13, 715-730.	2.0	78

#	ARTICLE	IF	CITATIONS
146	Tyrosine kinase inhibitors: New class of antimalarials on the horizon?. <i>Blood Cells, Molecules, and Diseases</i> , 2015, 55, 119-126.	0.6	17
147	K13-Propeller Polymorphisms in <i>Plasmodium falciparum</i> Isolates from Patients in Mayotte in 2013 and 2014. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 7878-7881.	1.4	23
148	A Single Mutation in K13 Predominates in Southern China and Is Associated With Delayed Clearance of <i>Plasmodium falciparum</i> Following Artemisinin Treatment. <i>Journal of Infectious Diseases</i> , 2015, 212, 1629-1635.	1.9	125
149	<i>In Vitro</i> and Molecular Surveillance for Antimalarial Drug Resistance in <i>Plasmodium falciparum</i> Parasites in Western Kenya Reveals Sustained Artemisinin Sensitivity and Increased Chloroquine Sensitivity. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 7540-7547.	1.4	25
150	Effect of crude leaf extract of <i>Osyris quadripartita</i> on <i>Plasmodium berghei</i> in Swiss albino mice. <i>BMC Complementary and Alternative Medicine</i> , 2015, 15, 184.	3.7	25
151	Maximizing antimalarial efficacy and the importance of dosing strategies. <i>BMC Medicine</i> , 2015, 13, 110.	2.3	8
152	The malaria parasite cation ATPase PfATP4 and its role in the mechanism of action of a new arsenal of antimalarial drugs. <i>International Journal for Parasitology: Drugs and Drug Resistance</i> , 2015, 5, 149-162.	1.4	90
153	Macrolides rapidly inhibit red blood cell invasion by the human malaria parasite, <i>Plasmodium falciparum</i> . <i>BMC Biology</i> , 2015, 13, 52.	1.7	64
154	Antimalarial drug resistance in Africa: key lessons for the future. <i>Annals of the New York Academy of Sciences</i> , 2015, 1342, 62-67.	1.8	83
155	How Robust Are Malaria Parasite Clearance Rates as Indicators of Drug Effectiveness and Resistance?. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 6428-6436.	1.4	59
156	Artemisinin-resistant <i>Plasmodium falciparum</i> clinical isolates can infect diverse mosquito vectors of Southeast Asia and Africa. <i>Nature Communications</i> , 2015, 6, 8614.	5.8	55
157	Comparison of genomic signatures of selection on <i>Plasmodium falciparum</i> between different regions of a country with high malaria endemicity. <i>BMC Genomics</i> , 2015, 16, 527.	1.2	34
158	Malaria eradication and elimination: views on how to translate a vision into reality. <i>BMC Medicine</i> , 2015, 13, 167.	2.3	101
159	Hit and lead criteria in drug discovery for infectious diseases of the developing world. <i>Nature Reviews Drug Discovery</i> , 2015, 14, 751-758.	21.5	437
160	Tolerability and safety of weekly primaquine against relapse of <i>Plasmodium vivax</i> in Cambodians with glucose-6-phosphate dehydrogenase deficiency. <i>BMC Medicine</i> , 2015, 13, 203.	2.3	59
161	Adaptive evolution of malaria parasites in French Guiana: Reversal of chloroquine resistance by acquisition of a mutation in <i>pfcr</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 11672-11677.	3.3	101
162	Oxidative stress-mediated antimalarial activity of plakortin, a natural endoperoxide from the tropical sponge <i>Plakortis simplex</i> . <i>Free Radical Biology and Medicine</i> , 2015, 89, 624-637.	1.3	21
163	Hemoglobin E and Glucose-6-Phosphate Dehydrogenase Deficiency and <i>Plasmodium falciparum</i> Malaria in the Chittagong Hill Districts of Bangladesh. <i>American Journal of Tropical Medicine and Hygiene</i> , 2015, 93, 281-286.	0.6	17

#	ARTICLE	IF	CITATIONS
164	Identification of β -hematin inhibitors in the MMV Malaria Box. <i>International Journal for Parasitology: Drugs and Drug Resistance</i> , 2015, 5, 84-91.	1.4	27
165	Profiling the host response to malaria vaccination and malaria challenge. <i>Vaccine</i> , 2015, 33, 5316-5320.	1.7	21
166	Artemisinin Resistance at the China-Myanmar Border and Association with Mutations in the K13 Propeller Gene. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 6952-6959.	1.4	84
167	Fosmidomycin as an antimalarial drug: a meta-analysis of clinical trials. <i>Future Microbiology</i> , 2015, 10, 1375-1390.	1.0	37
168	Measuring the Association Between Artemisinin-Based Case Management and Malaria Incidence in Southern Vietnam, 1991–2010. <i>American Journal of Tropical Medicine and Hygiene</i> , 2015, 92, 811-817.	0.6	9
169	Antimalarial Drug Resistance: Literature Review and Activities and Findings of the ICEMR Network. <i>American Journal of Tropical Medicine and Hygiene</i> , 2015, 93, 57-68.	0.6	250
170	Building an effective malaria vaccine pipeline to address global needs. <i>Vaccine</i> , 2015, 33, 7538-7543.	1.7	11
171	Open-Label, Single-Dose, Parallel-Group Study in Healthy Volunteers To Determine the Drug-Drug Interaction Potential between KAE609 (Cipargamin) and Piperaquine. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 3493-3500.	1.4	24
172	K13-propeller mutations confer artemisinin resistance in <i>Plasmodium falciparum</i> clinical isolates. <i>Science</i> , 2015, 347, 428-431.	6.0	563
173	Population transcriptomics of human malaria parasites reveals the mechanism of artemisinin resistance. <i>Science</i> , 2015, 347, 431-435.	6.0	362
174	Sulfonamide inhibition studies of the β -class carbonic anhydrase from the malaria pathogen <i>Plasmodium falciparum</i> . <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 526-531.	1.4	52
175	Synthetic spirocyclic endoperoxides: new antimalarial scaffolds. <i>MedChemComm</i> , 2015, 6, 357-362.	3.5	39
176	Synthetic chemistry fuels interdisciplinary approaches to the production of artemisinin. <i>Natural Product Reports</i> , 2015, 32, 359-366.	5.2	48
177	Antimalarial Action of Artesunate Involves DNA Damage Mediated by Reactive Oxygen Species. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 317-325.	1.4	120
178	Dimerization and comments on the reactivity of homophthalic anhydride. <i>Tetrahedron Letters</i> , 2015, 56, 3001-3004.	0.7	7
179	Independent Emergence of Artemisinin Resistance Mutations Among <i>Plasmodium falciparum</i> in Southeast Asia. <i>Journal of Infectious Diseases</i> , 2015, 211, 670-679.	1.9	368
180	Efficacy of Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine for Treatment of Uncomplicated Malaria in Children in Zaire and Uíge Provinces, Angola. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 437-443.	1.4	79
181	Evaluation of Antimalarial Resistance Marker Polymorphism in Returned Migrant Workers in China. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 326-330.	1.4	35

#	ARTICLE	IF	CITATIONS
182	Résistance de l'agent du paludisme, Plasmodium falciparum aux combinaisons thérapeutiques à base d'artémisinine (ACTs) : Craintes d'une chimiorésistance généralisée. Bulletin De L'Académie Nationale De Médecine, 2016, 200, 477-490.		2
183	Artemisinin-Resistant <i>Plasmodium falciparum</i> Malaria. , 0, , 409-429.		8
184	Health Inequalities, Public Sector Involvement and Malaria Control in Cambodia. Sojourn, 2016, 31, 81-115.	0.1	4
186	Identification and Validation of Novel Drug Targets for the Treatment of Plasmodium falciparum Malaria: New Insights. , 0, , .		8
187	Reply to Meshnick and Hastings et al. Clinical Infectious Diseases, 2016, 63, 1528-1529.	2.9	7
188	Assessing parasite clearance during uncomplicated &Plasmodium falciparum &infection treated with artesunate monotherapy in Suriname. Infection and Drug Resistance, 2016, Volume 9, 261-267.	1.1	9
189	Protection after Malaria Therapy: A Step-up to Immunity. Malaria Control & Elimination, 2016, 5, .	1.0	0
190	Meningococcal Group W Disease in Infants and Potential Prevention by Vaccination. Emerging Infectious Diseases, 2016, 22, 1505-1507.	2.0	9
191	Conclusion: Epidemics and the end of history. , 0, , 301-315.		0
192	RTS,S malaria vaccine development: progress and considerations for postapproval introduction. Vaccine (Auckland, N Z), 0, , 25.	1.7	6
193	Plasmodium falciparum In Vitro Resistance to Monodesethylamodiaquine, Dakar, Senegal, 2014. Emerging Infectious Diseases, 2016, 22, 841-845.	2.0	15
194	IASM: A System for the Intelligent Active Surveillance of Malaria. Computational and Mathematical Methods in Medicine, 2016, 2016, 1-11.	0.7	4
195	Genetic Polymorphism of <i>msp</i> 1 and <i>msp</i> 2 in <i>Plasmodium falciparum</i> Isolates from Côte d'Ivoire versus Gabon. Journal of Parasitology Research, 2016, 2016, 1-7.	0.5	33
196	Vaccines Against Parasites. , 2016, , 331-360.		5
197	Artemisinin-Resistant <i>Plasmodium falciparum</i> K13 Mutant Alleles, Thailand-Myanmar Border. Emerging Infectious Diseases, 2016, 22, 1503-1505.	2.0	37
198	Novel 2-Phenoxyanilide Congeners Derived from a Hit Structure of the TCAMS: Synthesis and Evaluation of Their in Vitro Activity against Plasmodium falciparum. Molecules, 2016, 21, 223.	1.7	2
199	Failure of dihydroartemisinin plus piperazine treatment of falciparum malaria by under-dosing in an overweight patient. Malaria Journal, 2016, 15, 479.	0.8	8
200	Asymptomatic Plasmodium infections in 18 villages of southern Savannakhet Province, Lao PDR (Laos). Malaria Journal, 2016, 15, 296.	0.8	45

#	ARTICLE	IF	CITATIONS
201	Prevalence of anti-malarial resistance genes in Dakar, Senegal from 2013 to 2014. <i>Malaria Journal</i> , 2016, 15, 347.	0.8	15
202	Therapeutic efficacy trial of artemisinin-based combination therapy for the treatment of uncomplicated malaria and investigation of mutations in k13 propeller domain in Togo, 2012–2013. <i>Malaria Journal</i> , 2016, 15, 331.	0.8	32
203	Functional genomic analyses of Enterobacter, Anopheles and Plasmodium reciprocal interactions that impact vector competence. <i>Malaria Journal</i> , 2016, 15, 425.	0.8	57
204	Assessing the asymptomatic reservoir and dihydroartemisinin–piperaquine effectiveness in a low transmission setting threatened by artemisinin resistant <i>Plasmodium falciparum</i> . <i>Malaria Journal</i> , 2016, 15, 446.	0.8	8
205	Cow-baited tents are highly effective in sampling diverse Anopheles malaria vectors in Cambodia. <i>Malaria Journal</i> , 2016, 15, 440.	0.8	42
206	Selection of N86F184D1246 haplotype of Pfmrd1 gene by artemether–lumefantrine drug pressure on <i>Plasmodium falciparum</i> populations in Senegal. <i>Malaria Journal</i> , 2016, 15, 433.	0.8	33
207	The acceptability of mass administrations of anti-malarial drugs as part of targeted malaria elimination in villages along the Thai–Myanmar border. <i>Malaria Journal</i> , 2016, 15, 494.	0.8	41
208	Probucol dramatically enhances dihydroartemisinin effect in murine malaria. <i>Malaria Journal</i> , 2016, 15, 472.	0.8	9
209	Ex vivo piperaquine resistance developed rapidly in <i>Plasmodium falciparum</i> isolates in northern Cambodia compared to Thailand. <i>Malaria Journal</i> , 2016, 15, 519.	0.8	28
210	Characterization of <i>Plasmodium falciparum</i> ATP-dependent DNA helicase RuvB3. <i>Malaria Journal</i> , 2016, 15, 526.	0.8	5
211	Limited genetic diversity in the PvK12 Kelch protein in <i>Plasmodium vivax</i> isolates from Southeast Asia. <i>Malaria Journal</i> , 2016, 15, 537.	0.8	21
212	Genetic diversity of the Pvk12 gene in <i>Plasmodium vivax</i> from the China-Myanmar border area. <i>Malaria Journal</i> , 2016, 15, 528.	0.8	16
213	Community engagement and population coverage in mass anti-malarial administrations: a systematic literature review. <i>Malaria Journal</i> , 2016, 15, 523.	0.8	86
214	Analysis of anti-malarial resistance markers in pfmdr1 and pfcr1 across Southeast Asia in the Tracking Resistance to Artemisinin Collaboration. <i>Malaria Journal</i> , 2016, 15, 541.	0.8	30
215	Target Product Profile for a Diagnostic Assay to Differentiate between Bacterial and Non-Bacterial Infections and Reduce Antimicrobial Overuse in Resource-Limited Settings: An Expert Consensus. <i>PLoS ONE</i> , 2016, 11, e0161721.	1.1	79
216	The Future of the RTS,S/AS01 Malaria Vaccine: An Alternative Development Plan. <i>PLoS Medicine</i> , 2016, 13, e1001994.	3.9	92
217	Rethinking Dosing Regimen Selection of Piperaquine for Malaria Chemoprevention: A Simulation Study. <i>PLoS ONE</i> , 2016, 11, e0154623.	1.1	8
218	Fine-Scale Mapping by Spatial Risk Distribution Modeling for Regional Malaria Endemicity and Its Implications under the Low-to-Moderate Transmission Setting in Western Cambodia. <i>PLoS ONE</i> , 2016, 11, e0158737.	1.1	6

#	ARTICLE	IF	CITATIONS
219	Na ⁺ Influx Induced by New Antimalarials Causes Rapid Alterations in the Cholesterol Content and Morphology of <i>Plasmodium falciparum</i> . <i>PLoS Pathogens</i> , 2016, 12, e1005647.	2.1	40
220	Molecular Farming in <i>Artemisia annua</i> , a Promising Approach to Improve Anti-malarial Drug Production. <i>Frontiers in Plant Science</i> , 2016, 7, 329.	1.7	35
221	Hubungan Polimorfisme Gen <i>Pf</i> PIA dengan Densitas <i>P. falciparum</i> dan Efikasi Dihidroartemisinin-Piperakuin. <i>Journal Kedokteran Indonesia</i> , 2016, 4, .	0.0	0
222	Recent advances in understanding apicomplexan parasites. <i>F1000Research</i> , 2016, 5, 1369.	0.8	56
223	Antiplasmodial activities of a Thai traditional antipyretic formulation, Bencha-Loga-Wichian: A comparative study between the roots and their substitutes, the stems. <i>Journal of Ethnopharmacology</i> , 2016, 193, 125-132.	2.0	10
224	Absence of Association between Polymorphisms in the RING E3 Ubiquitin Protein Ligase Gene and <i>In Vivo</i> Susceptibility to Conventional Antimalarial Drugs in <i>Plasmodium falciparum</i> Isolates from Dakar, Senegal. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 5010-5013.	1.4	6
225	The cryo-EM structure of the <i>Plasmodium falciparum</i> 20S proteasome and its use in the fight against malaria. <i>FEBS Journal</i> , 2016, 283, 4238-4243.	2.2	25
226	Molecular markers associated with resistance to commonly used antimalarial drugs among <i>Plasmodium falciparum</i> isolates from a malaria-endemic area in Taiz governorate, Yemen during the transmission season. <i>Acta Tropica</i> , 2016, 162, 174-179.	0.9	6
227	Incorporating Stage-Specific Drug Action into Pharmacological Modeling of Antimalarial Drug Treatment. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 2747-2756.	1.4	26
228	PI4 Kinase Is a Prophylactic but Not Radical Curative Target in <i>Plasmodium vivax</i> -Type Malaria Parasites. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 2858-2863.	1.4	45
229	Limited Polymorphism of the Kelch Propeller Domain in <i>Plasmodium malariae</i> and <i>P. ovale</i> Isolates from Thailand. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 4055-4062.	1.4	4
230	The mRNA-bound proteome of the human malaria parasite <i>Plasmodium falciparum</i> . <i>Genome Biology</i> , 2016, 17, 147.	3.8	87
231	New wedelolides, (9 <i>R</i>)-eudesman-9,12-olide β -lactones, from <i>Wedelia trilobata</i> . <i>Phytochemistry Letters</i> , 2016, 17, 304-309.	0.6	11
232	CRISPR-Cas9-modified <i>pfdmr1</i> protects <i>Plasmodium falciparum</i> asexual blood stages and gametocytes against a class of piperazine-containing compounds but potentiates artemisinin-based combination therapy partner drugs. <i>Molecular Microbiology</i> , 2016, 101, 381-393.	1.2	56
233	A Method for Amplicon Deep Sequencing of Drug Resistance Genes in <i>Plasmodium falciparum</i> Clinical Isolates from India. <i>Journal of Clinical Microbiology</i> , 2016, 54, 1500-1511.	1.8	41
234	Just-in-time expression of influential genes in the cellular networks of the malaria parasite <i>Plasmodium falciparum</i> during the red blood cycle. , 2016, , .		0
235	The threat of antimalarial drug resistance. <i>Tropical Diseases, Travel Medicine and Vaccines</i> , 2016, 2, 10.	0.9	65
236	Organism-like formation of <i>Schistosoma</i> hemozoin and its function suggest a mechanism for anti-malarial action of artemisinin. <i>Scientific Reports</i> , 2016, 6, 34463.	1.6	9

#	ARTICLE	IF	CITATIONS
237	Quantifying the pharmacology of antimalarial drug combination therapy. <i>Scientific Reports</i> , 2016, 6, 32762.	1.6	14
238	An optimised age-based dosing regimen for single low-dose primaquine for blocking malaria transmission in Cambodia. <i>BMC Medicine</i> , 2016, 14, 171.	2.3	15
239	Gametocyte clearance dynamics following oral artesunate treatment of uncomplicated <i>Plasmodium falciparum</i> malaria in Malian children. <i>Parasite</i> , 2016, 23, 3.	0.8	14
240	Distinctive origin of artemisinin-resistant <i>Plasmodium falciparum</i> on the China-Myanmar border. <i>Scientific Reports</i> , 2016, 6, 20100.	1.6	72
241	Efficacy and safety of artesunate-mefloquine therapy for treating uncomplicated <i>Plasmodium falciparum</i> malaria: systematic review and meta-analysis. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2016, 110, 626-636.	0.7	1
242	DNA damage regulation and its role in drug-related phenotypes in the malaria parasites. <i>Scientific Reports</i> , 2016, 6, 23603.	1.6	54
243	Global proteomic analysis of prenylated proteins in <i>Plasmodium falciparum</i> using an alkyne-modified isoprenoid analogue. <i>Scientific Reports</i> , 2016, 6, 38615.	1.6	63
244	Antiparasitic and disease-modifying activity of <i>Nyctanthes arbor-tristis</i> Linn. in malaria: An exploratory clinical study. <i>Journal of Ayurveda and Integrative Medicine</i> , 2016, 7, 238-248.	0.9	8
245	Phenotypic Screens Identify Parasite Genetic Factors Associated with Malarial Fever Response in <i>Plasmodium falciparum</i> PiggyBac Mutants. <i>MSphere</i> , 2016, 1, .	1.3	18
246	Prevalence of crt and mdr-1 mutations in <i>Plasmodium falciparum</i> isolates from Grande Comore island after withdrawal of chloroquine. <i>Malaria Journal</i> , 2016, 15, 414.	0.8	20
247	Extreme mutation bias and high AT content in <i>Plasmodium falciparum</i> . <i>Nucleic Acids Research</i> , 2017, 45, gkw1259.	6.5	89
248	A validated bioluminescence-based assay for the rapid determination of the initial rate of kill for discovery antimalarials. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, dkw449.	1.3	19
249	Parasite Clearance and Artemether Pharmacokinetics Parameters Over the Course of Artemether-Lumefantrine Treatment for Malaria in Human Immunodeficiency Virus (HIV)-Infected and HIV-Uninfected Ugandan Children. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw217.	0.4	6
250	The threat of artemisinin resistant malaria in Southeast Asia. <i>Travel Medicine and Infectious Disease</i> , 2016, 14, 548-550.	1.5	13
251	Challenges of research and development on antimalarial medicinal products in China: a bibliometric analysis and systematic review. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2016, 110, 649-656.	0.7	2
252	Artemisinin-Resistant <i>Plasmodium falciparum</i> Malaria. <i>Microbiology Spectrum</i> , 2016, 4, .	1.2	225
253	Characterization of the malaria parasite protein PFTip, a novel invasion-related protein. <i>Molecular Medicine Reports</i> , 2016, 13, 3303-3310.	1.1	1
254	Interactive cost of <i>Plasmodium</i> infection and insecticide resistance in the malaria vector <i>Anopheles gambiae</i> . <i>Scientific Reports</i> , 2016, 6, 29755.	1.6	65

#	ARTICLE	IF	CITATIONS
255	Mutations in the Plasmodium falciparum Cyclic Amine Resistance Locus (PfCARL) Confer Multidrug Resistance. MBio, 2016, 7, .	1.8	49
256	Alternatives to currently used antimalarial drugs: in search of a magic bullet. Infectious Diseases of Poverty, 2016, 5, 103.	1.5	22
257	Combating poor-quality anti-malarial medicines: a call to action. Malaria Journal, 2016, 15, 302.	0.8	41
258	Lack of artemisinin resistance in Plasmodium falciparum in northwest Benin after 10 years of use of artemisinin-based combination therapy. Parasite, 2016, 23, 28.	0.8	10
259	Gametocyte carriage in uncomplicated Plasmodium falciparum malaria following treatment with artemisinin combination therapy: a systematic review and meta-analysis of individual patient data. BMC Medicine, 2016, 14, 79.	2.3	104
260	<i>In vitro</i> selection of miltefosine resistance in promastigotes of <i>Leishmania donovani</i> from Nepal: genomic and metabolomic characterization. Molecular Microbiology, 2016, 99, 1134-1148.	1.2	67
261	Little Polymorphism at the K13 Propeller Locus in Worldwide Plasmodium falciparum Populations Prior to the Introduction of Artemisinin Combination Therapies. Antimicrobial Agents and Chemotherapy, 2016, 60, 3340-3347.	1.4	18
262	Antimalarial qinghaosu/artemisinin: The therapy worthy of a Nobel Prize. Asian Pacific Journal of Tropical Biomedicine, 2016, 6, 371-375.	0.5	21
263	Risk and Control of Mosquito-Borne Diseases in Southeast Asian Rubber Plantations. Trends in Parasitology, 2016, 32, 402-415.	1.5	36
264	A deep sequencing tool for partitioning clearance rates following antimalarial treatment in polyclonal infections. Evolution, Medicine and Public Health, 2016, 2016, 21-36.	1.1	38
265	Shifting from control to elimination: analysis of malaria epidemiological characteristics in Tengchong County around China-Myanmar border, 2005-2014. Malaria Journal, 2016, 15, 45.	0.8	19
266	Novel nucleoside-based antimalarial compounds. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 2861-2865.	1.0	8
267	Drug combination therapy increases successful drug repositioning. Drug Discovery Today, 2016, 21, 1189-1195.	3.2	284
268	Sustained efficacy of artesunate-sulfadoxine-pyrimethamine against Plasmodium falciparum in Yemen and a renewed call for an adjunct single dose primaquine to clear gametocytes. Malaria Journal, 2016, 15, 295.	0.8	6
269	Oral artemisinin monotherapy removal from the private sector in Eastern Myanmar between 2012 and 2014. Malaria Journal, 2016, 15, 286.	0.8	11
270	Back on TRAC: New trial launched in bid to outpace multidrug-resistant malaria. Nature Medicine, 2016, 22, 220-221.	15.2	11
271	Efficacy and Safety of Pyronaridine-Artesunate for Treatment of Uncomplicated Plasmodium falciparum Malaria in Western Cambodia. Antimicrobial Agents and Chemotherapy, 2016, 60, 3884-3890.	1.4	39
272	Malaria: global challenges for malaria eradication. Microbiology Australia, 2016, 37, 34.	0.1	9

#	ARTICLE	IF	CITATIONS
273	The population genetics of drug resistance evolution in natural populations of viral, bacterial and eukaryotic pathogens. <i>Molecular Ecology</i> , 2016, 25, 42-66.	2.0	41
274	Independent origins of loss-of-function mutations conferring oxamniquine resistance in a Brazilian schistosome population. <i>International Journal for Parasitology</i> , 2016, 46, 417-424.	1.3	31
275	Parasites resistant to the antimalarial atovaquone fail to transmit by mosquitoes. <i>Science</i> , 2016, 352, 349-353.	6.0	119
276	<i>Plasmodium falciparum</i> malaria: Convergent evolutionary trajectories towards delayed clearance following artemisinin treatment. <i>Medical Hypotheses</i> , 2016, 90, 19-22.	0.8	12
277	Parasite clearance rates in Upper Myanmar indicate a distinctive artemisinin resistance phenotype: a therapeutic efficacy study. <i>Malaria Journal</i> , 2016, 15, 185.	0.8	43
279	No Clinical or Molecular Evidence of <i>Plasmodium falciparum</i> Resistance to Artesunate-Mefloquine in Northwestern Brazil. <i>American Journal of Tropical Medicine and Hygiene</i> , 2016, 95, 148-154.	0.6	21
280	Antiretroviral Choice for HIV Impacts Antimalarial Exposure and Treatment Outcomes in Ugandan Children. <i>Clinical Infectious Diseases</i> , 2016, 63, 414-422.	2.9	29
281	An inter-laboratory comparison of standard membrane-feeding assays for evaluation of malaria transmission-blocking vaccines. <i>Malaria Journal</i> , 2016, 15, 463.	0.8	40
282	Metabolomics-Based Screening of the Malaria Box Reveals both Novel and Established Mechanisms of Action. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6650-6663.	1.4	82
283	Artemisinin Resistance-Associated K13 Polymorphisms of <i>Plasmodium falciparum</i> in Southern Rwanda, 2010-2015. <i>American Journal of Tropical Medicine and Hygiene</i> , 2016, 95, 1090-1093.	0.6	68
284	National Malaria Prevalence in Cambodia: Microscopy Versus Polymerase Chain Reaction Estimates. <i>American Journal of Tropical Medicine and Hygiene</i> , 2016, 95, 588-594.	0.6	9
285	Declining Efficacy of Artemisinin Combination Therapy Against <i>P. falciparum</i> Malaria on the Thai-Myanmar Border (2003-2013): The Role of Parasite Genetic Factors. <i>Clinical Infectious Diseases</i> , 2016, 63, 784-791.	2.9	178
286	Synthesis and biological evaluation of a series of non-hemiacetal ester derivatives of artemisinin. <i>European Journal of Medicinal Chemistry</i> , 2016, 122, 635-646.	2.6	15
287	Recent advances in malaria genomics and epigenomics. <i>Genome Medicine</i> , 2016, 8, 92.	3.6	37
288	Endoperoxide Drug Cross-Resistance Patterns for <i>Plasmodium falciparum</i> Exhibiting an Artemisinin Delayed-Clearance Phenotype. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6952-6956.	1.4	29
289	Towards Malaria Elimination: Monitoring and Evaluation of the 1-3-7 Approach at the China-Myanmar Border. <i>American Journal of Tropical Medicine and Hygiene</i> , 2016, 95, 806-810.	0.6	57
290	Structure and substrate fingerprint of aminopeptidase P from <i>Plasmodium falciparum</i> . <i>Biochemical Journal</i> , 2016, 473, 3189-3204.	1.7	11
291	Chemical diversity targets malaria. <i>Nature</i> , 2016, 538, 323-325.	13.7	3

#	ARTICLE	IF	CITATIONS
292	Whole-Genome Sequencing to Evaluate the Resistance Landscape Following Antimalarial Treatment Failure With Fosmidomycin-Clindamycin. <i>Journal of Infectious Diseases</i> , 2016, 214, 1085-1091.	1.9	28
293	Exploring the scope of new arylamino alcohol derivatives: Synthesis, antimalarial evaluation, toxicological studies, and target exploration. <i>International Journal for Parasitology: Drugs and Drug Resistance</i> , 2016, 6, 184-198.	1.4	16
294	Mapping <i>Plasmodium falciparum</i> Mortality in Africa between 1990 and 2015. <i>New England Journal of Medicine</i> , 2016, 375, 2435-2445.	13.9	205
295	Antimalarial mass drug administration: ethical considerations. <i>International Health</i> , 2016, 8, 235-238.	0.8	37
296	Comparison of artesunate-mefloquine and artemether-lumefantrine fixed-dose combinations for treatment of uncomplicated <i>Plasmodium falciparum</i> malaria in children younger than 5 years in sub-Saharan Africa: a randomised, multicentre, phase 4 trial. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 1123-1133.	4.6	42
297	Antimalarial Activity of KAF156 in <i>Falciparum</i> and <i>Vivax</i> Malaria. <i>New England Journal of Medicine</i> , 2016, 375, 1152-1160.	13.9	89
298	Efficacy of artemisinin-based combination therapies for the treatment of <i>falciparum</i> malaria in Pakistan (2007-2015): In vivo response and dhfr and dhps mutations. <i>Acta Tropica</i> , 2016, 164, 17-22.	0.9	7
299	Artemisinin: A Gift from Traditional Chinese Medicine to the World (Nobel Lecture). <i>Angewandte Chemie - International Edition</i> , 2016, 55, 10210-10226.	7.2	581
300	Artemisinin Resistance and the Blame Game. <i>Clinical Infectious Diseases</i> , 2016, 63, 1144-1145.	2.9	5
301	Pharmacokinetic/pharmacodynamic modelling of the antimalarial effect of Actelion 451840 in an induced blood stage malaria study in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 412-421.	1.1	28
302	Antibody responses to surface antigens of <i>Plasmodium falciparum</i> gametocyte-infected erythrocytes and their relation to gametocytaemia. <i>Parasite Immunology</i> , 2016, 38, 352-364.	0.7	24
304	Indels, structural variation, and recombination drive genomic diversity in <i>Plasmodium falciparum</i> . <i>Genome Research</i> , 2016, 26, 1288-1299.	2.4	180
305	West Africa International Centers of Excellence for Malaria Research: Drug Resistance Patterns to Artemether-Lumefantrine in Senegal, Mali, and The Gambia. <i>American Journal of Tropical Medicine and Hygiene</i> , 2016, 95, 1054-1060.	0.6	19
306	Structure-Activity Studies of Î²-Hairpin Peptide Inhibitors of the <i>Plasmodium falciparum</i> AMA1- <i>RON2</i> Interaction. <i>Journal of Molecular Biology</i> , 2016, 428, 3986-3998.	2.0	22
307	Quantitative insertion-site sequencing (Qlseq) for high throughput phenotyping of transposon mutants. <i>Genome Research</i> , 2016, 26, 980-989.	2.4	39
308	Insight into k13-propeller gene polymorphism and ex vivo DHA-response profiles from Cameroonian isolates. <i>Malaria Journal</i> , 2016, 15, 572.	0.8	23
309	Continued Sensitivity of <i>Plasmodium falciparum</i> to Artemisinin in Guyana, With Absence of Kelch Propeller Domain Mutant Alleles. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw185.	0.4	9
310	Globally prevalent PfMDR1 mutations modulate <i>Plasmodium falciparum</i> susceptibility to artemisinin-based combination therapies. <i>Nature Communications</i> , 2016, 7, 11553.	5.8	208

#	ARTICLE	IF	CITATIONS
311	Thrombin Cleavage of Plasmodium falciparum Erythrocyte Membrane Protein 1 Inhibits Cytoadherence. MBio, 2016, 7, .	1.8	9
312	Molecular surveillance of Plasmodium falciparum drug resistance markers reveals partial recovery of chloroquine susceptibility but sustained sulfadoxine-pyrimethamine resistance at two sites of different malaria transmission intensities in Rwanda. Acta Tropica, 2016, 164, 329-336.	0.9	30
313	Evaluation of the anti-malarial activity and cytotoxicity of 2,4-diamino-pyrimidine-based kinase inhibitors. European Journal of Medicinal Chemistry, 2016, 124, 896-905.	2.6	18
314	Intermittent Preventive Treatment with Dihydroartemisinin-Piperaquine in Ugandan Schoolchildren Selects for Plasmodium falciparum Transporter Polymorphisms That Modify Drug Sensitivity. Antimicrobial Agents and Chemotherapy, 2016, 60, 5649-5654.	1.4	25
315	Artemisinin-based antimalarial research: application of biotechnology to the production of artemisinin, its mode of action, and the mechanism of resistance of Plasmodium parasites. Journal of Natural Medicines, 2016, 70, 318-334.	1.1	42
316	Structural mapping of Kelch13 mutations associated with artemisinin resistance in malaria. Journal of Structural and Functional Genomics, 2016, 17, 51-56.	1.2	17
317	A Novel Fluorescence Resonance Energy Transfer-Based Screen in High-Throughput Format To Identify Inhibitors of Malarial and Human Glucose Transporters. Antimicrobial Agents and Chemotherapy, 2016, 60, 7407-7414.	1.4	16
318	Natural products from Zanthoxylum heitzii with potent activity against the malaria parasite. Malaria Journal, 2016, 15, 481.	0.8	20
319	UDP-galactose and acetyl-CoA transporters as Plasmodium multidrug resistance genes. Nature Microbiology, 2016, 1, 16166.	5.9	102
320	Persistence of Plasmodium falciparum parasitemia after artemisinin combination therapy: evidence from a randomized trial in Uganda. Scientific Reports, 2016, 6, 26330.	1.6	34
321	Antibiotics in malaria therapy: which antibiotics except tetracyclines and macrolides may be used against malaria?. Malaria Journal, 2016, 15, 556.	0.8	47
322	Longitudinal Pooled Deep Sequencing of the Plasmodium vivax K12 Kelch Gene in Cambodia Reveals a Lack of Selection by Artemisinin. American Journal of Tropical Medicine and Hygiene, 2016, 95, 1409-1412.	0.6	11
323	Development of a Novel High-Density [³ H]Hypoxanthine Scintillation Proximity Assay To Assess Plasmodium falciparum Growth. Antimicrobial Agents and Chemotherapy, 2016, 60, 5949-5956.	1.4	9
324	Plasmodium falciparum Resistance to Artemisinin Derivatives and Piperaquine: A Major Challenge for Malaria Elimination in Cambodia. American Journal of Tropical Medicine and Hygiene, 2016, 95, 1228-1238.	0.6	57
325	Plasmodium. , 2016, , 241-284.		0
326	A broad analysis of resistance development in the malaria parasite. Nature Communications, 2016, 7, 11901.	5.8	94
327	Plasmodium falciparum Choline Kinase Inhibition Leads to a Major Decrease in Phosphatidylethanolamine Causing Parasite Death. Scientific Reports, 2016, 6, 33189.	1.6	39
328	Genome-wide association analysis identifies genetic loci associated with resistance to multiple antimalarials in Plasmodium falciparum from China-Myanmar border. Scientific Reports, 2016, 6, 33891.	1.6	100

#	ARTICLE	IF	CITATIONS
329	Artemisinin: Ein Geschenk der traditionellen chinesischen Medizin an die Welt (Nobelâ€Aufsatz). <i>Angewandte Chemie</i> , 2016, 128, 10366-10382.	1.6	23
330	Parenteral Artesunate for Severe Imported <i>Plasmodium falciparum</i> Malaria in Children. <i>Pediatric Infectious Disease Journal</i> , 2016, 35, 1053-1054.	1.1	3
332	Malaria control along China-Myanmar Border during 2007â€“2013: an integrated impact evaluation. <i>Infectious Diseases of Poverty</i> , 2016, 5, 75.	1.5	42
333	Prevalence of K13-propeller gene polymorphisms among <i>Plasmodium falciparum</i> parasites isolated from adult symptomatic patients in northern Uganda. <i>BMC Infectious Diseases</i> , 2016, 16, 428.	1.3	14
334	Emerging polymorphisms in <i>falciparum</i> Kelch 13 gene in Northeastern region of India. <i>Malaria Journal</i> , 2016, 15, 583.	0.8	51
335	The return of chloroquine-susceptible <i>Plasmodium falciparum</i> malaria in Zambia. <i>Malaria Journal</i> , 2016, 15, 584.	0.8	45
336	Optimal health and disease management using spatial uncertainty: a geographic characterization of emergent artemisinin-resistant <i>Plasmodium falciparum</i> distributions in Southeast Asia. <i>International Journal of Health Geographics</i> , 2016, 15, 37.	1.2	13
337	Azithromycin for Malaria?. <i>American Journal of Tropical Medicine and Hygiene</i> , 2016, 95, 2-4.	0.6	31
338	Can Rapid Diagnostic Testing for Malaria Increase Adherence to Artemetherâ€“Lumefantrine?: A Randomized Controlled Trial in Uganda. <i>American Journal of Tropical Medicine and Hygiene</i> , 2016, 94, 857-867.	0.6	5
339	Use of Blood Smears and Dried Blood Spots for Polymerase Chain Reactionâ€“Based Detection and Quantification of Bacterial Infection and <i>Plasmodium falciparum</i> in Severely Ill Febrile African Children. <i>American Journal of Tropical Medicine and Hygiene</i> , 2016, 94, 322-326.	0.6	6
340	Antimalarial Benzoxaboroles Target <i>Plasmodium falciparum</i> Leucyl-tRNA Synthetase. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 4886-4895.	1.4	58
341	Comparative genome-wide analysis and evolutionary history of haemoglobin-processing and haem detoxification enzymes in malarial parasites. <i>Malaria Journal</i> , 2016, 15, 51.	0.8	11
342	Phenotypic Screens in Antimalarial Drug Discovery. <i>Trends in Parasitology</i> , 2016, 32, 697-707.	1.5	48
343	Discovering the cost of care: consumer, provider, and retailer surveys shed light on the determinants of malaria health-seeking behaviours. <i>Malaria Journal</i> , 2016, 15, 179.	0.8	16
344	Artesunate/Amodiaquine Versus Artemether/Lumefantrine for the Treatment of Uncomplicated Malaria in Uganda: A Randomized Trial. <i>Journal of Infectious Diseases</i> , 2016, 213, 1134-1142.	1.9	63
345	Public health interventions to protect against falsified medicines: a systematic review of international, national and local policies. <i>Health Policy and Planning</i> , 2016, 31, 1448-1466.	1.0	83
346	Building malaria out: improving health in the home. <i>Malaria Journal</i> , 2016, 15, 320.	0.8	30
347	Replication and maintenance of the <i>Plasmodium falciparum</i> apicoplast genome. <i>Molecular and Biochemical Parasitology</i> , 2016, 208, 56-64.	0.5	17

#	ARTICLE	IF	CITATIONS
348	K13-Propeller Mutations and Malaria Resistance. <i>New England Journal of Medicine</i> , 2016, 374, 2492-2493.	13.9	8
349	A Worldwide Map of <i>Plasmodium falciparum</i> K13-Propeller Polymorphisms. <i>New England Journal of Medicine</i> , 2016, 374, 2453-2464.	13.9	449
350	Insights into the pyrimidine biosynthetic pathway of human malaria parasite <i>Plasmodium falciparum</i> as chemotherapeutic target. <i>Asian Pacific Journal of Tropical Medicine</i> , 2016, 9, 525-534.	0.4	23
351	Antimalarial properties of crude extracts of seeds of <i>Brucea antidysenterica</i> and leaves of <i>Ocimum lamiiifolium</i> . <i>BMC Complementary and Alternative Medicine</i> , 2016, 16, 118.	3.7	29
352	Assessing the potential impact of artemisinin and partner drug resistance in sub-Saharan Africa. <i>Malaria Journal</i> , 2016, 15, 10.	0.8	48
353	Malaria community health workers in Myanmar: a cost analysis. <i>Malaria Journal</i> , 2016, 15, 41.	0.8	14
354	Alternative methods for the <i>Plasmodium falciparum</i> artemisinin ring-stage survival assay with increased simplicity and parasite stage-specificity. <i>Malaria Journal</i> , 2016, 15, 94.	0.8	25
355	Transmission-blocking strategies: the roadmap from laboratory bench to the community. <i>Malaria Journal</i> , 2016, 15, 95.	0.8	37
356	Reactive case-detection of malaria in Pailin Province, Western Cambodia: lessons from a year-long evaluation in a pre-elimination setting. <i>Malaria Journal</i> , 2016, 15, 132.	0.8	41
357	<i>Plasmodium falciparum</i> : multifaceted resistance to artemisinins. <i>Malaria Journal</i> , 2016, 15, 149.	0.8	91
358	Persistent <i>Plasmodium falciparum</i> and <i>Plasmodium vivax</i> infections in a western Cambodian population: implications for prevention, treatment and elimination strategies. <i>Malaria Journal</i> , 2016, 15, 181.	0.8	54
359	History of malaria treatment as a predictor of subsequent subclinical parasitaemia: a cross-sectional survey and malaria case records from three villages in Pailin, western Cambodia. <i>Malaria Journal</i> , 2016, 15, 240.	0.8	21
360	Cysteamine broadly improves the anti-plasmodial activity of artemisinins against murine blood stage and cerebral malaria. <i>Malaria Journal</i> , 2016, 15, 260.	0.8	10
361	The <i>Plasmodium falciparum</i> chloroquine resistance transporter is associated with the <i>ex vivo</i> <i>P. falciparum</i> African parasite response to pyronaridine. <i>Parasites and Vectors</i> , 2016, 9, 77.	1.0	12
362	Investigation and control of a <i>Plasmodium falciparum</i> malaria outbreak in Shan Special Region II of Myanmar along the China-Myanmar Border from June to December 2014. <i>Infectious Diseases of Poverty</i> , 2016, 5, 32.	1.5	14
363	The Spiroindolone KAE609 Does Not Induce Dormant Ring Stages in <i>Plasmodium falciparum</i> Parasites. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 5167-5174.	1.4	14
364	Substrate and Inhibitor Specificity of the <i>Plasmodium berghei</i> Equilibrative Nucleoside Transporter Type 1. <i>Molecular Pharmacology</i> , 2016, 89, 678-685.	1.0	8
365	Artemisinin Action and Resistance in <i>Plasmodium falciparum</i> . <i>Trends in Parasitology</i> , 2016, 32, 682-696.	1.5	271

#	ARTICLE	IF	CITATIONS
366	Lack of K13 mutations in <i>Plasmodium falciparum</i> persisting after artemisinin combination therapy treatment of Kenyan children. <i>Malaria Journal</i> , 2016, 15, 36.	0.8	54
367	Can new treatment developments combat resistance in malaria?. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1303-1307.	0.9	32
368	Effects of the spatial repellent metofluthrin on landing rates of outdoor biting anophelines in Cambodia, Southeast Asia. <i>Medical and Veterinary Entomology</i> , 2016, 30, 229-234.	0.7	20
369	Potent dual inhibitors of <i>Plasmodium falciparum</i> M1 and M17 aminopeptidases through optimization of S1 pocket interactions. <i>European Journal of Medicinal Chemistry</i> , 2016, 110, 43-64.	2.6	46
370	Deviance and resistance: Malaria elimination in the greater Mekong subregion. <i>Social Science and Medicine</i> , 2016, 150, 144-152.	1.8	34
371	Potential for reduction of burden and local elimination of malaria by reducing <i>Plasmodium falciparum</i> malaria transmission: a mathematical modelling study. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 465-472.	4.6	102
372	Artemisinin-based combination therapy (ACT) versus atovaquone-proguanil: do not choose between but, rather, combine them. <i>Evidence-Based Medicine</i> , 2016, 21, 64-64.	0.6	3
373	Limited artemisinin resistance-associated polymorphisms in <i>Plasmodium falciparum</i> K13-propeller and PfATPase6 gene isolated from Bioko Island, Equatorial Guinea. <i>International Journal for Parasitology: Drugs and Drug Resistance</i> , 2016, 6, 54-59.	1.4	29
374	Reinvestigating Old Pharmacophores: Are 4-Aminoquinolines and Tetraoxanes Potential Two-Stage Antimalarials?. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 264-281.	2.9	32
375	From one Nobel Prize (P. Ehrlich) to another (Tu Youyou): 100 years of chemotherapy of infectious diseases. <i>Clinical Microbiology and Infection</i> , 2016, 22, 213-214.	2.8	2
376	Spirocyclic chromanes exhibit antiplasmodial activities and inhibit all intraerythrocytic life cycle stages. <i>International Journal for Parasitology: Drugs and Drug Resistance</i> , 2016, 6, 85-92.	1.4	18
377	Artemisinin-Derived Dimers: Potent Antimalarial and Anticancer Agents. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 7360-7388.	2.9	132
378	In vitro inhibition of <i>Plasmodium falciparum</i> early and late stage gametocyte viability by extracts from eight traditionally used South African plant species. <i>Journal of Ethnopharmacology</i> , 2016, 185, 235-242.	2.0	27
379	Within-host competition and drug resistance in the human malaria parasite <i>Plasmodium falciparum</i> . <i>Proceedings of the Royal Society B: Biological Sciences</i> , 2016, 283, 20153038.	1.2	50
380	Molecular surveillance of antimalarial drug resistance related genes in <i>Plasmodium falciparum</i> isolates from Eritrea. <i>Acta Tropica</i> , 2016, 157, 158-161.	0.9	10
381	A Unique <i>Plasmodium falciparum</i> K13 Gene Mutation in Northwest Ethiopia. <i>American Journal of Tropical Medicine and Hygiene</i> , 2016, 94, 132-135.	0.6	44
382	Structure- and function-based design of <i>Plasmodium</i> -selective proteasome inhibitors. <i>Nature</i> , 2016, 530, 233-236.	13.7	208
383	Stearylamine Liposomal Delivery of Monensin in Combination with Free Artemisinin Eliminates Blood Stages of <i>Plasmodium falciparum</i> in Culture and <i>P. berghei</i> Infection in Murine Malaria. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 1304-1318.	1.4	49

#	ARTICLE	IF	CITATIONS
384	In Vivo Efficacy and Parasite Clearance of Artesunate + Sulfadoxineâ€“Pyrimethamine Versus Artemetherâ€“Lumefantrine in Mali. <i>American Journal of Tropical Medicine and Hygiene</i> , 2016, 94, 634-639.	0.6	18
385	Mallotojaponins B and C: Total Synthesis, Antiparasitic Evaluation, and Preliminary SAR Studies. <i>Organic Letters</i> , 2016, 18, 708-711.	2.4	16
386	K13 mutations and pfmdr1 copy number variation in <i>Plasmodium falciparum</i> malaria in Myanmar. <i>Malaria Journal</i> , 2016, 15, 110.	0.8	27
387	Maduramicin Rapidly Eliminates Malaria Parasites and Potentiates the Gametocytocidal Activity of the Pyrazoleamide PA21A050. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 1492-1499.	1.4	23
388	Treatment of Malaria in Pregnancy. <i>New England Journal of Medicine</i> , 2016, 374, 981-982.	13.9	28
389	Revealing the Binding Process of New 3-Alkylpyridine Marine Alkaloid Analogue Antimalarials and the Heme Group: An Experimental and Theoretical Investigation. <i>Journal of Chemical Information and Modeling</i> , 2016, 56, 571-579.	2.5	16
390	Cell based assays for anti- <i>Plasmodium</i> activity evaluation. <i>European Journal of Pharmaceutical Sciences</i> , 2016, 84, 26-36.	1.9	6
391	Malaria Vaccine Development: Focusing Field Erythrocyte Invasion Studies on Phenotypic Diversity. <i>Trends in Parasitology</i> , 2016, 32, 274-283.	1.5	12
392	Identification of Compounds with Efficacy against Malaria Parasites from Common North American Plants. <i>Journal of Natural Products</i> , 2016, 79, 490-498.	1.5	29
393	Dihydroartemisininâ€“piperazine resistance in <i>Plasmodium falciparum</i> malaria in Cambodia: a multisite prospective cohort study. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 357-365.	4.6	381
394	NINA-LAMP compared to microscopy, RDT, and nested PCR for the detection of imported malaria. <i>Diagnostic Microbiology and Infectious Disease</i> , 2016, 85, 149-153.	0.8	38
395	<i>Plasmodium falciparum</i> kelch 13: a potential molecular marker for tackling artemisinin-resistant malaria parasites. <i>Expert Review of Anti-Infective Therapy</i> , 2016, 14, 125-135.	2.0	21
396	Is the A578S Single-Nucleotide Polymorphism in <i>K13-propeller</i> a Marker of Emerging Resistance to Artemisinin Among <i>Plasmodium falciparum</i> in Africa?: Table 1.. <i>Journal of Infectious Diseases</i> , 2016, 213, 165-166.	1.9	20
397	Artefenomel: a promising new antimalarial drug. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 6-8.	4.6	21
398	Emergence of Mutations in the K13 Propeller Gene of <i>Plasmodium falciparum</i> Isolates from Dakar, Senegal, in 2013-2014. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 624-627.	1.4	51
399	Verapamil-Sensitive Transport of Quinacrine and Methylene Blue via the <i>Plasmodium falciparum</i> Chloroquine Resistance Transporter Reduces the Parasite's Susceptibility to these Tricyclic Drugs. <i>Journal of Infectious Diseases</i> , 2016, 213, 800-810.	1.9	22
400	Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with <i>Plasmodium falciparum</i> and <i>Plasmodium vivax</i> malaria: an open-label phase 2 trial. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 61-69.	4.6	147
401	Parasitic Infections. , 2016, , 682-698.e8.		1

#	ARTICLE	IF	CITATIONS
402	Esterase mutation is a mechanism of resistance to antimalarial compounds. Nature Communications, 2017, 8, 14240.	5.8	47
403	Artesunate-tafenoquine combination therapy promotes clearance and abrogates transmission of the avian malaria parasite Plasmodium gallinaceum. Veterinary Parasitology, 2017, 233, 97-106.	0.7	10
404	Association between Polymorphisms in the Pf mdr6 Gene and Ex Vivo Susceptibility to Quinine in Plasmodium falciparum Parasites from Dakar, Senegal. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	9
405	Rescuing artemisinin combination therapy in Africa. The Lancet Global Health, 2017, 5, e8-e9.	2.9	4
406	A Review of Pharmacogenetics of Antimalarials and Associated Clinical Implications. European Journal of Drug Metabolism and Pharmacokinetics, 2017, 42, 745-756.	0.6	29
407	SC83288 is a clinical development candidate for the treatment of severe malaria. Nature Communications, 2017, 8, 14193.	5.8	19
408	<i>pfk13</i> -Independent Treatment Failure in Four Imported Cases of Plasmodium falciparum Malaria Treated with Artemether-Lumefantrine in the United Kingdom. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	91
409	K13 Propeller Mutations in Plasmodium falciparum Populations in Regions of Malaria Endemicity in Vietnam from 2009 to 2016. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	41
410	The Antimalarial Effect of Curcumin Is Mediated by the Inhibition of Glycogen Synthase Kinase-3 β . Journal of Medicinal Food, 2017, 20, 152-161.	0.8	17
411	Molecular Epidemiology of Plasmodium falciparum kelch13 Mutations in Senegal Determined by Using Targeted Amplicon Deep Sequencing. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	35
412	A characterization of the antimalarial activity of the bark of Cylicodiscus gabunensis Harms. Journal of Ethnopharmacology, 2017, 198, 221-225.	2.0	22
413	Emergence of Indigenous Artemisinin-Resistant <i>Plasmodium falciparum</i> in Africa. New England Journal of Medicine, 2017, 376, 991-993.	13.9	219
414	New hydrazine and hydrazide quinoxaline 1,4-di- N -oxide derivatives: In silico ADMET, antiplasmodial and antileishmanial activity. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 1820-1825.	1.0	32
415	Synthesis and activity of nucleoside-based antiprotozoan compounds. Bioorganic and Medicinal Chemistry, 2017, 25, 2091-2104.	1.4	13
416	New derivatives of quinoline-4-carboxylic acid with antiplasmodial activity. Bioorganic and Medicinal Chemistry, 2017, 25, 2251-2259.	1.4	6
417	Synthesis of 1,3,5-trisubstituted pyrazolines as potential antimalarial and antimicrobial agents. Bioorganic and Medicinal Chemistry, 2017, 25, 1949-1962.	1.4	51
418	Molecular surveillance of artemisinin resistance falciparum malaria among migrant goldmine workers in Myanmar. Malaria Journal, 2017, 16, 97.	0.8	13
419	Therapeutic strategies of drug repositioning targeting autophagy to induce cancer cell death: from pathophysiology to treatment. Journal of Hematology and Oncology, 2017, 10, 67.	6.9	189

#	ARTICLE	IF	CITATIONS
420	Malaria parasite clearance. <i>Malaria Journal</i> , 2017, 16, 88.	0.8	138
421	Efficacy of artesunate + sulphadoxine/pyrimethamine and artemether + lumefantrine and <i>dhfr</i> and <i>dhps</i> mutations in Somalia: evidence for updating the malaria treatment policy. <i>Tropical Medicine and International Health</i> , 2017, 22, 415-422.	1.0	14
422	The spread of artemisinin-resistant <i>Plasmodium falciparum</i> in the Greater Mekong subregion: a molecular epidemiology observational study. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 491-497.	4.6	371
423	New developments in anti-malarial target candidate and product profiles. <i>Malaria Journal</i> , 2017, 16, 26.	0.8	360
424	Controlled release of artemisone for the treatment of experimental cerebral malaria. <i>Parasites and Vectors</i> , 2017, 10, 117.	1.0	11
425	4-Nitro styrylquinoline is an antimalarial inhibiting multiple stages of <i>Plasmodium falciparum</i> asexual life cycle. <i>International Journal for Parasitology: Drugs and Drug Resistance</i> , 2017, 7, 120-129.	1.4	35
426	How to Contain Artemisinin- and Multidrug-Resistant <i>Falciparum</i> Malaria. <i>Trends in Parasitology</i> , 2017, 33, 353-363.	1.5	71
427	Structure-Based Targeting of Orthologous Pathogen Proteins Accelerates Antiparasitic Drug Discovery. <i>ACS Infectious Diseases</i> , 2017, 3, 281-292.	1.8	13
428	Target Elucidation by Cocrystal Structures of NADH-Ubiquinone Oxidoreductase of <i>Plasmodium falciparum</i> (<i>Pf</i> NDH2) with Small Molecule To Eliminate Drug-Resistant Malaria. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 1994-2005.	2.9	51
429	Efficacy and safety of artemether+lumefantrine for the treatment of uncomplicated <i>falciparum</i> malaria at sentinel sites in Mozambique, 2015. <i>Acta Tropica</i> , 2017, 171, 146-150.	0.9	12
430	The need to compare: assessing the level of agreement of three high-throughput assays against <i>Plasmodium falciparum</i> mature gametocytes. <i>Scientific Reports</i> , 2017, 7, 45992.	1.6	15
431	<i>Plasmodium falciparum</i> K13 Mutations Differentially Impact Ozonide Susceptibility and Parasite Fitness <i>In Vitro</i> . <i>MBio</i> , 2017, 8, .	1.8	103
432	CD36 receptor regulates malaria-induced immune responses primarily at early blood stage infection contributing to parasitemia control and resistance to mortality. <i>Journal of Biological Chemistry</i> , 2017, 292, 9394-9408.	1.6	17
433	Vaccines to Accelerate Malaria Elimination and Eventual Eradication. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2017, 7, a025627.	2.9	28
434	A Variant <i>Pf</i> CRT Isoform Can Contribute to <i>Plasmodium falciparum</i> Resistance to the First-Line Partner Drug Piperaquine. <i>MBio</i> , 2017, 8, .	1.8	82
435	Artemisinin resistance without <i>pfkelch13</i> mutations in <i>Plasmodium falciparum</i> isolates from Cambodia. <i>Malaria Journal</i> , 2017, 16, 195.	0.8	99
436	Longitudinal genomic surveillance of <i>Plasmodium falciparum</i> malaria parasites reveals complex genomic architecture of emerging artemisinin resistance. <i>Genome Biology</i> , 2017, 18, 78.	3.8	120
437	Absence of association between polymorphisms in the K13 gene and the presence of <i>Plasmodium falciparum</i> parasites at day 3 after treatment with artemisinin derivatives in Senegal. <i>International Journal of Antimicrobial Agents</i> , 2017, 49, 754-756.	1.1	42

#	ARTICLE	IF	CITATIONS
438	Antiplasmodial Sesquiterpenoid Lactones from <i>Trichospira verticillata</i> : Structure Elucidation by Spectroscopic Methods and Comparison of Experimental and Calculated ECD Data. <i>Journal of Natural Products</i> , 2017, 80, 1639-1647.	1.5	23
439	Unpacking Artemisinin Resistance™. <i>Trends in Pharmacological Sciences</i> , 2017, 38, 506-511.	4.0	44
440	Molecular Profile of Malaria Drug Resistance Markers of <i>Plasmodium falciparum</i> in Suriname. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	24
441	Discovery and Development of Artemisinin and Related Compounds. <i>Chinese Herbal Medicines</i> , 2017, 9, 101-114.	1.2	35
442	Design, synthesis and evaluation of 4-aminoquinoline-purine hybrids as potential antiplasmodial agents. <i>European Journal of Medicinal Chemistry</i> , 2017, 126, 675-686.	2.6	24
443	Published randomized trials performed in Sub-Saharan Africa focus on high-burden diseases but are frequently funded and led by high-income countries. <i>Journal of Clinical Epidemiology</i> , 2017, 82, 29-36.e6.	2.4	10
444	Malaria 2017: Update on the Clinical Literature and Management. <i>Current Infectious Disease Reports</i> , 2017, 19, 28.	1.3	16
445	The <i>Plasmodium</i> PI(4)K inhibitor KDU691 selectively inhibits dihydroartemisinin-pretreated <i>Plasmodium falciparum</i> ring-stage parasites. <i>Scientific Reports</i> , 2017, 7, 2325.	1.6	21
446	Generating conditional gene knockouts in <i>Plasmodium</i> – a toolkit to produce stable DiCre recombinase-expressing parasite lines using CRISPR/Cas9. <i>Scientific Reports</i> , 2017, 7, 3881.	1.6	139
447	High-resolution cryo-EM proteasome structures in drug development. <i>Acta Crystallographica Section D: Structural Biology</i> , 2017, 73, 522-533.	1.1	10
448	Combating multidrug-resistant <i>Plasmodium falciparum</i> malaria. <i>FEBS Journal</i> , 2017, 284, 2569-2578.	2.2	114
449	<i>Plasmodium falciparum</i> Maf1 Confers Survival upon Amino Acid Starvation. <i>MBio</i> , 2017, 8, .	1.8	32
450	Antimalarial Inhibitors Targeting Serine Hydroxymethyltransferase (SHMT) with in Vivo Efficacy and Analysis of their Binding Mode Based on X-ray Cocrystal Structures. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 4840-4860.	2.9	40
451	Clinical and molecular monitoring of <i>Plasmodium falciparum</i> resistance to antimalarial drug (artesunate+sulphadoxine-pyrimethamine) in two highly malarious district of Madhya Pradesh, Central India from 2012–2014. <i>Pathogens and Global Health</i> , 2017, 111, 186-194.	1.0	17
452	High throughput resistance profiling of <i>Plasmodium falciparum</i> infections based on custom dual indexing and Illumina next generation sequencing-technology. <i>Scientific Reports</i> , 2017, 7, 2398.	1.6	57
453	Vector bionomics and malaria transmission along the Thailand-Myanmar border: a baseline entomological survey. <i>Journal of Vector Ecology</i> , 2017, 42, 84-93.	0.5	27
454	Proteases as antimalarial targets: strategies for genetic, chemical, and therapeutic validation. <i>FEBS Journal</i> , 2017, 284, 2604-2628.	2.2	57
455	<i>Plasmodium falciparum</i> erythrocyte-binding antigen 175 triggers a biophysical change in the red blood cell that facilitates invasion. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 4225-4230.	3.3	71

#	ARTICLE	IF	CITATIONS
456	Multi-omics Based Identification of Specific Biochemical Changes Associated With PfKelch13-Mutant Artemisinin-Resistant Plasmodium falciparum. <i>Journal of Infectious Diseases</i> , 2017, 215, 1435-1444.	1.9	84
457	Impact of Extended Duration of Artesunate Treatment on Parasitological Outcome in a Cytocidal Murine Malaria Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	11
458	Local constraints to access appropriate malaria treatment in the context of parasite resistance in Cambodia: a qualitative study. <i>Malaria Journal</i> , 2017, 16, 81.	0.8	23
460	Drug Resistance in Malaria. , 2017, , 429-447.		3
461	How Pathogens Survive Drug Pressure?. , 2017, , 141-159.		0
462	Current challenges in the management of sepsis in ICUs in resource-poor settings and suggestions for the future. <i>Intensive Care Medicine</i> , 2017, 43, 612-624.	3.9	140
463	pfmdr1 (Plasmodium falciparum multidrug drug resistance gene 1): a pivotal factor in malaria resistance to artemisinin combination therapies. <i>Expert Review of Anti-Infective Therapy</i> , 2017, 15, 527-543.	2.0	43
464	Not ordinary antimalarial drugs: Madagascar plant decoctions potentiating the chloroquine action against Plasmodium parasites. <i>Industrial Crops and Products</i> , 2017, 103, 19-38.	2.5	25
465	N -Piperonyl substitution on aminoquinoline-pyrimidine hybrids: Effect on the antiplasmodial potency. <i>European Journal of Medicinal Chemistry</i> , 2017, 131, 126-140.	2.6	16
466	Host immunity to <i>Plasmodium falciparum</i> and the assessment of emerging artemisinin resistance in a multinational cohort. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 3515-3520.	3.3	78
467	Antimalarial Drug Resistance: A Threat to Malaria Elimination. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2017, 7, a025619.	2.9	301
468	Significant Divergence in Sensitivity to Antimalarial Drugs between Neighboring Plasmodium falciparum Populations along the Eastern Border of Myanmar. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	12
469	Aryl-alkyl-lysines: small molecular membrane-active antiplasmodial agents. <i>MedChemComm</i> , 2017, 8, 434-439.	3.5	6
470	Population Parameters Underlying an Ongoing Soft Sweep in Southeast Asian Malaria Parasites. <i>Molecular Biology and Evolution</i> , 2017, 34, 131-144.	3.5	87
471	Examining the human infectious reservoir for Plasmodium falciparum malaria in areas of differing transmission intensity. <i>Nature Communications</i> , 2017, 8, 1133.	5.8	174
472	Synthesis, characterization, and cellular localization of a fluorescent probe of the antimalarial 8-aminoquinoline primaquine. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 4597-4600.	1.0	6
473	Aminoquinoline-Pyrimidine-Modified Anilines: Synthesis, In Vitro Antiplasmodial Activity, Cytotoxicity, Mechanistic Studies and ADME Predictions. <i>ChemistrySelect</i> , 2017, 2, 9074-9083.	0.7	7
474	MEPICides: potent antimalarial prodrugs targeting isoprenoid biosynthesis. <i>Scientific Reports</i> , 2017, 7, 8400.	1.6	26

#	ARTICLE	IF	CITATIONS
475	Split dosing of artemisinins does not improve antimalarial therapeutic efficacy. <i>Scientific Reports</i> , 2017, 7, 12132.	1.6	16
476	Changing Antimalarial Drug Sensitivities in Uganda. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	52
477	Population Pharmacokinetic and Pharmacodynamic Modeling of Artemisinin Resistance in Southeast Asia. <i>AAPS Journal</i> , 2017, 19, 1842-1854.	2.2	12
478	K13 Propeller Alleles, <i>mdr1</i> Polymorphism, and Drug Effectiveness at Day 3 after Artemether-Lumefantrine Treatment for <i>Plasmodium falciparum</i> Malaria in Colombia, 2014-2015. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	6
479	Antimalarial activity of Malaria Box Compounds against <i>Plasmodium falciparum</i> clinical isolates. <i>International Journal for Parasitology: Drugs and Drug Resistance</i> , 2017, 7, 399-406.	1.4	8
480	<i>Plasmodium falciparum</i> specific helicase 3 is nucleocytoplasmic protein and unwinds DNA duplex in 3â€² to 5â€² direction. <i>Scientific Reports</i> , 2017, 7, 13146.	1.6	9
481	A Dynamic Stress Model Explains the Delayed Drug Effect in Artemisinin Treatment of <i>Plasmodium falciparum</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	9
482	Synergistic malaria vaccine combinations identified by systematic antigen screening. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 12045-12050.	3.3	49
483	Impact of Intermittent Preventive Treatment During Pregnancy on <i>Plasmodium falciparum</i> Drug Resistanceâ€”Mediating Polymorphisms in Uganda. <i>Journal of Infectious Diseases</i> , 2017, 216, 1008-1017.	1.9	25
484	Alkoxy carbonate Ester Prodrugs of Preclinical Drug Candidate ELQ-300 for Prophylaxis and Treatment of Malaria. <i>ACS Infectious Diseases</i> , 2017, 3, 728-735.	1.8	38
485	Spread of a single multidrug resistant malaria parasite lineage (PfPailin) to Vietnam. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 1022-1023.	4.6	136
486	A potent series targeting the malarial cGMP-dependent protein kinase clears infection and blocks transmission. <i>Nature Communications</i> , 2017, 8, 430.	5.8	110
487	Elements of effective community engagement: lessons from a targeted malaria elimination study in Lao PDR (Laos). <i>Global Health Action</i> , 2017, 10, 1366136.	0.7	86
488	Isolation of the New Antiplasmodial Butanolide, Malleastrumolide A, from <i>Malleastrum</i> sp. (Meliaceae) from Madagascar. <i>Chemistry and Biodiversity</i> , 2017, 14, e1700331.	1.0	9
489	Heterologous Expression, Purification, and Functional Analysis of <i>Plasmodium falciparum</i> Phosphatidylinositol 3â€²-Kinase. <i>Biochemistry</i> , 2017, 56, 4335-4345.	1.2	21
490	A mechanistic model quantifies artemisinin-induced parasite growth retardation in blood-stage <i>Plasmodium falciparum</i> infection. <i>Journal of Theoretical Biology</i> , 2017, 430, 117-127.	0.8	9
491	Adaptive immunity is essential in preventing recrudescence of <i>Plasmodium yoelii</i> malaria parasites after artesunate treatment. <i>Cellular Microbiology</i> , 2017, 19, e12763.	1.1	7
492	Stephanine from <i>Stephania venosa</i> (Blume) Spreng Showed Effective Antiplasmodial and Anticancer Activities, the Latter by Inducing Apoptosis through the Reverse of Mitotic Exit. <i>Phytotherapy Research</i> , 2017, 31, 1357-1368.	2.8	26

#	ARTICLE	IF	CITATIONS
493	Ex vivo activity of Proveblue, a methylene blue, against field isolates of Plasmodium falciparum in Dakar, Senegal from 2013–2015. <i>International Journal of Antimicrobial Agents</i> , 2017, 50, 155-158.	1.1	9
494	Chalcone analogue as potent anti-malarial compounds against Plasmodium falciparum : Synthesis, biological evaluation, and docking simulation study. <i>Asian Pacific Journal of Tropical Biomedicine</i> , 2017, 7, 675-679.	0.5	44
495	Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic. <i>Nature Medicine</i> , 2017, 23, 917-928.	15.2	384
496	Mapping global policy discourse on antimicrobial resistance. <i>BMJ Global Health</i> , 2017, 2, e000378.	2.0	61
497	Plasmodium Peekaboo: PK4 Mediates Parasite Latency. <i>Cell Host and Microbe</i> , 2017, 22, 724-725.	5.1	0
498	Prevalence of mutations linked to antimalarial resistance in Plasmodium falciparum from Chhattisgarh, Central India: A malaria elimination point of view. <i>Scientific Reports</i> , 2017, 7, 16690.	1.6	32
499	Chrysofenetin, in the absence and presence of artemisinin, alters breast cancer resistance protein-mediated transport activity in Caco-2 cell monolayers using aristolochic acid I as a specific probe substrate. <i>Revista Brasileira De Farmacognosia</i> , 2017, 27, 780-784.	0.6	3
500	Prevalence of substandard and falsified artemisinin-based combination antimalarial medicines on Bioko Island, Equatorial Guinea. <i>BMJ Global Health</i> , 2017, 2, e000409.	2.0	13
501	Systematic review of the clinical manifestations of glucose-6-phosphate dehydrogenase deficiency in the Greater Mekong Subregion: implications for malaria elimination and beyond. <i>BMJ Global Health</i> , 2017, 2, e000415.	2.0	23
502	Small molecule–based inhibition of MEK1/2 proteins dampens inflammatory responses to malaria, reduces parasite load, and mitigates pathogenic outcomes. <i>Journal of Biological Chemistry</i> , 2017, 292, 13615-13634.	1.6	15
503	Protein Degradation Systems as Antimalarial Therapeutic Targets. <i>Trends in Parasitology</i> , 2017, 33, 731-743.	1.5	46
504	Community perceptions of targeted anti-malarial mass drug administrations in two provinces in Vietnam: a quantitative survey. <i>Malaria Journal</i> , 2017, 16, 17.	0.8	24
505	Absence of in vivo selection for K13 mutations after artemether–lumefantrine treatment in Uganda. <i>Malaria Journal</i> , 2017, 16, 23.	0.8	24
506	Rapid decline in the susceptibility of Plasmodium falciparum to dihydroartemisinin–piperazine in the south of Vietnam. <i>Malaria Journal</i> , 2017, 16, 27.	0.8	130
507	In vitro activity of anti-malarial ozonides against an artemisinin-resistant isolate. <i>Malaria Journal</i> , 2017, 16, 45.	0.8	23
508	Efficacy of text-message reminders on paediatric malaria treatment adherence and their post-treatment return to health facilities in Kenya: a randomized controlled trial. <i>Malaria Journal</i> , 2017, 16, 46.	0.8	11
509	Submicroscopic Plasmodium prevalence in relation to malaria incidence in 20 villages in western Cambodia. <i>Malaria Journal</i> , 2017, 16, 56.	0.8	40
510	Unexpected selections of Plasmodium falciparum polymorphisms in previously treatment-naïve areas after monthly presumptive administration of three different anti-malarial drugs in Liberia 1976–78. <i>Malaria Journal</i> , 2017, 16, 113.	0.8	5

#	ARTICLE	IF	CITATIONS
511	Confirmation of <i>Plasmodium falciparum</i> in vitro resistance to monodesethylamodiaquine and chloroquine in Dakar, Senegal, in 2015. <i>Malaria Journal</i> , 2017, 16, 118.	0.8	10
512	Therapeutic efficacy and artemisinin resistance in northern Myanmar: evidence from in vivo and molecular marker studies. <i>Malaria Journal</i> , 2017, 16, 143.	0.8	19
513	An intricate case of multidrug resistant <i>Plasmodium falciparum</i> isolate imported from Cambodia. <i>Malaria Journal</i> , 2017, 16, 149.	0.8	7
514	The end of a dogma: the safety of doxycycline use in young children for malaria treatment. <i>Malaria Journal</i> , 2017, 16, 148.	0.8	49
515	Assessment of copy number variation in genes related to drug resistance in <i>Plasmodium vivax</i> and <i>Plasmodium falciparum</i> isolates from the Brazilian Amazon and a systematic review of the literature. <i>Malaria Journal</i> , 2017, 16, 152.	0.8	27
516	What happened to anti-malarial markets after the Affordable Medicines Facility-malaria pilot? Trends in ACT availability, price and market share from five African countries under continuation of the private sector co-payment mechanism. <i>Malaria Journal</i> , 2017, 16, 173.	0.8	39
517	Immunity as a predictor of anti-malarial treatment failure: a systematic review. <i>Malaria Journal</i> , 2017, 16, 158.	0.8	13
518	Safety and efficacy of the choline analogue SAR97276 for malaria treatment: results of two phase 2, open-label, multicenter trials in African patients. <i>Malaria Journal</i> , 2017, 16, 188.	0.8	8
519	Mass anti-malarial administration in western Cambodia: a qualitative study of factors affecting coverage. <i>Malaria Journal</i> , 2017, 16, 206.	0.8	44
520	Molecular markers of anti-malarial drug resistance in Central, West and East African children with severe malaria. <i>Malaria Journal</i> , 2017, 16, 217.	0.8	20
521	Longitudinal study of <i>Plasmodium</i> pathogens identifies new loci associated with artemisinin resistance. <i>Genome Biology</i> , 2017, 18, 79.	3.8	4
522	Detection of the <i>Plasmodium falciparum</i> Kelch-13 gene P553L mutation in sporozoites isolated from mosquito salivary glands in South-Central Vietnam. <i>Parasites and Vectors</i> , 2017, 10, 308.	1.0	6
523	Genetic polymorphisms in <i>Plasmodium falciparum</i> chloroquine resistance genes, <i>pfcr</i> and <i>pfmdr1</i> , in North Sulawesi, Indonesia. <i>BMC Research Notes</i> , 2017, 10, 147.	0.6	6
524	Hidden reservoir of resistant parasites: the missing link in the elimination of <i>falciparum</i> malaria. <i>Infectious Diseases of Poverty</i> , 2017, 6, 12.	1.5	10
525	Knockout of the peroxiredoxin 5 homologue PFAOP does not affect the artemisinin susceptibility of <i>Plasmodium falciparum</i> . <i>Scientific Reports</i> , 2017, 7, 4410.	1.6	8
526	Caged Garcinia Xanthenes, a Novel Chemical Scaffold with Potent Antimalarial Activity. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	15
527	Genetic markers associated with dihydroartemisininâ€“piperazine failure in <i>Plasmodium falciparum</i> malaria in Cambodia: a genotypeâ€“phenotype association study. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 164-173.	4.6	301
528	<i>Plasmodium falciparum</i> Genetic Diversity in Continental Equatorial Guinea before and after Introduction of Artemisinin-Based Combination Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	17

#	ARTICLE	IF	CITATIONS
529	A surrogate marker of piperaquine-resistant <i>Plasmodium falciparum</i> malaria: a phenotype–genotype association study. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 174-183.	4.6	302
531	Receptor for Activated C-Kinase 1 (PfRACK1) is required for <i>Plasmodium falciparum</i> intra-erythrocytic proliferation. <i>Molecular and Biochemical Parasitology</i> , 2017, 211, 62-66.	0.5	11
532	The clinical impact of artemisinin resistance in Southeast Asia and the potential for future spread. <i>FEMS Microbiology Reviews</i> , 2017, 41, 34-48.	3.9	171
533	Abundance and distribution of <i>Anopheles</i> mosquitoes in a malaria endemic area along the Thai-Lao border. <i>Journal of Vector Ecology</i> , 2017, 42, 325-334.	0.5	15
534	Methylene blue for treating malaria. <i>The Cochrane Library</i> , 2022, 2022, .	1.5	6
535	Randomised controlled trial of two sequential artemisinin-based combination therapy regimens to treat uncomplicated falciparum malaria in African children: a protocol to investigate safety, efficacy and adherence. <i>BMJ Global Health</i> , 2017, 2, e000371.	2.0	23
536	Redefining priorities towards graded travel-related infectious disease research. <i>Journal of Travel Medicine</i> , 2017, 24, .	1.4	22
537	PageRank influence analysis of protein-protein association networks in the malaria parasite <i>Plasmodium falciparum</i> . <i>International Journal of Computational Biology and Drug Design</i> , 2017, 10, 137.	0.3	3
538	Supply chain management of anti-malarials in the district hospitals in Kumasi Metropolitan Area, Ashanti region of Ghana. <i>International Journal of Medicine and Medical Sciences</i> , 2017, 9, 22-32.	0.3	0
539	Spatiotemporal Modeling for Fine-Scale Maps of Regional Malaria Endemicity and Its Implications for Transitional Complexities in a Routine Surveillance Network in Western Cambodia. <i>Frontiers in Public Health</i> , 2017, 5, 262.	1.3	8
540	Application of nanodiagnostics in point-of-care tests for infectious diseases. <i>International Journal of Nanomedicine</i> , 2017, Volume 12, 4789-4803.	3.3	88
541	Genetic markers of artemisinin resistance in <i>Plasmodium</i> spp. parasites. <i>Emerging Topics in Life Sciences</i> , 2017, 1, 525-531.	1.1	5
542	Antimalarials with Benzothiophene Moieties as Aminoquinoline Partners. <i>Molecules</i> , 2017, 22, 343.	1.7	15
543	Application of the Triazolization Reaction to Afford Dihydroartemisinin Derivatives with Anti-HIV Activity. <i>Molecules</i> , 2017, 22, 303.	1.7	36
544	<i>Infectious Disease Genomics</i> , , 2017, , 211-225.		2
545	Drug-Resistant Polymorphisms and Copy Numbers in <i>Plasmodium falciparum</i> , Mozambique, 2015. <i>Emerging Infectious Diseases</i> , 2017, 24, 40-48.	2.0	42
546	Hormesis and Defense of Infectious Disease. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1273.	1.8	22
547	Immunity to $\hat{\pm}$ -Gal: The Opportunity for Malaria and Tuberculosis Control. <i>Frontiers in Immunology</i> , 2017, 8, 1733.	2.2	17

#	ARTICLE	IF	CITATIONS
548	<i>In Vivo</i> Antimalarial Activity of the Solvent Fractions of Fruit Rind and Root of <i>Carica papaya</i> Linn (Caricaceae) against <i>Plasmodium berghei</i> in Mice. <i>Journal of Parasitology Research</i> , 2017, 2017, 1-9.	0.5	19
549	Bibliometric Analysis of Worldwide Publications on Antimalarial Drug Resistance (2006–2015). <i>Malaria Research and Treatment</i> , 2017, 2017, 1-13.	2.0	27
550	Naturally Acquired Antibody Responses to a Synthetic Malaria Antigen AS202.11. <i>Journal of Tropical Medicine</i> , 2017, 2017, 1-5.	0.6	1
551	Sustained Effectiveness of a Fixed-Dose Combination of Artesunate and Amodiaquine in 480 Patients with Uncomplicated <i>Plasmodium falciparum</i> Malaria in Côte d'Ivoire. <i>Malaria Research and Treatment</i> , 2017, 2017, 1-8.	2.0	1
552	Drug resistance in protozoan parasites. <i>Emerging Topics in Life Sciences</i> , 2017, 1, 627-632.	1.1	37
553	Mexican Medicinal Plants as an Alternative for the Development of New Compounds Against Protozoan Parasites. , 0, , .		5
554	Declining Transmission and Immunity to Malaria and Emerging Artemisinin Resistance in Thailand: A Longitudinal Study. <i>Journal of Infectious Diseases</i> , 2017, 216, 723-731.	1.9	15
555	Single dose primaquine to reduce gametocyte carriage and <i>Plasmodium falciparum</i> transmission in Cambodia: An open-label randomized trial. <i>PLoS ONE</i> , 2017, 12, e0168702.	1.1	26
556	Adverse effects of mefloquine for the treatment of uncomplicated malaria in Thailand: A pooled analysis of 19, 850 individual patients. <i>PLoS ONE</i> , 2017, 12, e0168780.	1.1	26
557	Malaria in Dielmo, a Senegal village: Is its elimination possible after seven years of implementation of long-lasting insecticide-treated nets?. <i>PLoS ONE</i> , 2017, 12, e0179528.	1.1	26
558	Response of imported malaria patients to antimalarial medicines in Sri Lanka following malaria elimination. <i>PLoS ONE</i> , 2017, 12, e0188613.	1.1	12
560	The US President's Malaria Initiative, <i>Plasmodium falciparum</i> transmission and mortality: A modelling study. <i>PLoS Medicine</i> , 2017, 14, e1002448.	3.9	23
561	Very high carriage of gametocytes in asymptomatic low-density <i>Plasmodium falciparum</i> and <i>P. vivax</i> infections in western Thailand. <i>Parasites and Vectors</i> , 2017, 10, 512.	1.0	51
562	Modest heterologous protection after <i>Plasmodium falciparum</i> sporozoite immunization: a double-blind randomized controlled clinical trial. <i>BMC Medicine</i> , 2017, 15, 168.	2.3	78
563	Malaria epidemiology in central Myanmar: identification of a multi-species asymptomatic reservoir of infection. <i>Malaria Journal</i> , 2017, 16, 16.	0.8	48
564	Do anti-malarials in Africa meet quality standards? The market penetration of non quality-assured artemisinin combination therapy in eight African countries. <i>Malaria Journal</i> , 2017, 16, 204.	0.8	24
565	Anti-malarial treatment outcomes in Ethiopia: a systematic review and meta-analysis. <i>Malaria Journal</i> , 2017, 16, 269.	0.8	14
566	Malaria in Brazil, Colombia, Peru and Venezuela: current challenges in malaria control and elimination. <i>Malaria Journal</i> , 2017, 16, 273.	0.8	173

#	ARTICLE	IF	CITATIONS
567	Challenges to replace ACT as first-line drug. <i>Malaria Journal</i> , 2017, 16, 296.	0.8	24
568	Systematic review on traditional medicinal plants used for the treatment of malaria in Ethiopia: trends and perspectives. <i>Malaria Journal</i> , 2017, 16, 307.	0.8	59
569	Comparison of anti-malarial drug efficacy in the treatment of uncomplicated malaria in African children and adults using network meta-analysis. <i>Malaria Journal</i> , 2017, 16, 311.	0.8	19
570	Clinical and molecular surveillance of artemisinin resistant falciparum malaria in Myanmar (2009–2013). <i>Malaria Journal</i> , 2017, 16, 333.	0.8	18
571	Household beliefs about malaria testing and treatment in Western Kenya: the role of health worker adherence to malaria test results. <i>Malaria Journal</i> , 2017, 16, 349.	0.8	4
572	The use of respondent-driven sampling to assess malaria knowledge, treatment-seeking behaviours and preventive practices among mobile and migrant populations in a setting of artemisinin resistance in Western Cambodia. <i>Malaria Journal</i> , 2017, 16, 378.	0.8	10
573	In vivo anti-malarial activity and toxicity studies of triterpenic esters isolated from <i>Keetia leucantha</i> and crude extracts. <i>Malaria Journal</i> , 2017, 16, 406.	0.8	11
574	Malaria risk factors and care-seeking behaviour within the private sector among high-risk populations in Vietnam: a qualitative study. <i>Malaria Journal</i> , 2017, 16, 414.	0.8	15
575	Factors associated with population coverage of targeted malaria elimination (TME) in southern Savannakhet Province, Lao PDR. <i>Malaria Journal</i> , 2017, 16, 424.	0.8	33
576	<i>Plasmodium falciparum</i> Kelch 13 mutations and treatment response in patients in Hpa-Pun District, Northern Kayin State, Myanmar. <i>Malaria Journal</i> , 2017, 16, 480.	0.8	20
577	Towards malaria elimination in Savannakhet, Lao PDR: mathematical modelling driven strategy design. <i>Malaria Journal</i> , 2017, 16, 483.	0.8	18
578	Return of chloroquine sensitivity to Africa? Surveillance of African <i>Plasmodium falciparum</i> chloroquine resistance through malaria imported to China. <i>Parasites and Vectors</i> , 2017, 10, 355.	1.0	33
579	Sharing Individual-Level Health Research Data: Experiences, Challenges and a Research Agenda. <i>Asian Bioethics Review</i> , 2017, 9, 393-400.	0.9	7
580	Functional analysis of <i>Plasmodium falciparum</i> subpopulations associated with artemisinin resistance in Cambodia. <i>Malaria Journal</i> , 2017, 16, 493.	0.8	17
581	Partner-Drug Resistance and Population Substructuring of Artemisinin-Resistant <i>Plasmodium falciparum</i> in Cambodia. <i>Genome Biology and Evolution</i> , 2017, 9, 1673-1686.	1.1	45
582	Polymorphisms of <i>Plasmodium falciparum</i> k13-propeller gene among migrant workers returning to Henan Province, China from Africa. <i>BMC Infectious Diseases</i> , 2017, 17, 560.	1.3	28
583	Severe <i>Plasmodium falciparum</i> malaria in a traveller returning from Mozambique. <i>Jammi</i> , 2017, 2, 97-101.	0.3	0
584	Molecular Evidence of Drug Resistance in Asymptomatic Malaria Infections, Myanmar, 2015. <i>Emerging Infectious Diseases</i> , 2017, 23, 517-520.	2.0	22

#	ARTICLE	IF	CITATIONS
585	<i>Plasmodium falciparum</i> . Emerging Topics in Life Sciences, 2017, 1, 517-523.	1.1	3
586	Novel <i>Plasmodium falciparum</i> metabolic network reconstruction identifies shifts associated with clinical antimalarial resistance. BMC Genomics, 2017, 18, 543.	1.2	36
587	Methods for monitoring artemisinin-based combination therapies efficacy. Clinical Reviews and Opinions, 2017, 8, 1-13.	1.0	4
588	In vivo efficacy of artemether–lumefantrine against uncomplicated <i>Plasmodium falciparum</i> malaria in Dembia District, northwest Ethiopia. Therapeutics and Clinical Risk Management, 2017, Volume 13, 201-206.	0.9	5
589	Capacity Development through the US Presidentâ€™s Malaria Initiativeâ€™Supported Antimalarial Resistance Monitoring in Africa Network. Emerging Infectious Diseases, 2017, 23, .	2.0	23
590	Protozoan Diseases: Malaria Clinical Features, Management, and Prevention. , 2017, , 103-113.		1
591	Antiparasitic Agents. , 2017, , 717-750.		0
592	Catalytic Enantioselective Synthesis of a Pyrrolizidineâ€™Alkaloid-Inspired Compound Collection with Antiplasmodial Activity. Journal of Organic Chemistry, 2018, 83, 7033-7041.	1.7	7
593	Bioavailability and Pharmacokinetics of Dihydroartemisinin (DHA) and its Analogsâ€™Mechanistic Studies on its ADME. Current Pharmacology Reports, 2018, 4, 33-44.	1.5	2
594	Rocaglates as dual-targeting agents for experimental cerebral malaria. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E2366-E2375.	3.3	24
595	Kelch Mutations in <i>Plasmodium falciparum</i> Protein K13 Do Not Modulate Dormancy after Artemisinin Exposure and Sorbitol Selection <i>In Vitro</i> . Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	13
596	A Novel Single-Nucleotide Polymorphism Loop Mediated Isothermal Amplification Assay for Detection of Artemisinin-Resistant <i>Plasmodium falciparum</i> Malaria. Open Forum Infectious Diseases, 2018, 5, ofy011.	0.4	20
597	The prevalence of molecular markers of drug resistance in <i>Plasmodium vivax</i> from the border regions of Thailand in 2008 and 2014. International Journal for Parasitology: Drugs and Drug Resistance, 2018, 8, 229-237.	1.4	30
598	Interaction of $\hat{\pm}$ -Thymidine Inhibitors with Thymidylate Kinase from <i>Plasmodium falciparum</i> . Biochemistry, 2018, 57, 2868-2875.	1.2	6
599	Potent Inhibitors of <i>Plasmodial</i> Serine Hydroxymethyltransferase (SHMT) Featuring a Spirocyclic Scaffold. ChemMedChem, 2018, 13, 931-943.	1.6	21
600	Malaria. Lancet, The, 2018, 391, 1608-1621.	6.3	374
601	The mitochondrial ribosomal protein L13 is critical for the structural and functional integrity of the mitochondrion in <i>Plasmodium falciparum</i> . Journal of Biological Chemistry, 2018, 293, 8128-8137.	1.6	50
602	Rapid selection of sulphadoxine-resistant <i>Plasmodium falciparum</i> and its effect on within-population genetic diversity in Papua New Guinea. Scientific Reports, 2018, 8, 5565.	1.6	6

#	ARTICLE	IF	CITATIONS
603	Endoperoxide-8-aminoquinoline hybrids as dual-stage antimalarial agents with enhanced metabolic stability. <i>European Journal of Medicinal Chemistry</i> , 2018, 149, 69-78.	2.6	30
604	Genetic diversity of the <i>Plasmodium vivax</i> phosphatidylinositol 3-kinase gene in two regions of the China-Myanmar border. <i>Infection, Genetics and Evolution</i> , 2018, 61, 45-52.	1.0	4
605	Origins of the current outbreak of multidrug-resistant malaria in southeast Asia: a retrospective genetic study. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 337-345.	4.6	161
606	Evolutionary ARMS Race: Antimalarial Resistance Molecular Surveillance. <i>Trends in Parasitology</i> , 2018, 34, 322-334.	1.5	9
607	Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 5822-5880.	2.9	1,524
608	A Macrophage Colony-Stimulating-Factor-Producing $\hat{\gamma}$ T Cell Subset Prevents Malarial Parasitemic Recurrence. <i>Immunity</i> , 2018, 48, 350-363.e7.	6.6	105
609	Multistage inhibitors of the malaria parasite: Emerging hope for chemoprotection and malaria eradication. <i>Medicinal Research Reviews</i> , 2018, 38, 1511-1535.	5.0	26
610	Development of a Photo-Cross-Linkable Diaminoquinazoline Inhibitor for Target Identification in <i>Plasmodium falciparum</i> . <i>ACS Infectious Diseases</i> , 2018, 4, 523-530.	1.8	20
611	Artemisinin Therapy for Malaria in Hemoglobinopathies: A Systematic Review. <i>Clinical Infectious Diseases</i> , 2018, 66, 799-804.	2.9	7
612	Emergence and Spread of <i>kelch13</i> Mutations Associated with Artemisinin Resistance in <i>Plasmodium falciparum</i> Parasites in 12 Thai Provinces from 2007 to 2016. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	19
613	Vigilance and Sentinels in Global Health Security. <i>Medical Anthropology: Cross Cultural Studies in Health and Illness</i> , 2018, 37, 327-342.	0.6	4
614	Antimalarial Terpenic Compounds Isolated from Plants Used in Traditional Medicine (2010–July 2016). <i>Sustainable Development and Biodiversity</i> , 2018, , 247-268.	1.4	3
615	Discovery of <i>Plasmodium</i> (M)TRAP–Aldolase Interaction Stabilizers Interfering with Sporozoite Motility and Invasion. <i>ACS Infectious Diseases</i> , 2018, 4, 620-634.	1.8	6
616	Pyrimidine-chloroquinoline hybrids: Synthesis and antiplasmodial activity. <i>European Journal of Medicinal Chemistry</i> , 2018, 148, 39-53.	2.6	44
617	Probabilistic data integration identifies reliable gametocyte-specific proteins and transcripts in malaria parasites. <i>Scientific Reports</i> , 2018, 8, 410.	1.6	39
618	Drug resistance in <i>Plasmodium</i> . <i>Nature Reviews Microbiology</i> , 2018, 16, 156-170.	13.6	296
619	Remodeling of the malaria parasite and host human red cell by vesicle amplification that induces artemisinin resistance. <i>Blood</i> , 2018, 131, 1234-1247.	0.6	80
620	Engineering the chloroplast of <i>Chlamydomonas reinhardtii</i> to express the recombinant PfCelTOS-II2 antigen-adjuvant fusion protein. <i>Journal of Biotechnology</i> , 2018, 266, 111-117.	1.9	11

#	ARTICLE	IF	CITATIONS
621	Parasite-Mediated Degradation of Synthetic Ozonide Antimalarials Impacts <i>In Vitro</i> Antimalarial Activity. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	17
622	Malaria in Children. <i>Infectious Disease Clinics of North America</i> , 2018, 32, 189-200.	1.9	14
623	Genome-wide survey and phylogenetic analysis of histone acetyltransferases and histone deacetylases of <i>Plasmodium falciparum</i> . <i>FEBS Journal</i> , 2018, 285, 1767-1782.	2.2	38
624	Beyond Hemoglobin: Screening for Malaria Host Factors. <i>Trends in Genetics</i> , 2018, 34, 133-141.	2.9	15
625	Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. <i>Science</i> , 2018, 359, 191-199.	6.0	194
626	Malaria—Update on Antimalarial Resistance and Treatment Approaches. <i>Pediatric Infectious Disease Journal</i> , 2018, 37, 367-369.	1.1	14
627	Effects of lipophilicity, protecting group and stereochemistry on the antimalarial activity of carbohydrate-derived thiochromans. <i>Medicinal Chemistry Research</i> , 2018, 27, 817-833.	1.1	7
628	Calcium-dependent phosphorylation of <i>Plasmodium falciparum</i> serine repeat antigen 5 triggers merozoite egress. <i>Journal of Biological Chemistry</i> , 2018, 293, 9736-9746.	1.6	25
629	Uncovering the essential genes of the human malaria parasite <i>Plasmodium falciparum</i> by saturation mutagenesis. <i>Science</i> , 2018, 360, .	6.0	687
630	Profiling of the anti-malarial drug candidate SC83288 against artemisinins in <i>Plasmodium falciparum</i> . <i>Malaria Journal</i> , 2018, 17, 121.	0.8	6
631	Optimal control of malaria: combining vector interventions and drug therapies. <i>Malaria Journal</i> , 2018, 17, 174.	0.8	15
632	Plasmepsin II copy number accounts for bimodal piperazine resistance among Cambodian <i>Plasmodium falciparum</i> . <i>Nature Communications</i> , 2018, 9, 1769.	5.8	85
633	Effect of generalised access to early diagnosis and treatment and targeted mass drug administration on <i>Plasmodium falciparum</i> malaria in Eastern Myanmar: an observational study of a regional elimination programme. <i>Lancet, The</i> , 2018, 391, 1916-1926.	6.3	131
634	Can improving access to care help to eliminate malaria?. <i>Lancet, The</i> , 2018, 391, 1870-1871.	6.3	4
635	Imidazolopiperazines Kill both Rings and Dormant Rings in Wild-Type and K13 Artemisinin-Resistant <i>Plasmodium falciparum</i> <i>In Vitro</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	12
636	Plumbagin, a vitamin K3 analogue ameliorate malaria pathogenesis by inhibiting oxidative stress and inflammation. <i>Inflammopharmacology</i> , 2018, 26, 983-991.	1.9	16
637	Beyond mosquitoes—Essential oil toxicity and repellency against bloodsucking insects. <i>Industrial Crops and Products</i> , 2018, 117, 382-392.	2.5	110
638	Synthesis and study of the antimalarial cardamom peroxide. <i>Tetrahedron</i> , 2018, 74, 3358-3369.	1.0	7

#	ARTICLE	IF	CITATIONS
639	Calcium-Dependent Protein Kinase 5 Is Required for Release of Egress-Specific Organelles in <i>Plasmodium falciparum</i> . MBio, 2018, 9, .	1.8	56
640	Access to artemisinin-based combination therapies and other anti-malarial drugs in Kinshasa. MÃ©decine Et Maladies Infectieuses, 2018, 48, 269-277.	5.1	6
641	Antimicrobial effects of N-benzyloxycarbonyl-S-(2,4-dinitrophenyl) glutathione diesters against chloroquine sensitive (NF54) and resistant (K1) strains of <i>Plasmodium falciparum</i> . Bioorganic Chemistry, 2018, 78, 115-118.	2.0	1
642	Updates on k13 mutant alleles for artemisinin resistance in <i>Plasmodium falciparum</i> . Journal of Microbiology, Immunology and Infection, 2018, 51, 159-165.	1.5	20
643	Drug repurposing screens and synergistic drug combinations for infectious diseases. British Journal of Pharmacology, 2018, 175, 181-191.	2.7	181
644	Predictors of antimalarial self-medication in illegal gold miners in French Guiana: a pathway towards artemisinin resistance. Journal of Antimicrobial Chemotherapy, 2018, 73, 231-239.	1.3	32
645	Cyclic GMP-AMP Synthase Is the Cytosolic Sensor of <i>Plasmodium falciparum</i> Genomic DNA and Activates Type I IFN in Malaria. Journal of Immunology, 2018, 200, 768-774.	0.4	50
646	Lack of significant recovery of chloroquine sensitivity in <i>Plasmodium falciparum</i> parasites following discontinuance of chloroquine use in Papua New Guinea. Malaria Journal, 2018, 17, 434.	0.8	13
647	The dynamic of asymptomatic <i>Plasmodium falciparum</i> infections following mass drug administrations with dihydroartemisinin-piperazine plus a single low dose of primaquine in Savannakhet Province, Laos. Malaria Journal, 2018, 17, 405.	0.8	18
648	Epidemiology, drug resistance, and pathophysiology of <i>Plasmodium vivax</i> malaria. Journal of Vector Borne Diseases, 2018, 55, 1.	0.1	66
649	Malaria Elimination in the People's Republic of China: Current Progress, Challenges, and Prospects. , 0, , .		7
650	Challenges arising when seeking broad consent for health research data sharing: a qualitative study of perspectives in Thailand. BMC Medical Ethics, 2018, 19, 86.	1.0	18
651	Assessment of drug resistance associated genetic diversity in Mauritanian isolates of <i>Plasmodium vivax</i> reveals limited polymorphism. Malaria Journal, 2018, 17, 416.	0.8	9
652	Artemisinin resistance phenotypes and K13 inheritance in a <i>Plasmodium falciparum</i> cross and <i>Aotus</i> model. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 12513-12518.	3.3	46
653	<i>Plasmodium falciparum</i> Treated with Artemisinin-based Combined Therapy Exhibits Enhanced Mutation, Heightened Cortisol and TNF- α Induction. International Journal of Medical Sciences, 2018, 15, 1449-1457.	1.1	4
654	Mutations in <i>Plasmodium falciparum</i> actin-binding protein coronin confer reduced artemisinin susceptibility. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 12799-12804.	3.3	114
655	Suppression of Drug Resistance Reveals a Genetic Mechanism of Metabolic Plasticity in Malaria Parasites. MBio, 2018, 9, .	1.8	15
656	Community-informed research on malaria in pregnancy in Monrovia, Liberia: a grounded theory study. Malaria Journal, 2018, 17, 382.	0.8	4

#	ARTICLE	IF	CITATIONS
657	Cluster-randomized trial of monthly malaria prophylaxis versus focused screening and treatment: a study protocol to define malaria elimination strategies in Cambodia. <i>Trials</i> , 2018, 19, 558.	0.7	4
658	Assessment of parasite clearance following treatment of severe malaria with intravenous artesunate in Ugandan children enrolled in a randomized controlled clinical trial. <i>Malaria Journal</i> , 2018, 17, 400.	0.8	10
659	Heterogeneous distribution of k13 mutations in <i>Plasmodium falciparum</i> in Laos. <i>Malaria Journal</i> , 2018, 17, 483.	0.8	9
660	Perceptions of asymptomatic malaria infection and their implications for malaria control and elimination in Laos. <i>PLoS ONE</i> , 2018, 13, e0208912.	1.1	28
661	Patients' adherence to artemisinin-based combination therapy and healthcare workers' perception and practice in Savannakhet province, Lao PDR. <i>Tropical Medicine and Health</i> , 2018, 46, 44.	1.0	8
662	<i>Plasmodium falciparum</i> artemisinin resistance monitoring in Sabah, Malaysia: in vivo therapeutic efficacy and kelch13 molecular marker surveillance. <i>Malaria Journal</i> , 2018, 17, 463.	0.8	8
663	Evidence that the <i>Plasmodium falciparum</i> Protein Sortilin Potentially Acts as an Escorter for the Trafficking of the Rhoptry-Associated Membrane Antigen to the Rhoptries. <i>MSphere</i> , 2018, 3, .	1.3	18
664	Genetic association between the Pfk13 gene mutation and artemisinin resistance phenotype in <i>Plasmodium falciparum</i> isolates from Yunnan Province, China. <i>Malaria Journal</i> , 2018, 17, 478.	0.8	11
665	Prevalence of molecular markers of sulfadoxine-pyrimethamine and artemisinin resistance in <i>Plasmodium falciparum</i> from Pakistan. <i>Malaria Journal</i> , 2018, 17, 471.	0.8	17
666	Effectiveness of repellent delivered through village health volunteers on malaria incidence in villages in South-East Myanmar: a stepped-wedge cluster-randomised controlled trial protocol. <i>BMC Infectious Diseases</i> , 2018, 18, 663.	1.3	10
667	Novel Strategies for Malaria Vaccine Design. <i>Frontiers in Immunology</i> , 2018, 9, 2769.	2.2	41
668	Commercial drugs containing flavonoids are active in mice with malaria and in vitro against chloroquine-resistant <i>Plasmodium falciparum</i> . <i>Memorias Do Instituto Oswaldo Cruz</i> , 2018, 113, e180279.	0.8	15
669	The origins of malaria artemisinin resistance defined by a genetic and transcriptomic background. <i>Nature Communications</i> , 2018, 9, 5158.	5.8	41
670	Fitness Loss under Amino Acid Starvation in Artemisinin-Resistant <i>Plasmodium falciparum</i> Isolates from Cambodia. <i>Scientific Reports</i> , 2018, 8, 12622.	1.6	21
671	Inhibition of JNK signaling in the Asian malaria vector <i>Anopheles stephensi</i> extends mosquito longevity and improves resistance to <i>Plasmodium falciparum</i> infection. <i>PLoS Pathogens</i> , 2018, 14, e1007418.	2.1	25
672	Diagnostic accuracy of molecular methods for detecting markers of antimalarial drug resistance in clinical samples of <i>Plasmodium falciparum</i> : protocol for an update to a systematic review and meta-analysis. <i>Systematic Reviews</i> , 2018, 7, 221.	2.5	1
673	Alternative pathway to reduced artemisinin susceptibility in <i>Plasmodium falciparum</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 12556-12558.	3.3	9
674	Molecular assays for antimalarial drug resistance surveillance: A target product profile. <i>PLoS ONE</i> , 2018, 13, e0204347.	1.1	24

#	ARTICLE	IF	CITATIONS
675	Accessible and distinct decoquinone derivatives active against Mycobacterium tuberculosis and apicomplexan parasites. Communications Chemistry, 2018, 1, .	2.0	30
676	High-level artemisinin-resistance with quinine co-resistance emerges in <i>P. falciparum</i> malaria under in vivo artesunate pressure. BMC Medicine, 2018, 16, 181.	2.3	26
677	<i>In Silico</i> Investigation of the Decline in Clinical Efficacy of Artemisinin Combination Therapies Due to Increasing Artemisinin and Partner Drug Resistance. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	4
678	Sharing public health data and information across borders: lessons from Southeast Asia. Globalization and Health, 2018, 14, 94.	2.4	18
679	Malaria parasite clearance from patients following artemisinin-based combination therapy in Cote d'Ivoire. Infection and Drug Resistance, 2018, Volume 11, 2031-2038.	1.1	11
680	Synthesis of five libraries of 6,5-fused heterocycles to establish the importance of the heterocyclic core for antiplasmodial activity. Bioorganic and Medicinal Chemistry, 2018, 26, 5730-5741.	1.4	9
681	Anti-Plasmodium falciparum Activity of Extracts from 10 Cameroonian Medicinal Plants. Medicines (Basel, Switzerland), 2018, 5, 115.	0.7	8
682	Selective sweeps and genetic lineages of Plasmodium falciparum multi-drug resistance (pfmdr1) gene in Kenya. Malaria Journal, 2018, 17, 398.	0.8	7
683	Population pharmacokinetics of mefloquine given as a 3-day artesunate+mefloquine in patients with acute uncomplicated Plasmodium falciparum malaria in a multidrug-resistant area along the Thai-Myanmar border. Malaria Journal, 2018, 17, 322.	0.8	5
684	Gametocytes from K13 Propeller Mutant Plasmodium falciparum Clinical Isolates Demonstrate Reduced Susceptibility to Dihydroartemisinin in the Male Gamete Exflagellation Inhibition Assay. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	10
685	Nanomedicines for Malaria Chemotherapy: Encapsulation vs. Polymer Therapeutics. Pharmaceutical Research, 2018, 35, 237.	1.7	16
686	A single nucleotide polymorphism in the Plasmodium falciparum atg18 gene associates with artemisinin resistance and confers enhanced parasite survival under nutrient deprivation. Malaria Journal, 2018, 17, 391.	0.8	30
687	Reproductive indices in malaria infested mice treated with antimalarials, Phyllanthus amarus combined with vitamins. Bulletin of Faculty of Pharmacy, Cairo University, 2018, 56, 179-184.	0.2	3
688	Prevalence of Plasmodium falciparum antimalarial drug resistance genes in Southeastern Gabon from 2011 to 2014. Infection and Drug Resistance, 2018, Volume 11, 1329-1338.	1.1	30
689	One-pot, multi-component synthesis and structure-activity relationships of peptoid-based histone deacetylase (HDAC) inhibitors targeting malaria parasites. European Journal of Medicinal Chemistry, 2018, 158, 801-813.	2.6	29
690	Malaria, tuberculosis and HIV: what's new? Contribution of the Institut Hospitalo-Universitaire MÃ©diterranÃ©e Infection in updated data. New Microbes and New Infections, 2018, 26, S23-S30.	0.8	1
691	MEPicides: $\hat{1},\hat{1}^2$ -Unsaturated Fosmidomycin Analogues as DXR Inhibitors against Malaria. Journal of Medicinal Chemistry, 2018, 61, 8847-8858.	2.9	26
692	Absence of a High Level of Duplication of the Plasmeprin II Gene in Africa. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	11

#	ARTICLE	IF	CITATIONS
693	Investigating the Efficacy of Triple Artemisinin-Based Combination Therapies for Treating Plasmodium falciparum Malaria Patients Using Mathematical Modeling. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	43
694	Epigenetics and Malaria Susceptibility/Protection: A Missing Piece of the Puzzle. Frontiers in Immunology, 2018, 9, 1733.	2.2	13
695	Quantification of host-mediated parasite clearance during blood-stage Plasmodium infection and anti-malarial drug treatment in mice. International Journal for Parasitology, 2018, 48, 903-913.	1.3	8
696	Pfcr1 genotypes and related microsatellite DNA polymorphisms on Plasmodium falciparum differed among populations in the Greater Mekong Subregion. Parasitology International, 2018, 67, 816-823.	0.6	0
697	Resistance screening and trend analysis of imported falciparum malaria in NSW, Australia (2010 to) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.1	13
698	The Artemisinin Resistance in Southeast Asia: An Imminent Global Threat to Malaria Elimination. , 0, , .		8
699	Malaria Transmission-Blocking Vaccines: Present Status and Future Perspectives. , 0, , .		12
700	Novel antimalarial chloroquine- and primaquine-quinoline 1,4-di-N-oxide hybrids: Design, synthesis, Plasmodium life cycle stage profile, and preliminary toxicity studies. European Journal of Medicinal Chemistry, 2018, 158, 68-81.	2.6	43
701	A barcode of multilocus nuclear DNA identifies genetic relatedness in pre- and post-Artemether/Lumefantrine treated Plasmodium falciparum in Nigeria. BMC Infectious Diseases, 2018, 18, 392.	1.3	10
702	Implications of population-level immunity for the emergence of artemisinin-resistant malaria: a mathematical model. Malaria Journal, 2018, 17, 279.	0.8	26
703	Efficacy of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Nepal. Tropical Diseases, Travel Medicine and Vaccines, 2018, 4, 9.	0.9	3
704	Drugs in Development for Malaria. Drugs, 2018, 78, 861-879.	4.9	154
705	Nervous System Infections and the Global Traveler. Seminars in Neurology, 2018, 38, 247-262.	0.5	4
706	Heterologous expression of CTP:phosphocholine cytidyltransferase from Plasmodium falciparum rescues Chinese Hamster Ovary cells deficient in the Kennedy phosphatidylcholine biosynthesis pathway. Scientific Reports, 2018, 8, 8932.	1.6	2
707	Artemisinin and Derivatives. , 2018, , 197-351.		1
708	Design of Novel Dual-Target Hits Against Malaria and Tuberculosis Using Computational Docking. Methods in Pharmacology and Toxicology, 2018, , 419-442.	0.1	0
709	Efficacy of artemisinin-based combination therapies and prevalence of molecular markers associated with artemisinin, piperaquine and sulfadoxine-pyrimethamine resistance in Sierra Leone. Acta Tropica, 2018, 185, 363-370.	0.9	13
710	Long circulatory liposomal maduramicin inhibits the growth of Plasmodium falciparum blood stages in culture and cures murine models of experimental malaria. Nanoscale, 2018, 10, 13773-13791.	2.8	25

#	ARTICLE	IF	CITATIONS
711	Artemisinin-resistant <i>Plasmodium falciparum</i> with High Survival Rates, Uganda, 2014–2016. Emerging Infectious Diseases, 2018, 24, 718-726.	2.0	104
712	Absence of K13 Polymorphism in <i>Plasmodium falciparum</i> from Brazilian Areas Where the Parasite Is Endemic. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	8
713	Effectiveness and safety of 3 and 5-day courses of artemether-lumefantrine for the treatment of uncomplicated <i>falciparum</i> malaria in an area of emerging artemisinin resistance in Myanmar. Malaria Journal, 2018, 17, 258.	0.8	27
714	Phenotypic and genotypic characterization of Thai isolates of <i>Plasmodium falciparum</i> after an artemisinin resistance containment project. Malaria Journal, 2018, 17, 197.	0.8	5
715	The decline of malaria in Vietnam, 1991–2014. Malaria Journal, 2018, 17, 226.	0.8	24
716	Improved efficacy of doxycycline in liposomes against <i>Plasmodium falciparum</i> in culture and <i>Plasmodium berghei</i> infection in mice. Canadian Journal of Physiology and Pharmacology, 2018, 96, 1145-1152.	0.7	12
717	Cell Penetration, Herbicidal Activity, and <i>in vivo</i> Toxicity of Oligoarginine Derivatives and of Novel Guanidinium-Rich Compounds Derived from the Biopolymer Cyanophycin. Helvetica Chimica Acta, 2018, 101, e1800112.	1.0	17
718	High efficacy of artemether-lumefantrine and dihydroartemisinin-piperazine for the treatment of uncomplicated <i>falciparum</i> malaria in Muheza and Kigoma Districts, Tanzania. Malaria Journal, 2018, 17, 261.	0.8	19
719	Multidrug-resistant malaria and the impact of mass drug administration. Infection and Drug Resistance, 2018, Volume 11, 299-306.	1.1	31
720	Malaria Elimination in the Greater Mekong Subregion: Challenges and Prospects. , 0, , .		12
721	Combinatorial Effects of Monensin in Liposome Formulations with Antimalarial Drugs Against Blood Stages of <i>Plasmodium falciparum</i> in Culture and <i>P. berghei</i> Infection. Current Drug Therapy, 2018, 13, 74-82.	0.2	5
722	Introduction of F446I mutation in the K13 propeller gene leads to increased ring survival rates in <i>Plasmodium falciparum</i> isolates. Malaria Journal, 2018, 17, 248.	0.8	25
723	<i>Plasmodium falciparum</i> dipeptidyl aminopeptidase 3 activity is important for efficient erythrocyte invasion by the malaria parasite. PLoS Pathogens, 2018, 14, e1007031.	2.1	32
724	Low uptake of preventive interventions among malaria cases in Swaziland: towards malaria elimination. Public Health Action, 2018, 8, S29-S33.	0.4	3
725	How to combat emerging artemisinin resistance: Lessons from ‘The Three Little Pigs’. PLoS Pathogens, 2018, 14, e1006923.	2.1	7
726	Dihydroartemisinin-piperazine treatment failure in uncomplicated <i>Plasmodium falciparum</i> malaria case imported from Ethiopia. Infection, 2018, 46, 867-870.	2.3	18
727	Increasing the Strength and Production of Artemisinin and Its Derivatives. Molecules, 2018, 23, 100.	1.7	24
728	Use of primaquine and glucose-6-phosphate dehydrogenase deficiency testing: Divergent policies and practices in malaria endemic countries. PLoS Neglected Tropical Diseases, 2018, 12, e0006230.	1.3	120

#	ARTICLE	IF	CITATIONS
729	Identifying Recrudescence of <i>Plasmodium falciparum</i> in Treated Malaria Patients by Real-time PCR and High Resolution Melt Analysis of Genetic Diversity. <i>Scientific Reports</i> , 2018, 8, 10097.	1.6	14
730	Randomized, Double-Blind, Placebo-Controlled Studies to Assess Safety and Prophylactic Efficacy of Naphthoquine-Azithromycin Combination for Malaria Prophylaxis in Southeast Asia. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	5
731	Tools for surveillance of anti-malarial drug resistance: an assessment of the current landscape. <i>Malaria Journal</i> , 2018, 17, 75.	0.8	57
732	Expanding the SAR of Nontoxic Antiplasmodial Indolyl- β -ketoethanone Ethers and Thioethers. <i>ChemMedChem</i> , 2018, 13, 1353-1362.	1.6	11
733	Single low-dose primaquine for blocking transmission of <i>Plasmodium falciparum</i> malaria – a proposed model-derived age-based regimen for sub-Saharan Africa. <i>BMC Medicine</i> , 2018, 16, 11.	2.3	10
734	Why do people participate in mass anti-malarial administration? Findings from a qualitative study in Nong District, Savannakhet Province, Lao PDR (Laos). <i>Malaria Journal</i> , 2018, 17, 15.	0.8	41
735	A phase 1 evaluation of the pharmacokinetic/pharmacodynamic interaction of the anti-malarial agents KAF156 and piperazine. <i>Malaria Journal</i> , 2018, 17, 7.	0.8	18
736	Efficacy of artesunate + amodiaquine, dihydroartemisinin + piperazine and artemether + lumefantrine for the treatment of uncomplicated <i>Plasmodium falciparum</i> malaria in Maradi, Niger. <i>Malaria Journal</i> , 2018, 17, 52.	0.8	20
737	In vivo validation of anti-malarial activity of crude extracts of <i>Terminalia macroptera</i> , a Malian medicinal plant. <i>Malaria Journal</i> , 2018, 17, 68.	0.8	31
738	The D113N mutation in the RING E3 ubiquitin protein ligase gene is not associated with ex vivo susceptibility to common anti-malarial drugs in African <i>Plasmodium falciparum</i> isolates. <i>Malaria Journal</i> , 2018, 17, 108.	0.8	6
739	Population pharmacokinetic and pharmacodynamic properties of artesunate in patients with artemisinin sensitive and resistant infections in Southern Myanmar. <i>Malaria Journal</i> , 2018, 17, 126.	0.8	15
740	Diagnostic tools in childhood malaria. <i>Parasites and Vectors</i> , 2018, 11, 53.	1.0	34
741	New endoperoxides highly active in vivo and in vitro against artemisinin-resistant <i>Plasmodium falciparum</i> . <i>Malaria Journal</i> , 2018, 17, 145.	0.8	27
742	Medicinal fungi: a source of antiparasitic secondary metabolites. <i>Applied Microbiology and Biotechnology</i> , 2018, 102, 5791-5810.	1.7	25
743	The impact of packaging and messaging on adherence to malaria treatment: Evidence from a randomized controlled trial in Uganda. <i>Journal of Development Economics</i> , 2018, 134, 68-95.	2.1	14
744	The Complement System Contributes to Functional Antibody-Mediated Responses Induced by Immunization with <i>Plasmodium falciparum</i> Malaria Sporozoites. <i>Infection and Immunity</i> , 2018, 86, .	1.0	51
745	Emerging Southeast Asian PfCRT mutations confer <i>Plasmodium falciparum</i> resistance to the first-line antimalarial piperazine. <i>Nature Communications</i> , 2018, 9, 3314.	5.8	183
746	Within-host modeling of blood-stage malaria. <i>Immunological Reviews</i> , 2018, 285, 168-193.	2.8	26

#	ARTICLE	IF	CITATIONS
747	Genetic Crosses and Linkage Mapping in Schistosome Parasites. Trends in Parasitology, 2018, 34, 982-996.	1.5	29
748	Defining the Determinants of Specificity of <i>Plasmodium</i> Proteasome Inhibitors. Journal of the American Chemical Society, 2018, 140, 11424-11437.	6.6	54
749	The feasibility and acceptability of mass drug administration for malaria in Cambodia: a mixed-methods study. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2018, 112, 264-271.	0.7	20
750	<i>Plasmodium falciparum</i> gametocyte dynamics after pyronaridine-artesunate or artemether-lumefantrine treatment. Malaria Journal, 2018, 17, 223.	0.8	8
751	Novel Defense Peptides from Platelets Kill Malaria Parasites. Trends in Parasitology, 2018, 34, 729-731.	1.5	6
752	Pyronaridine-artesunate and artemether-lumefantrine for the treatment of uncomplicated <i>Plasmodium falciparum</i> malaria in Kenyan children: a randomized controlled non-inferiority trial. Malaria Journal, 2018, 17, 199.	0.8	22
753	Deciphering the targets of retroviral protease inhibitors in <i>Plasmodium berghei</i> . PLoS ONE, 2018, 13, e0201556.	1.1	18
754	Photo-Induced Electron Transfer Real-Time PCR for Detection of <i>Plasmodium falciparum</i> plasmepsin 2 Gene Copy Number. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	4
755	Th1 immune response to <i>Plasmodium falciparum</i> recombinant thrombospondin-related adhesive protein (TRAP) antigen is enhanced by TLR3-specific adjuvant, poly(I:C) in BALB/c mice. Parasite Immunology, 2018, 40, e12538.	0.7	8
756	Oxidative stress and protein damage responses mediate artemisinin resistance in malaria parasites. PLoS Pathogens, 2018, 14, e1006930.	2.1	129
757	First Polarimetric Investigation of Malaria Mosquitoes as Lidar Targets. IEEE Journal of Selected Topics in Quantum Electronics, 2019, 25, 1-8.	1.9	10
758	Molecular detection of drug resistant malaria in Southern Thailand. Malaria Journal, 2019, 18, 275.	0.8	28
759	Failures in the case management of children with uncomplicated malaria in Bata district of Equatorial Guinea and associated factors. PLoS ONE, 2019, 14, e0220789.	1.1	4
760	Targeting the apicoplast in malaria. Biochemical Society Transactions, 2019, 47, 973-983.	1.6	27
761	The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. Journal of Medicinal Chemistry, 2019, 62, 10526-10562.	2.9	53
762	Genomic and biological features of <i>Plasmodium falciparum</i> resistance against antimalarial endoperoxide N-89. Gene, 2019, 716, 144016.	1.0	4
763	Fever in travellers returning from the tropics. Medicina Clínica (English Edition), 2019, 153, 205-212.	0.1	3
764	Identification via a Parallel Hit Progression Strategy of Improved Small Molecule Inhibitors of the Malaria Purine Uptake Transporter that Inhibit <i>Plasmodium falciparum</i> Parasite Proliferation. ACS Infectious Diseases, 2019, 5, 1738-1753.	1.8	6

#	ARTICLE	IF	CITATIONS
765	<i>Plasmodium</i> Genomics and Genetics: New Insights into Malaria Pathogenesis, Drug Resistance, Epidemiology, and Evolution. <i>Clinical Microbiology Reviews</i> , 2019, 32, .	5.7	65
767	Phenotypic Evidence of T Cell Exhaustion and Senescence During Symptomatic <i>Plasmodium falciparum</i> Malaria. <i>Frontiers in Immunology</i> , 2019, 10, 1345.	2.2	25
768	High therapeutic efficacy of artemetherâ€“lumefantrine and dihydroartemisininâ€“piperazine for the treatment of uncomplicated <i>falciparum</i> malaria in Somalia. <i>Malaria Journal</i> , 2019, 18, 231.	0.8	21
769	In vitro and in vivo characterization of anti-malarial acylphenoxazine derivatives prepared from basic blue 3. <i>Malaria Journal</i> , 2019, 18, 237.	0.8	3
770	Elucidating Mechanisms of Drug-Resistant <i>Plasmodium falciparum</i> . <i>Cell Host and Microbe</i> , 2019, 26, 35-47.	5.1	85
771	Five Solid Forms of a Potent Imidazopyridazine Antimalarial Drug Lead: A Preformulation Study. <i>Crystal Growth and Design</i> , 2019, 19, 4683-4697.	1.4	8
772	Evolution and expansion of multidrug-resistant malaria in southeast Asia: a genomic epidemiology study. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 943-951.	4.6	219
773	Accelerated evolution and spread of multidrug-resistant <i>Plasmodium falciparum</i> takes down the latest first-line antimalarial drug in southeast Asia. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 916-917.	4.6	27
774	Decreased <i>In Vitro</i> Artemisinin Sensitivity of <i>Plasmodium falciparum</i> across India. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	14
775	Determinants of dihydroartemisinin-piperazine treatment failure in <i>Plasmodium falciparum</i> malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 952-961.	4.6	252
776	Marine Microbiome as a Source of Antimalarials. <i>Tropical Medicine and Infectious Disease</i> , 2019, 4, 103.	0.9	5
777	Spatiotemporal epidemiology, environmental correlates, and demography of malaria in Tak Province, Thailand (2012â€“2015). <i>Malaria Journal</i> , 2019, 18, 240.	0.8	23
778	Antimalarial drug resistance in Africa: the calm before the storm?. <i>Lancet Infectious Diseases</i> , The, 2019, 19, e338-e351.	4.6	167
779	Genetic diversity and drug resistance surveillance of <i>Plasmodium falciparum</i> for malaria elimination: is there an ideal tool for resource-limited sub-Saharan Africa?. <i>Malaria Journal</i> , 2019, 18, 217.	0.8	46
780	Safety and tolerability of single low-dose primaquine in a low-intensity transmission area in South Africa: an open-label, randomized controlled trial. <i>Malaria Journal</i> , 2019, 18, 209.	0.8	18
781	The effect of dose on the antimalarial efficacy of artesunate-mefloquine against <i>Plasmodium falciparum</i> malaria: a protocol for systematic review and individual patient data (IPD) meta-analysis. <i>BMJ Open</i> , 2019, 9, e027738.	0.8	4
782	Malaria Control and Elimination. <i>Methods in Molecular Biology</i> , 2019, , .	0.4	2
783	Sampling Adult Populations of Anopheles Mosquitoes. <i>Methods in Molecular Biology</i> , 2019, 2013, 233-285.	0.4	2

#	ARTICLE	IF	CITATIONS
784	Plasmodium falciparum In Vitro Drug Resistance Selections and Gene Editing. <i>Methods in Molecular Biology</i> , 2019, 2013, 123-140.	0.4	21
785	In Vivo Assessments to Detect Antimalarial Resistance. <i>Methods in Molecular Biology</i> , 2019, 2013, 105-121.	0.4	1
786	Polyunsaturated fatty acids promote <i>Plasmodium falciparum</i> gametocytogenesis. <i>Biology Open</i> , 2019, 8, .	0.6	11
787	Ozonide Antimalarials Alkylate Heme in the Malaria Parasite <i>Plasmodium falciparum</i> . <i>ACS Infectious Diseases</i> , 2019, 5, 2076-2086.	1.8	16
788	Pairwise growth competitions identify relative fitness relationships among artemisinin resistant <i>Plasmodium falciparum</i> field isolates. <i>Malaria Journal</i> , 2019, 18, 295.	0.8	30
789	Absence of kelch13 artemisinin resistance markers but strong selection for lumefantrine-tolerance molecular markers following 18 years of artemisinin-based combination therapy use in Mpumalanga Province, South Africa (2001–2018). <i>Malaria Journal</i> , 2019, 18, 280.	0.8	18
790	Sulfide, sulfoxide and sulfone bridged acyclic nucleoside phosphonates as inhibitors of the <i>Plasmodium falciparum</i> and human 6-oxopurine phosphoribosyltransferases: Synthesis and evaluation. <i>European Journal of Medicinal Chemistry</i> , 2019, 183, 111667.	2.6	12
791	Profiles of Kelch mutations in <i>Plasmodium falciparum</i> across South Asia and their implications for tracking drug resistance. <i>International Journal for Parasitology: Drugs and Drug Resistance</i> , 2019, 11, 49-58.	1.4	26
792	Genetic mapping of fitness determinants across the malaria parasite <i>Plasmodium falciparum</i> life cycle. <i>PLoS Genetics</i> , 2019, 15, e1008453.	1.5	33
793	Biochemical characterization of <i>Plasmodium falciparum</i> parasite specific helicase 1 (PfPSH1). <i>FEBS Open Bio</i> , 2019, 9, 1909-1927.	1.0	3
794	South African Abietane Diterpenoids and Their Analogs as Potential Antimalarials: Novel Insights from Hybrid Computational Approaches. <i>Molecules</i> , 2019, 24, 4036.	1.7	6
795	Artemisinin Bioactivity and Resistance in Malaria Parasites. <i>Trends in Parasitology</i> , 2019, 35, 953-963.	1.5	80
796	Advances in omics-based methods to identify novel targets for malaria and other parasitic protozoan infections. <i>Genome Medicine</i> , 2019, 11, 63.	3.6	54
797	<i>Plasmodium falciparum</i> Kelch Propeller Polymorphisms in Clinical Isolates from Ghana from 2007 to 2016. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	25
798	Artesunate activation by heme in an aqueous medium. <i>Inorganica Chimica Acta</i> , 2019, 496, 119029.	1.2	5
800	Are k13 and plasmepsin II genes, involved in <i>Plasmodium falciparum</i> resistance to artemisinin derivatives and piperazine in Southeast Asia, reliable to monitor resistance surveillance in Africa?. <i>Malaria Journal</i> , 2019, 18, 285.	0.8	14
801	Deployment and utilization of next-generation sequencing of <i>Plasmodium falciparum</i> to guide anti-malarial drug policy decisions in sub-Saharan Africa: opportunities and challenges. <i>Malaria Journal</i> , 2019, 18, 267.	0.8	21
802	K-13 propeller gene polymorphisms isolated between 2014 and 2017 from Cameroonian <i>Plasmodium falciparum</i> malaria patients. <i>PLoS ONE</i> , 2019, 14, e0221895.	1.1	17

#	ARTICLE	IF	CITATIONS
803	Malaria eradication within a generation: ambitious, achievable, and necessary. <i>Lancet</i> , The, 2019, 394, 1056-1112.	6.3	240
804	Dengue and chikungunya among outpatients with acute undifferentiated fever in Kinshasa, Democratic Republic of Congo: A cross-sectional study. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007047.	1.3	38
805	Persistence of High In Vivo Efficacy and Safety of Artesunate–Amodiaquine and Artemether–Lumefantrine as the First- and Second-Line Treatments for Uncomplicated <i>Plasmodium falciparum</i> Malaria 10 Years After Their Implementation in Gabon. <i>Acta Parasitologica</i> , 2019, 64, 898-902.	0.4	3
806	Reduction of malaria vector mosquitoes in a large-scale intervention trial in rural Burkina Faso using Bti based larval source management. <i>Malaria Journal</i> , 2019, 18, 311.	0.8	28
807	Development of Chemical Entities Endowed with Potent Fast-Killing Properties against <i>Plasmodium falciparum</i> Malaria Parasites. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 9217-9235.	2.9	26
808	Rare mutations in <i>Pfmdr1</i> gene of <i>Plasmodium falciparum</i> detected in clinical isolates from patients treated with anti-malarial drug in Nigeria. <i>Malaria Journal</i> , 2019, 18, 319.	0.8	15
809	Genetic Variations Associated with Drug Resistance Markers in Asymptomatic <i>Plasmodium falciparum</i> Infections in Myanmar. <i>Genes</i> , 2019, 10, 692.	1.0	20
810	A systematic review on anti-malarial drug discovery and antiplasmodial potential of green synthesis mediated metal nanoparticles: overview, challenges and future perspectives. <i>Malaria Journal</i> , 2019, 18, 337.	0.8	18
811	Triple artemisinin-containing combination anti-malarial treatments should be implemented now to delay the emergence of resistance: the case against. <i>Malaria Journal</i> , 2019, 18, 339.	0.8	18
812	Low polymorphisms in <i>pfact</i> , <i>pfugt</i> and <i>pfcarl</i> genes in African <i>Plasmodium falciparum</i> isolates and absence of association with susceptibility to common anti-malarial drugs. <i>Malaria Journal</i> , 2019, 18, 293.	0.8	1
813	<i>Plasmodium falciparum</i> : Multidrug resistance. <i>Chemical Biology and Drug Design</i> , 2019, 93, 737-759.	1.5	36
814	New hybrid trifluoromethylquinolines as antiplasmodium agents. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 1002-1008.	1.4	24
815	Association of mutations in the <i>Plasmodium falciparum</i> <i>Kelch13</i> gene (<i>Pf3D7_1343700</i>) with parasite clearance rates after artemisinin-based treatments—a WWARN individual patient data meta-analysis. <i>BMC Medicine</i> , 2019, 17, 1.	2.3	465
816	Malaria parasite clearance rate regression: an R software package for a Bayesian hierarchical regression model. <i>Malaria Journal</i> , 2019, 18, 4.	0.8	7
817	Malaria Resurgence in the Americas: An Underestimated Threat. <i>Pathogens</i> , 2019, 8, 11.	1.2	16
818	Disruption of Apicoplast Biogenesis by Chemical Stabilization of an Imported Protein Evades the Delayed-Death Phenotype in Malaria Parasites. <i>MSphere</i> , 2019, 4, .	1.3	13
819	Artemisinin Resistance in Eastern India. <i>Clinical Infectious Diseases</i> , 2019, 69, 1153-1155.	2.9	6
820	The promise, problems and pitfalls of mass drug administration for malaria elimination: a qualitative study with scientists and policymakers. <i>International Health</i> , 2019, 11, 166-176.	0.8	27

#	ARTICLE	IF	CITATIONS
821	Artemisinin Resistance and Stage Dependency of Parasite Clearance in Falciparum Malaria. Journal of Infectious Diseases, 2019, 219, 1483-1489.	1.9	25
822	Sequential Open-Label Study of the Safety, Tolerability, and Pharmacokinetic Interactions between Dihydroartemisinin-Piperaquine and Mefloquine in Healthy Thai Adults. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	9
823	Detection of Single-Nucleotide Polymorphism Markers of Antimalarial Drug Resistance Directly from Whole Blood. Journal of Molecular Diagnostics, 2019, 21, 623-631.	1.2	9
824	Multiple-Strain Malaria Infection and Its Impacts on Plasmodium falciparum Resistance to Antimalarial Therapy: A Mathematical Modelling Perspective. Computational and Mathematical Methods in Medicine, 2019, 2019, 1-26.	0.7	5
825	Genomic structure and diversity of Plasmodium falciparum in Southeast Asia reveal recent parasite migration patterns. Nature Communications, 2019, 10, 2665.	5.8	46
826	<p>High adherence level to artemisinin-based combination therapies in rural settlement 11 years after their introduction in the health system, Nanoro, Burkina Faso</p>. Patient Preference and Adherence, 2019, Volume 13, 371-380.	0.8	4
827	Artemisinin-Resistant Malaria as a Global Catastrophic Biological Threat. Current Topics in Microbiology and Immunology, 2019, 424, 33-57.	0.7	6
828	Prospects and strategies for malaria elimination in the Greater Mekong Sub-region: a qualitative study. Malaria Journal, 2019, 18, 203.	0.8	29
829	Optimisation of artemisinin and scopoletin extraction from Artemisia annua with a new modern pressurised cyclic solidâ€“liquid (PCSL) extraction technique. Phytochemical Analysis, 2019, 30, 564-571.	1.2	9
830	Reply to Velavan et al.: Polymorphisms of pfcoroninin natural populations: Implications for functional significance. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 12613-12614.	3.3	5
831	Ozonide Antimalarial Activity in the Context of Artemisinin-Resistant Malaria. Trends in Parasitology, 2019, 35, 529-543.	1.5	40
832	Covalent Plasmodium falciparum-selective proteasome inhibitors exhibit a low propensity for generating resistance in vitro and synergize with multiple antimalarial agents. PLoS Pathogens, 2019, 15, e1007722.	2.1	58
833	Artemisinin-Based Antimalarial Drug Therapy: Molecular Pharmacology and Evolving Resistance. Tropical Medicine and Infectious Disease, 2019, 4, 89.	0.9	30
834	Naturally acquired immunity against immature <i>Plasmodium falciparum</i> gametocytes. Science Translational Medicine, 2019, 11, .	5.8	31
835	Improvement of Asparagine Ethylenediamines as Anti-malarial <i>Plasmodium</i>-Selective Proteasome Inhibitors. Journal of Medicinal Chemistry, 2019, 62, 6137-6145.	2.9	28
836	Kelch 13 propeller gene polymorphism among Plasmodium falciparum isolates in Lagos, Nigeria: Molecular Epidemiologic Study. Tropical Medicine and International Health, 2019, 24, 1011-1017.	1.0	8
837	Characterization of P. falciparum dipeptidyl aminopeptidase 3 specificity identifies differences in amino acid preferences between peptideâ€“based substrates and covalent inhibitors. FEBS Journal, 2019, 286, 3998-4023.	2.2	7
838	Malaria today: advances in management and control. Tropical Doctor, 2019, 49, 160-164.	0.2	4

#	ARTICLE	IF	CITATIONS
839	Modulation of in vitro antimalarial responses by polymorphisms in Plasmodium falciparum ABC transporters (pfmdr1 and pfmdr5). <i>Acta Tropica</i> , 2019, 196, 126-134.	0.9	5
840	Community engagement, social context and coverage of mass anti-malarial administration: Comparative findings from multi-site research in the Greater Mekong sub-Region. <i>PLoS ONE</i> , 2019, 14, e0214280.	1.1	45
841	Plants with antimalarial properties: A systematic review of the current clinical evidence. <i>European Journal of Integrative Medicine</i> , 2019, 28, 76-85.	0.8	1
842	Evolution and Genetic Diversity of the <i>K13</i> Gene Associated with Artemisinin Delayed Parasite Clearance in Plasmodium falciparum. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	15
843	Contribution of Functional Antimalarial Immunity to Measures of Parasite Clearance in Therapeutic Efficacy Studies of Artemisinin Derivatives. <i>Journal of Infectious Diseases</i> , 2019, 220, 1178-1187.	1.9	21
844	Development of artemisinin resistance in malaria therapy. <i>Pharmacological Research</i> , 2019, 146, 104275.	3.1	34
845	Data management and sharing policy: the first step towards promoting data sharing. <i>BMC Medicine</i> , 2019, 17, 80.	2.3	41
846	In vitro susceptibility of Plasmodium falciparum isolates from the China-Myanmar border area to artemisinins and correlation with K13 mutations. <i>International Journal for Parasitology: Drugs and Drug Resistance</i> , 2019, 10, 20-27.	1.4	20
847	A Temporizing Solution to "Artemisinin Resistance". <i>New England Journal of Medicine</i> , 2019, 380, 2087-2089.	13.9	69
848	Investigation and Evaluation of Genetic Diversity of Plasmodium falciparum Kelch 13 Polymorphisms Imported From Southeast Asia and Africa in Southern China. <i>Frontiers in Public Health</i> , 2019, 7, 95.	1.3	13
849	Marine natural products as strategic prototypes in the development of a new generation of antimalarial agents. , 2019, , 7-47.		3
850	Polymorphisms in Plasmodium falciparum Kelch 13 and P. vivax Kelch 12 Genes in Parasites Collected from Three South Pacific Countries Prior to Extensive Exposure to Artemisinin Combination Therapies. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	5
851	Global Spread of Mutant PfCRT and Its Pleiotropic Impact on Plasmodium falciparum Multidrug Resistance and Fitness. <i>MBio</i> , 2019, 10, .	1.8	35
852	Absence of K13 gene mutations among artesunate/sulfadoxine-pyrimethamine treatment failures of Sudanese Plasmodium falciparum isolates from Damazin, southeast Sudan. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2019, 113, 428-430.	0.7	4
853	Polymorphisms in Pvk12 and gene amplification of Pvplasmepsin4 in Plasmodium vivax from Thailand, Lao PDR and Cambodia. <i>Malaria Journal</i> , 2019, 18, 114.	0.8	4
854	Artemisinin resistance-associated markers in Plasmodium falciparum parasites from the China-Myanmar border: predicted structural stability of K13 propeller variants detected in a low-prevalence area. <i>PLoS ONE</i> , 2019, 14, e0213686.	1.1	18
855	Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated malaria and prevalence of Pfk13 and Pfmdr1 polymorphisms after a decade of using artemisinin-based combination therapy in mainland Tanzania. <i>Malaria Journal</i> , 2019, 18, 88.	0.8	40
856	Emerging Challenges and Opportunities in Infectious Disease Epidemiology. <i>American Journal of Epidemiology</i> , 2019, 188, 873-882.	1.6	14

#	ARTICLE	IF	CITATIONS
857	Efficacy of artemetherâ€“lumefantrine versus dihydroartemisininâ€“piperazine for the treatment of uncomplicated malaria among children in Rwanda: an open-label, randomized controlled trial. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2019, 113, 312-319.	0.7	11
858	Application of In Silico Drug Repurposing in Infectious Diseases. , 2019, , 427-462.		0
859	K13-propeller gene polymorphisms in <i>Plasmodium falciparum</i> parasite population in malaria affected countries: a systematic review of prevalence and risk factors. <i>Malaria Journal</i> , 2019, 18, 60.	0.8	32
860	An Experimental Human Blood-Stage Model for Studying <i>Plasmodium malariae</i> Infection. <i>Journal of Infectious Diseases</i> , 2020, 221, 948-955.	1.9	18
861	More on Artemisinin-Resistant <i>Plasmodium falciparum</i> in Eastern India. <i>New England Journal of Medicine</i> , 2019, 380, e14.	13.9	3
862	How can interventions that target forest-goers be tailored to accelerate malaria elimination in the Greater Mekong Subregion? A systematic review of the qualitative literature. <i>Malaria Journal</i> , 2019, 18, 32.	0.8	57
863	Imported malaria: key messages in an era of elimination. <i>Clinical Medicine</i> , 2019, 19, 153-156.	0.8	2
864	High cure rates and tolerability of artesunateâ€“amodiaquine and dihydroartemisininâ€“piperazine for the treatment of uncomplicated <i>falciparum</i> malaria in Kibaha and Kigoma, Tanzania. <i>Malaria Journal</i> , 2019, 18, 99.	0.8	13
865	Transmission-Blocking Vaccines: Old Friends and New Prospects. <i>Infection and Immunity</i> , 2019, 87, .	1.0	32
866	Cocrystal and Salt Forms of an Imidazopyridazine Antimalarial Drug Lead. <i>Journal of Pharmaceutical Sciences</i> , 2019, 108, 2349-2357.	1.6	13
867	Disordered Metabolic Profiling in Plasma and Tissues of Mice Infected with Artemisinin-Sensitive and -Resistant <i>Plasmodium berghei</i> K173 Determined by ¹ H NMR Spectroscopy. <i>Journal of Proteome Research</i> , 2019, 18, 1970-1993.	1.8	8
868	Horizontal Cell Biology: Monitoring Global Changes of Protein Interaction States with the Proteome-Wide Cellular Thermal Shift Assay (CETSA). <i>Annual Review of Biochemistry</i> , 2019, 88, 383-408.	5.0	83
869	Clinical impact of the two ART resistance markers, K13 gene mutations and DPC3 in Vietnam. <i>PLoS ONE</i> , 2019, 14, e0214667.	1.1	11
870	Identification of Bis-Cyclic Guanidines as Antiplasmodial Compounds from Positional Scanning Mixture-Based Libraries. <i>Molecules</i> , 2019, 24, 1100.	1.7	7
871	Synthesis and structure-activity relationships for new 6-fluoroquinoline derivatives with antiplasmodial activity. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 2052-2065.	1.4	11
872	Viability Screen of LOPAC ¹²⁸⁰ Reveals Tyrosine Kinase Inhibitor Tyrphostin A9 as a Novel Partner Drug for Artesunate Combinations To Target the <i>Plasmodium falciparum</i> Ring Stage. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	2
873	Are malaria elimination efforts on right track? An analysis of gains achieved and challenges ahead. <i>Infectious Diseases of Poverty</i> , 2019, 8, 14.	1.5	92
874	The impact of targeted malaria elimination with mass drug administrations on <i>falciparum</i> malaria in Southeast Asia: A cluster randomised trial. <i>PLoS Medicine</i> , 2019, 16, e1002745.	3.9	105

#	ARTICLE	IF	CITATIONS
875	Current Challenges in the Management of Sepsis in ICUs in Resource-Poor Settings and Suggestions for the Future. , 2019, , 1-24.		4
876	Plasmodium falciparum specific helicase 2 is a dual, bipolar helicase and is crucial for parasite growth. Scientific Reports, 2019, 9, 1519.	1.6	5
877	Accessibility of substituted cysteines in TM2 and TM10 transmembrane segments in the Plasmodium falciparum equilibrative nucleoside transporter PfENT1. Journal of Biological Chemistry, 2019, 294, 1924-1935.	1.6	3
878	Immune Responses to the Sexual Stages of Plasmodium falciparum Parasites. Frontiers in Immunology, 2019, 10, 136.	2.2	17
879	Identification of Antimalarial Compounds That Require CLAG3 for Their Uptake by Plasmodium falciparum-Infected Erythrocytes. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	17
880	Baseline Ex Vivo and Molecular Responses of Plasmodium falciparum Isolates to Piperaquine before Implementation of Dihydroartemisinin-Piperaquine in Senegal. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	10
881	Association of high Plasmodium falciparum parasite densities with polyclonal microscopic infections in asymptomatic children from Toubacouta, Senegal. Malaria Journal, 2019, 18, 48.	0.8	9
882	Targeting malaria parasite invasion of red blood cells as an antimalarial strategy. FEMS Microbiology Reviews, 2019, 43, 223-238.	3.9	56
883	Artesunate compared with quinine for the treatment of severe malaria in adult patients managed in an intensive care unit: A retrospective observational study. Southern African Journal of Critical Care, 2019, 35, 12.	0.2	0
884	The resistome and genomic reconnaissance in the age of malaria elimination. DMM Disease Models and Mechanisms, 2019, 12, .	1.2	10
885	Modification of PfPAP2 ^{1/4} and PfUBP1 Markedly Reduces Ring-Stage Susceptibility of Plasmodium falciparum to Artemisinin In Vitro. Antimicrobial Agents and Chemotherapy, 2019, 64, .	1.4	45
886	No Evidence of Plasmodium falciparum K13 Artemisinin Resistance-Confering Mutations over a 24-Year Analysis in Coastal Kenya but a Near Complete Reversion to Chloroquine-Sensitive Parasites. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	26
887	Fiebre en el viajero retornado del trpico. Medicina Clnica, 2019, 153, 205-212.	0.3	4
888	The Diversity of the Plasmodium falciparum K13 Propeller Domain Did Not Increase after Implementation of Artemisinin-Based Combination Therapy in Uganda. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	9
889	New Molecular Targets and Strategies for Antimalarial Discovery. Current Medicinal Chemistry, 2019, 26, 4380-4402.	1.2	16
890	Safety and effectiveness of apheresis in the treatment of infectious diseases: A systematic review. Journal of Infection, 2019, 79, 513-520.	1.7	7
891	Artemether for severe malaria. The Cochrane Library, 2019, 6, CD010678.	1.5	24
892	A comprehensive analysis of drug resistance molecular markers and Plasmodium falciparum genetic diversity in two malaria endemic sites in Mali. Malaria Journal, 2019, 18, 361.	0.8	25

#	ARTICLE	IF	CITATIONS
893	Chalcones as a basis for computer-aided drug design: innovative approaches to tackle malaria. <i>Future Medicinal Chemistry</i> , 2019, 11, 2635-2646.	1.1	4
894	Identification of Plasmodium dipeptidyl aminopeptidase allosteric inhibitors by high throughput screening. <i>PLoS ONE</i> , 2019, 14, e0226270.	1.1	7
895	Adherence to the referral advice after introduction of rectal artesunate for pre-referral treatment of severe malaria at the community level: a noninferiority trial in the Democratic Republic of the Congo. <i>Malaria Journal</i> , 2019, 18, 438.	0.8	17
896	In vitro anti-malarial efficacy of chalcones: cytotoxicity profile, mechanism of action and their effect on erythrocytes. <i>Malaria Journal</i> , 2019, 18, 421.	0.8	46
897	Typhoidal Salmonella human challenge studies: ethical and practical challenges and considerations for low-resource settings. <i>Trials</i> , 2019, 20, 704.	0.7	6
898	Forest work and its implications for malaria elimination: a qualitative study. <i>Malaria Journal</i> , 2019, 18, 376.	0.8	35
899	Rubber plantations and drug resistant malaria: a cross-sectional survey in Cambodia. <i>Malaria Journal</i> , 2019, 18, 379.	0.8	8
900	Global Catastrophic Biological Risks. <i>Current Topics in Microbiology and Immunology</i> , 2019, , .	0.7	1
901	Anti-malarial ozonides OZ439 and OZ609 tested at clinically relevant compound exposure parameters in a novel ring-stage survival assay. <i>Malaria Journal</i> , 2019, 18, 427.	0.8	13
902	Terminalia albidia treatment improves survival in experimental cerebral malaria through reactive oxygen species scavenging and anti-inflammatory properties. <i>Malaria Journal</i> , 2019, 18, 431.	0.8	21
903	The genomic architecture of antimalarial drug resistance. <i>Briefings in Functional Genomics</i> , 2019, 18, 314-328.	1.3	66
904	Prevalence of asymptomatic malaria parasitaemia following mass testing and treatment in Pakro sub-district of Ghana. <i>BMC Public Health</i> , 2019, 19, 1622.	1.2	13
905	Integrative Multi-Kinase Approach for the Identification of Potent Antiplasmodial Hits. <i>Frontiers in Chemistry</i> , 2019, 7, 773.	1.8	19
906	NONE TOO S.M.A. <sc>LL</sc>: the global challenge of severe malarial anaemia and its transfusion support. <i>ISBT Science Series</i> , 2019, 14, 9-17.	1.1	0
907	Overexpression of plasmepsin II and plasmepsin III does not directly cause reduction in Plasmodium falciparum sensitivity to artesunate, chloroquine and piperazine. <i>International Journal for Parasitology: Drugs and Drug Resistance</i> , 2019, 9, 16-22.	1.4	32
908	Changing Molecular Markers of Antimalarial Drug Sensitivity across Uganda. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	39
909	Fast-Acting Small Molecules Targeting Malarial Aspartyl Proteases, Plasmepsins, Inhibit Malaria Infection at Multiple Life Stages. <i>ACS Infectious Diseases</i> , 2019, 5, 184-198.	1.8	16
910	Novel pfkelch13 Gene Polymorphism Associates With Artemisinin Resistance in Eastern India. <i>Clinical Infectious Diseases</i> , 2019, 69, 1144-1152.	2.9	59

#	ARTICLE	IF	CITATIONS
911	Plasmodium PK9 Inhibitors Promote Growth of Liver-Stage Parasites. <i>Cell Chemical Biology</i> , 2019, 26, 411-419.e7.	2.5	11
912	Artemisinin, the Magic Drug Discovered from Traditional Chinese Medicine. <i>Engineering</i> , 2019, 5, 32-39.	3.2	107
913	Plasmodium genomics: an approach for learning about and ending human malaria. <i>Parasitology Research</i> , 2019, 118, 1-27.	0.6	45
914	Optimization and validation of extraction and quantification methods of antimalarial triterpenic esters in <i>Keetia leucantha</i> plant and plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2019, 1104, 109-118.	1.2	3
915	Current scenario and future strategies to fight artemisinin resistance. <i>Parasitology Research</i> , 2019, 118, 29-42.	0.6	11
916	Diversity and biting patterns of <i>Anopheles</i> species in a malaria endemic area, Umphang Valley, Tak Province, western Thailand. <i>Acta Tropica</i> , 2019, 190, 183-192.	0.9	16
917	Synthesis of new betulinic acid/betulin-derived dimers and hybrids with potent antimalarial and antiviral activities. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 110-115.	1.4	43
918	N-Substituted aminoquinoline-pyrimidine hybrids: Synthesis, <i>in vitro</i> antimalarial activity evaluation and docking studies. <i>European Journal of Medicinal Chemistry</i> , 2019, 162, 277-289.	2.6	37
919	Comparative Efficacy of Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Malaria in Ugandan Children. <i>Journal of Infectious Diseases</i> , 2019, 219, 1112-1120.	1.9	30
920	Unpacking the Pathogen Box—An Open Source Tool for Fighting Neglected Tropical Disease. <i>ChemMedChem</i> , 2019, 14, 386-453.	1.6	46
921	Antimalarial Pyrido[1,2-a]benzimidazole Derivatives with Mannich Base Side Chains: Synthesis, Pharmacological Evaluation, and Reactive Metabolite Trapping Studies. <i>ACS Infectious Diseases</i> , 2019, 5, 372-384.	1.8	22
922	Evaluation of 4-Amino 2-Anilinoquinazolines against <i>Plasmodium</i> and Other Apicomplexan Parasites <i>In Vitro</i> and in a <i>P. falciparum</i> Humanized NOD- β 2M ^{-/-} Mouse Model of Malaria. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	12
923	8-Aminoquinolines with an Aminoxyalkyl Side Chain Exert <i>in vitro</i> Dual-Stage Antiplasmodial Activity. <i>ChemMedChem</i> , 2019, 14, 501-511.	1.6	6
924	Potential of Vitamin E Deficiency, Induced by Inhibition of α -Tocopherol Efflux, in Murine Malaria Infection. <i>International Journal of Molecular Sciences</i> , 2019, 20, 64.	1.8	13
925	Mass Drug Administration to Control and Eliminate Malaria in Africa: How Do We Best Utilize the Tools at Hand?. <i>Clinical Infectious Diseases</i> , 2019, 69, 287-289.	2.9	2
926	Theoretical Evaluation of the Reaction Mechanism of Serine Hydroxymethyltransferase. <i>Journal of Physical Chemistry B</i> , 2019, 123, 407-418.	1.2	6
927	Hydroxamic Acid Inhibitors Provide Cross-Species Inhibition of <i>Plasmodium</i> M1 and M17 Aminopeptidases. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 622-640.	2.9	30
928	Multistage Antiplasmodium Activity of Astemizole Analogues and Inhibition of Hemozoin Formation as a Contributor to Their Mode of Action. <i>ACS Infectious Diseases</i> , 2019, 5, 303-315.	1.8	16

#	ARTICLE	IF	CITATIONS
929	Design, synthesis, and antiplasmodial evaluation of a series of novel sulfoximine analogues of carbohydrate-based thiochromans. <i>Chemical Biology and Drug Design</i> , 2019, 93, 254-261.	1.5	10
930	Transitional Complexity of Health Information System of Systems: Managing by the Engineering Systems Multiple-Domain Modeling Approach. <i>IEEE Systems Journal</i> , 2019, 13, 952-963.	2.9	10
931	Management of severe imported malaria in adults. <i>Médecine Et Maladies Infectieuses</i> , 2020, 50, 213-225.	5.1	13
932	Efficacy and resistance of different artemisinin-based combination therapies: a systematic review and network meta-analysis. <i>Parasitology International</i> , 2020, 74, 101919.	0.6	23
933	Artesunate Versus Quinine: Keeping Our Options Open. <i>Clinical Infectious Diseases</i> , 2020, 70, 288-289.	2.9	2
934	Management and prevention of imported malaria in children. Update of the French guidelines. <i>Médecine Et Maladies Infectieuses</i> , 2020, 50, 127-140.	5.1	20
935	Importance of kelch 13 C580Y mutation in the studies of artemisinin resistance in <i>Plasmodium falciparum</i> in Greater Mekong Subregion. <i>Journal of Microbiology, Immunology and Infection</i> , 2020, 53, 676-681.	1.5	8
936	Isolation and characterization of antiprotozoal compound-producing <i>Streptomyces</i> species from Mongolian soils. <i>Parasitology International</i> , 2020, 74, 101961.	0.6	19
937	Combining antimalarial drugs and vaccine for malaria elimination campaigns: a randomized safety and immunogenicity trial of RTS,S/AS01 administered with dihydroartemisinin, piperaquine, and primaquine in healthy Thai adult volunteers. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 33-41.	1.4	9
938	Changes in malaria epidemiology in France and worldwide, 2000-2015. <i>Médecine Et Maladies Infectieuses</i> , 2020, 50, 99-112.	5.1	19
939	Structure-Activity Relationship Studies of a Novel Class of Transmission Blocking Antimalarials Targeting Male Gametes. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 2240-2262.	2.9	11
940	Hybrid molecules with potential in vitro antiplasmodial and in vivo antimalarial activity against drug-resistant <i>Plasmodium falciparum</i> . <i>Medicinal Research Reviews</i> , 2020, 40, 931-971.	5.0	50
941	Improving the immunogenicity and protective efficacy of a whole-killed malaria blood-stage vaccine by chloroquine. <i>Parasite Immunology</i> , 2020, 42, e12682.	0.7	3
942	Antiplasmodial Bis-Indole Alkaloids from the Bark of <i>Flindersia pimenteliana</i> . <i>Planta Medica</i> , 2020, 86, 19-25.	0.7	6
943	Falcipain cysteine proteases of malaria parasites: An update. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2020, 1868, 140362.	1.1	32
944	Ethnopharmacological survey of herbal remedies used for treating malaria in Yemen. <i>Journal of Herbal Medicine</i> , 2020, 21, 100332.	1.0	3
945	In vivo/ex vivo efficacy of artemether-lumefantrine and artesunate-amodiaquine as first-line treatment for uncomplicated <i>falciparum</i> malaria in children: an open label randomized controlled trial in Burkina Faso. <i>Malaria Journal</i> , 2020, 19, 8.	0.8	17
946	Impact of Field Isolate Identified Nonsynonymous Single Nucleotide Polymorphisms on <i>Plasmodium falciparum</i> Equilibrative Nucleoside Transporter 1 Inhibitor Efficacy. <i>ACS Infectious Diseases</i> , 2020, 6, 205-214.	1.8	2

#	ARTICLE	IF	CITATIONS
947	Detecting sequence variants in clinically important protozoan parasites. <i>International Journal for Parasitology</i> , 2020, 50, 1-18.	1.3	2
948	Identification of Selective Inhibitors of <i>Plasmodium</i> N-Myristoyltransferase by High-Throughput Screening. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 591-600.	2.9	17
949	A preformulation co-crystal screening case study: Polymorphic co-crystals of an imidazopyridazine antimalarial drug lead with the cofomer succinic acid. <i>Journal of Molecular Structure</i> , 2020, 1204, 127561.	1.8	7
950	DeepMalaria: Artificial Intelligence Driven Discovery of Potent Antiplasmodials. <i>Frontiers in Pharmacology</i> , 2019, 10, 1526.	1.6	47
951	Design, synthesis, heme binding and density functional theory studies of isoindoline-dione-4-aminoquinolines as potential antiplasmodials. <i>Future Medicinal Chemistry</i> , 2020, 12, 193-205.	1.1	12
952	Impact of Three-Year Intermittent Preventive Treatment Using Artemisinin-Based Combination Therapies on Malaria Morbidity in Malian Schoolchildren. <i>Tropical Medicine and Infectious Disease</i> , 2020, 5, 148.	0.9	6
953	Comparison of leucocyte profiles between healthy children and those with asymptomatic and symptomatic <i>Plasmodium falciparum</i> infections. <i>Malaria Journal</i> , 2020, 19, 364.	0.8	7
954	Absence of association between polymorphisms in the pfcoronin and pfk13 genes and the presence of <i>Plasmodium falciparum</i> parasites after treatment with artemisinin derivatives in Senegal. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106190.	1.1	11
955	Global estimation of anti-malarial drug effectiveness for the treatment of uncomplicated <i>Plasmodium falciparum</i> malaria 1991–2019. <i>Malaria Journal</i> , 2020, 19, 374.	0.8	18
956	A comprehensive RNA handling and transcriptomics guide for high-throughput processing of <i>Plasmodium</i> blood-stage samples. <i>Malaria Journal</i> , 2020, 19, 363.	0.8	19
957	Retargeting azithromycin analogues to have dual-modality antimalarial activity. <i>BMC Biology</i> , 2020, 18, 133.	1.7	13
958	The gut microbiome, immunity, and <i>Plasmodium</i> severity. <i>Current Opinion in Microbiology</i> , 2020, 58, 56-61.	2.3	10
959	Efficacy and Safety of a Naphthoquine-Azithromycin Co-Formulation for Malaria Prophylaxis in Southeast Asia: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial. <i>Clinical Infectious Diseases</i> , 2020, 73, e2470-e2476.	2.9	4
960	Advances and roadblocks in the treatment of malaria. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 374-382.	1.1	36
961	K13, the Cytostome, and Artemisinin Resistance. <i>Trends in Parasitology</i> , 2020, 36, 533-544.	1.5	54
962	Polymorphisms of pfcrt, pfmdr1, and K13-propeller genes in imported <i>falciparum</i> malaria isolates from Africa in Guizhou province, China. <i>BMC Infectious Diseases</i> , 2020, 20, 513.	1.3	3
963	Identification of compounds active against quiescent artemisinin-resistant <i>Plasmodium falciparum</i> parasites via the quiescent-stage survival assay (QSA). <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2826-2834.	1.3	14
964	Associations between Aminoquinoline Resistance Genotypes and Clinical Presentations of <i>Plasmodium falciparum</i> Infection in Uganda. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	3

#	ARTICLE	IF	CITATIONS
965	From control to elimination: a spatial-temporal analysis of malaria along the China-Myanmar border. <i>Infectious Diseases of Poverty</i> , 2020, 9, 158.	1.5	15
966	<i>Plasmodium berghei</i> K13 Mutations Mediate <i>In Vivo</i> Artemisinin Resistance That Is Reversed by Proteasome Inhibition. <i>MBio</i> , 2020, 11, .	1.8	15
967	Kelch 13-propeller polymorphisms in <i>Plasmodium falciparum</i> from Jazan region, southwest Saudi Arabia. <i>Malaria Journal</i> , 2020, 19, 397.	0.8	3
968	Arthropod-Borne Disease Control at a Glance: What's New on Drug Development?. <i>Molecules</i> , 2020, 25, 5175.	1.7	4
969	Molecular detection of drug resistant polymorphisms in <i>Plasmodium falciparum</i> isolates from Southwest, Nigeria. <i>BMC Research Notes</i> , 2020, 13, 497.	0.6	7
970	Molecular epidemiology of resistance to antimalarial drugs in the Greater Mekong subregion: an observational study. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 1470-1480.	4.6	94
971	K13-Mediated Reduced Susceptibility to Artemisinin in <i>Plasmodium falciparum</i> Is Overlaid on a Trait of Enhanced DNA Damage Repair. <i>Cell Reports</i> , 2020, 32, 107996.	2.9	21
972	The risk of malaria infection for travelers visiting the Brazilian Amazonian region: A mathematical modeling approach. <i>Travel Medicine and Infectious Disease</i> , 2020, 37, 101792.	1.5	6
973	Antimalarial activity of basic phospholipases A2 isolated from Paraguayan <i>Bothrops diporus</i> venom against <i>Plasmodium falciparum</i> . <i>Toxicon: X</i> , 2020, 8, 100056.	1.2	10
974	Implementing parasite genotyping into national surveillance frameworks: feedback from control programmes and researchers in the Asia-Pacific region. <i>Malaria Journal</i> , 2020, 19, 271.	0.8	31
975	The <i>Plasmodium falciparum</i> eIK1 kinase (PfeIK1) is central for melatonin synchronization in the human malaria parasite. Melatonin blocks melatonin action on parasite cell cycle. <i>Journal of Pineal Research</i> , 2020, 69, e12685.	3.4	9
976	Identifying and combating the impacts of COVID-19 on malaria. <i>BMC Medicine</i> , 2020, 18, 239.	2.3	84
977	Emergence and clonal expansion of in vitro artemisinin-resistant <i>Plasmodium falciparum</i> kelch13 R561H mutant parasites in Rwanda. <i>Nature Medicine</i> , 2020, 26, 1602-1608.	15.2	459
978	Population genomics identifies a distinct <i>Plasmodium vivax</i> population on the China-Myanmar border of Southeast Asia. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008506.	1.3	18
979	Sulfoximines as Rising Stars in Modern Drug Discovery? Current Status and Perspective on an Emerging Functional Group in Medicinal Chemistry. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 14243-14275.	2.9	184
980	Correlation between anti-malarial and anti-haemozoin activities of anti-malarial compounds. <i>Malaria Journal</i> , 2020, 19, 298.	0.8	7
981	N6-Adenosine methylation on mRNA is recognized by YTH2 domain protein of human malaria parasite <i>Plasmodium falciparum</i> . <i>Epigenetics and Chromatin</i> , 2020, 13, 33.	1.8	12
982	Prevalence of <i>Plasmodium falciparum</i> Kelch 13 (PfK13) and Ubiquitin-Specific Protease 1 (Tj ETQq1) in <i>Overlooked Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	7

#	ARTICLE	IF	CITATIONS
983	Evaluation of the Combination of Azithromycin and Naphthoquine in Animal Malaria Models. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	4
984	Efficacy of artemether-lumefantrine for treating uncomplicated <i>Plasmodium falciparum</i> cases and molecular surveillance of drug resistance genes in Western Myanmar. <i>Malaria Journal</i> , 2020, 19, 304.	0.8	8
985	No evidence of amplified <i>Plasmodium falciparum</i> plasmepsin II gene copy number in an area with artemisinin-resistant malaria along the China–Myanmar border. <i>Malaria Journal</i> , 2020, 19, 334.	0.8	5
986	Drugging the Phosphoinositide 3-Kinase (PI3K) and Phosphatidylinositol 4-Kinase (PI4K) Family of Enzymes for Treatment of Cancer, Immune Disorders, and Viral/Parasitic Infections. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1274, 203-222.	0.8	16
987	A protocol for systematic review and meta-analysis of optimizing treatment for malaria. <i>Medicine (United States)</i> , 2020, 99, e22044.	0.4	0
988	Molecular Mechanisms of Drug Resistance in <i>Plasmodium falciparum</i> . <i>Annual Review of Microbiology</i> , 2020, 74, 431-454.	2.9	123
989	The characterization of extracellular vesicles-derived microRNAs in Thai malaria patients. <i>Malaria Journal</i> , 2020, 19, 285.	0.8	26
990	QSAR Study of Fusidic Acid Derivative as Anti-Malaria Agents by using Artificial Neural Network-Genetic Algorithm. , 2020, , .		7
991	Assessment of molecular markers of anti-malarial drug resistance among children participating in a therapeutic efficacy study in western Kenya. <i>Malaria Journal</i> , 2020, 19, 291.	0.8	10
992	Antimalarial drug resistance molecular makers of <i>Plasmodium falciparum</i> isolates from Sudan during 2015–2017. <i>PLoS ONE</i> , 2020, 15, e0235401.	1.1	18
993	Safety and parasite clearance of artemisinin-resistant <i>Plasmodium falciparum</i> infection: A pilot and a randomised volunteer infection study in Australia. <i>PLoS Medicine</i> , 2020, 17, e1003203.	3.9	26
994	The lack of K13-propeller mutations associated with artemisinin resistance in <i>Plasmodium falciparum</i> in Democratic Republic of Congo (DRC). <i>PLoS ONE</i> , 2020, 15, e0237791.	1.1	6
995	Synthesis and In Vitro Antiprotozoan Evaluation of 4-/8-Aminoquinoline-based Lactams and Tetrazoles. <i>Molecules</i> , 2020, 25, 5941.	1.7	1
996	Gut Microbiota Composition Modulates the Magnitude and Quality of Germinal Centers during <i>Plasmodium</i> Infections. <i>Cell Reports</i> , 2020, 33, 108503.	2.9	16
997	Increased prevalence of <i>pf dhfr</i> and <i>pf dhps</i> mutations associated with sulfadoxine–pyrimethamine resistance in <i>Plasmodium falciparum</i> isolates from Jazan Region, Southwestern Saudi Arabia: important implications for malaria treatment policy. <i>Malaria Journal</i> , 2020, 19, 446.	0.8	8
998	Chemical Composition and In Vitro Antiplasmodial Activity of the Ethanolic Extract of <i>Cyperus articulatus</i> var. <i>nodosus</i> Residue. <i>Pathogens</i> , 2020, 9, 889.	1.2	7
999	Transmission of Artemisinin-Resistant Malaria Parasites to Mosquitoes under Antimalarial Drug Pressure. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 65, .	1.4	29
1000	The <i>Plasmodium falciparum</i> Artemisinin Susceptibility-Associated AP-2 Adaptin $\hat{1}/4$ Subunit is Clathrin Independent and Essential for Schizont Maturation. <i>MBio</i> , 2020, 11, .	1.8	27

#	ARTICLE	IF	CITATIONS
1001	In silico evaluation and in vitro growth inhibition of Plasmodium falciparum by natural amides and synthetic analogs. Parasitology Research, 2020, 119, 1879-1887.	0.6	5
1002	Molecular surveillance of the Pfm _{dr1} N86Y allele among Congolese pregnant women with asymptomatic malaria. Malaria Journal, 2020, 19, 178.	0.8	3
1003	Lead Optimization of Second-Generation Acridones as Broad-Spectrum Antimalarials. Journal of Medicinal Chemistry, 2020, 63, 6179-6202.	2.9	7
1004	Recurrence of Plasmodium malariae and P. falciparum Following Treatment of Uncomplicated Malaria in North Sumatera With Dihydroartemisinin-Piperaquine or Artemether-Lumefantrine. Open Forum Infectious Diseases, 2020, 7, ofaa116.	0.4	16
1005	Plasmodium falciparum Isolates Carrying <i>pf</i> k13 Polymorphisms Harbor the SVMNT Allele of <i>pfcr</i> in Northwestern Indonesia. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	4
1006	Efficacy and safety of artemisinin-based combination therapy and the implications of Pfk _{elch13} and Pfc _{oronin} molecular markers in treatment failure in Senegal. Scientific Reports, 2020, 10, 8907.	1.6	29
1007	Role of Plasmodium falciparum Kelch 13 Protein Mutations in P. falciparum Populations from Northeastern Myanmar in Mediating Artemisinin Resistance. MBio, 2020, 11, .	1.8	56
1008	Graphing and reporting heterogeneous treatment effects through reference classes. Trials, 2020, 21, 386.	0.7	3
1009	Antimalarial diterpenoids from Vitex rotundifolia: Isolation, structure elucidation, and in vitro antiplasmodial activity. Bioorganic Chemistry, 2020, 100, 103925.	2.0	7
1010	Baseline and multinormal distribution of ex vivo susceptibilities of Plasmodium falciparum to methylene blue in Africa, 2013-18. Journal of Antimicrobial Chemotherapy, 2020, 75, 2141-2148.	1.3	5
1011	Efficacy of dihydroartemisinin/piperaquine and artesunate monotherapy for the treatment of uncomplicated Plasmodium falciparum malaria in Central Vietnam. Journal of Antimicrobial Chemotherapy, 2020, 75, 2272-2281.	1.3	9
1012	Evolution of Antimalarial Drug Resistance Markers in the Reservoir of Plasmodium falciparum Infections in the Upper East Region of Ghana. Journal of Infectious Diseases, 2020, 222, 1692-1701.	1.9	8
1013	Utility of Plasmodium falciparum DNA from rapid diagnostic test kits for molecular analysis and whole genome amplification. Malaria Journal, 2020, 19, 193.	0.8	8
1014	Ex vivo susceptibilities of Plasmodium vivax isolates from the China-Myanmar border to antimalarial drugs and association with polymorphisms in Pvm _{dr1} and Pvc _{rt-o} genes. PLoS Neglected Tropical Diseases, 2020, 14, e0008255.	1.3	18
1015	Significant Efficacy of a Single Low Dose of Primaquine Compared to Stand-Alone Artemisinin Combination Therapy in Reducing Gametocyte Carriage in Cambodian Patients with Uncomplicated Multidrug-Resistant Plasmodium falciparum Malaria. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	8
1016	Malaria eradication. Lancet, The, 2020, 395, e69.	6.3	9
1017	Ultrastructural alterations in Plasmodium falciparum induced by chalcone derivatives. BMC Research Notes, 2020, 13, 290.	0.6	7
1018	Prevalence of mutations in the Plasmodium falciparum chloroquine resistance transporter, PfCRT, and association with ex vivo susceptibility to common anti-malarial drugs against African Plasmodium falciparum isolates. Malaria Journal, 2020, 19, 201.	0.8	11

#	ARTICLE	IF	CITATIONS
1019	Calcium-dependent Protein Kinases in Malaria Parasite Development and Infection. Cell Transplantation, 2020, 29, 096368971988488.	1.2	25
1020	Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial. Lancet, The, 2020, 395, 1345-1360.	6.3	182
1021	Mapping the travel patterns of people with malaria in Bangladesh. BMC Medicine, 2020, 18, 45.	2.3	11
1022	Structure-Activity Relationship between Thiol Group-Trapping Ability of Morphinan Compounds with a Michael Acceptor and Anti-Plasmodium falciparum Activities. Molecules, 2020, 25, 1112.	1.7	3
1023	Synthesis of neocryptolepines and carbocycle-fused quinolines and evaluation of their anticancer and antiplasmodial activities. Bioorganic Chemistry, 2020, 98, 103732.	2.0	24
1024	Structure-Based Screening of Plasmodium berghei Glutathione S-Transferase Identifies CB-27 as a Novel Antiplasmodial Compound. Frontiers in Pharmacology, 2020, 11, 246.	1.6	7
1025	Are three drugs for malaria better than two?. Lancet, The, 2020, 395, 1316-1317.	6.3	12
1026	Speed of action and stage specificity of Bencha-loga-wichian, a Thai traditional antipyretic formulation, against Plasmodium falciparum and the chloroquine-potentiating activity of its active compounds, tiliacorinine and yanangcorinine. Journal of Ethnopharmacology, 2020, 258, 112909.	2.0	0
1027	The <i>In Vitro</i> Antiplasmodial Activities of Aqueous Extracts of Selected Ghanaian Herbal Plants. Journal of Parasitology Research, 2020, 2020, 1-8.	0.5	11
1028	In silico and in vivo anti-malarial investigation on 1-(heteroaryl)-2-((5-nitroheteroaryl)methylene) hydrazine derivatives. Malaria Journal, 2020, 19, 231.	0.8	6
1029	Identification of Mutations in Antimalarial Resistance Gene Kelch13 from Plasmodium falciparum Isolates in Kano, Nigeria. Tropical Medicine and Infectious Disease, 2020, 5, 85.	0.9	9
1030	Parasite clearance, cure rate, post-treatment prophylaxis and safety of standard 3-day versus an extended 6-day treatment of artemether-lumefantrine and a single low-dose primaquine for uncomplicated Plasmodium falciparum malaria in Bagamoyo district, Tanzania: a randomized controlled trial. Malaria Journal, 2020, 19, 216.	0.8	7
1031	Efficacy and safety of artesunate-amodiaquine and artemether-lumefantrine and prevalence of molecular markers associated with resistance, Guinea: an open-label two-arm randomised controlled trial. Malaria Journal, 2020, 19, 223.	0.8	9
1032	Altered Drug Transport by Plasmodium falciparum Chloroquine Resistance Transporter Isoforms Harboring Mutations Associated with Piperaquine Resistance. Biochemistry, 2020, 59, 2484-2493.	1.2	11
1033	Artemisinin Resistance™: Something New or Old? Something of a Misnomer?. Trends in Parasitology, 2020, 36, 735-744.	1.5	20
1034	Asymmetric trisalkylamine cyclopropenium derivatives with antimicrobial activity. Bioorganic Chemistry, 2020, 102, 104069.	2.0	1
1035	Sarco/Endoplasmic Reticulum Calcium ATPase Inhibitors: Beyond Anticancer Perspective. Journal of Medicinal Chemistry, 2020, 63, 1937-1963.	2.9	34
1036	QSAR studies on benzothioephene derivatives as Plasmodium falciparum N-myristoyltransferase inhibitors: Molecular insights into affinity and selectivity. Drug Development Research, 2020, , .	1.4	6

#	ARTICLE	IF	CITATIONS
1037	Deep Learning-driven research for drug discovery: Tackling Malaria. PLoS Computational Biology, 2020, 16, e1007025.	1.5	34
1038	Machine learning analysis plans for randomised controlled trials: detecting treatment effect heterogeneity with strict control of type I error. Trials, 2020, 21, 156.	0.7	11
1039	lkoamide, an Antimalarial Lipopeptide from an <i>Okeania</i> sp. Marine Cyanobacterium. Journal of Natural Products, 2020, 83, 481-488.	1.5	24
1040	Antimalarial Drug Resistance Profiling of Plasmodium falciparum Infections in Ghana Using Molecular Inversion Probes and Next-Generation Sequencing. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	21
1041	Re-Engineering of Yohimbine's Biological Activity through Ring Distortion: Identification and Structure-Activity Relationships of a New Class of Antiplasmodial Agents. ACS Infectious Diseases, 2020, 6, 159-167.	1.8	20
1043	Novel broad-spectrum activity-based probes to profile malarial cysteine proteases. PLoS ONE, 2020, 15, e0227341.	1.1	9
1044	The extended recovery ring-stage survival assay provides a superior association with patient clearance half-life and increases throughput. Malaria Journal, 2020, 19, 54.	0.8	15
1045	Experimentally Engineered Mutations in a Ubiquitin Hydrolase, UBP-1, Modulate <i>In Vivo</i> Susceptibility to Artemisinin and Chloroquine in Plasmodium berghei. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	18
1046	Detecting geospatial patterns of Plasmodium falciparum parasite migration in Cambodia using optimized estimated effective migration surfaces. International Journal of Health Geographics, 2020, 19, 13.	1.2	2
1047	Recent progress in the synthesis of antimalarial indoloquinoline natural products and analogues. Studies in Natural Products Chemistry, 2020, , 59-84.	0.8	4
1048	Malaria Parasite Clearance: What Are We Really Measuring?. Trends in Parasitology, 2020, 36, 413-426.	1.5	21
1049	<i>Plasmodium falciparum</i> Artemisinin Resistance: The Effect of Heme, Protein Damage, and Parasite Cell Stress Response. ACS Infectious Diseases, 2020, 6, 1599-1614.	1.8	34
1050	Severe malaria. Current concepts and practical overview: What every intensivist should know. Intensive Care Medicine, 2020, 46, 907-918.	3.9	6
1051	Opinions of key stakeholders on alternative interventions for malaria control and elimination in Tanzania. Malaria Journal, 2020, 19, 164.	0.8	31
1052	Different Plasmodium falciparum clearance times in two Malian villages following artesunate monotherapy. International Journal of Infectious Diseases, 2020, 95, 399-405.	1.5	16
1053	An Individual Participant Data Population Pharmacokinetic Meta-analysis of Drug-Drug Interactions between Lumefantrine and Commonly Used Antiretroviral Treatment. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	14
1054	Evaluation of residual submicroscopic Plasmodium falciparum parasites 3 days after initiation of treatment with artemisinin-based combination therapy. Malaria Journal, 2020, 19, 162.	0.8	12
1055	Insights into the intracellular localization, protein associations and artemisinin resistance properties of Plasmodium falciparum K13. PLoS Pathogens, 2020, 16, e1008482.	2.1	60

#	ARTICLE	IF	CITATIONS
1056	CD19+CD1dhiCD5hi B Cells Can Downregulate Malaria ITV Protection by IL-10 Secretion. <i>Frontiers in Public Health</i> , 2020, 8, 77.	1.3	0
1057	Safety assessment of MEFAS: an innovative hybrid salt of mefloquine and artesunate for malaria treatment. <i>Drug and Chemical Toxicology</i> , 2021, 44, 380-385.	1.2	3
1058	Changing Prevalence of Potential Mediators of Aminoquinoline, Antifolate, and Artemisinin Resistance Across Uganda. <i>Journal of Infectious Diseases</i> , 2021, 223, 985-994.	1.9	111
1059	Azacarbazole n-3 and n-6 polyunsaturated fatty acids ethyl esters nanoemulsion with enhanced efficacy against <i>Plasmodium falciparum</i> . <i>Bioactive Materials</i> , 2021, 6, 1163-1174.	8.6	9
1060	Antiplasmodial Combined Formulation of Artemisinin with <i>Peschiera fuchsiae</i> Bis-Indole Alkaloids. <i>Journal of Pharmaceutical Sciences</i> , 2021, 110, 135-145.	1.6	2
1061	A novel class of fast-acting antimalarial agents: Substituted 15-membered azalides. <i>British Journal of Pharmacology</i> , 2021, 178, 363-377.	2.7	5
1062	In vitro activity of eravacycline, a novel synthetic halogenated tetracycline, against the malaria parasite <i>Plasmodium falciparum</i> . <i>Journal of Global Antimicrobial Resistance</i> , 2021, 24, 93-97.	0.9	8
1063	Can individuals' beliefs help us understand nonadherence to malaria test results? Evidence from rural Kenya. <i>Review of Development Economics</i> , 2021, 25, 163-182.	1.0	3
1064	Increase in <i>Pfkelch13</i> Polymorphisms in <i>Plasmodium falciparum</i> , Southern Rwanda. <i>Emerging Infectious Diseases</i> , 2021, 27, 294-296.	2.0	52
1065	Genetic polymorphism of <i>vir</i> genes of <i>Plasmodium vivax</i> in Myanmar. <i>Parasitology International</i> , 2021, 80, 102233.	0.6	2
1066	You've got a friend in me: How social networks and mobile phones facilitate healthcare access among marginalised groups in rural Thailand and Lao PDR. <i>World Development</i> , 2021, 137, 105156.	2.6	11
1067	Artemisinin susceptibility in the malaria parasite <i>Plasmodium falciparum</i> : propellers, adaptor proteins and the need for cellular healing. <i>FEMS Microbiology Reviews</i> , 2021, 45, .	3.9	24
1068	Spatial and molecular mapping of <i>Pfkelch13</i> gene polymorphism in Africa in the era of emerging <i>Plasmodium falciparum</i> resistance to artemisinin: a systematic review. <i>Lancet Infectious Diseases</i> , The, 2021, 21, e82-e92.	4.6	42
1069	Intervention of standardized ethanol leaf extract of <i>Annickia polycarpa</i> , (DC.) Setten and Maas ex I.M. Turner. (Annonaceae), in <i>Plasmodium berghei</i> infested mice produced anti-malaria action and normalized gross hematological indices. <i>Journal of Ethnopharmacology</i> , 2021, 267, 113449.	2.0	5
1070	Triple Artemisinin-Based Combination Therapies for Malaria – A New Paradigm?. <i>Trends in Parasitology</i> , 2021, 37, 15-24.	1.5	67
1071	Polymorphism Analysis of <i>pfmdr1</i> and <i>pfcr1</i> from <i>Plasmodium falciparum</i> Isolates in Northwestern Nigeria Revealed the Major Markers Associated with Antimalarial Resistance. <i>Diseases (Basel)</i> , 2021, 11, 10784314.	1.0	10
1072	Dynamic association of the H3K64 trimethylation mark with genes encoding exported proteins in <i>Plasmodium falciparum</i> . <i>Journal of Biological Chemistry</i> , 2021, 296, 100614.	1.6	5
1073	Ex vivo Sensitivity Profile of <i>Plasmodium falciparum</i> Clinical Isolates to a Panel of Antimalarial Drugs in Ghana 13 Years After National Policy Change. <i>Infection and Drug Resistance</i> , 2021, Volume 14, 267-276.	1.1	5

#	ARTICLE	IF	CITATIONS
1075	Surveillance of molecular markers of antimalarial drug resistance in <i>Plasmodium falciparum</i> and <i>Plasmodium vivax</i> in Federally Administered Tribal Area (FATA), Pakistan. <i>Revista Do Instituto De Medicina Tropical De Sao Paulo</i> , 2021, 63, e59.	0.5	3
1076	Surveillance of molecular markers of antimalarial drug resistance in <i>Plasmodium falciparum</i> and <i>Plasmodium vivax</i> in Federally Administered Tribal Area (FATA), Pakistan. <i>Revista Do Instituto De Medicina Tropical De Sao Paulo</i> , 0, 63, .	0.5	1
1077	Persistence of mRNA indicative of <i>Plasmodium falciparum</i> ring-stage parasites 42Âdays after artemisinin and non-artemisinin combination therapy in naturally infected Malians. <i>Malaria Journal</i> , 2021, 20, 34.	0.8	4
1078	Transition of radical, preventive and presumptive treatment regimens for malaria in China: aÂsystematic review. <i>Malaria Journal</i> , 2021, 20, 10.	0.8	12
1079	Vector saliva controlled inflammatory response of the host may represent the Achilles heel during pathogen transmission. <i>Journal of Venomous Animals and Toxins Including Tropical Diseases</i> , 2021, 27, e20200155.	0.8	3
1080	Fansidar drug induces cytotoxicity in some vital tissues in a rat model: combination defensive effect of selenium and zinc capsules. <i>Therapeutic Advances in Drug Safety</i> , 2021, 12, 204209862110271.	1.0	2
1081	Automated Malaria Cells Detection from Blood Smears Under Severe Class Imbalance via Importance-Aware Balanced Group Softmax. <i>Lecture Notes in Computer Science</i> , 2021, , 455-465.	1.0	5
1082	Development of nanocarriers for innovative antimalarial combination strategies. , 2021, , 141-167.		0
1084	An update on prevention of malaria in travelers. <i>Therapeutic Advances in Infectious Disease</i> , 2021, 8, 204993612110406.	1.1	3
1085	The Impact of Renewing Long-Lasting Insecticide-Treated Nets in the Event of Malaria Resurgence: Lessons from 10 Years of Net Use in Dielmo, Senegal. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, 104, 255-262.	0.6	4
1086	Orthostericâ€“allosteric dual inhibitors of PfHT1 as selective antimalarial agents. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	17
1087	Genomic Epidemiology of Antimalarial Drug Resistance in <i>Plasmodium falciparum</i> in Southern China. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 610985.	1.8	0
1088	Physicochemical Profiling and Comparison of Research Antiplasmodials and Advanced Stage Antimalarials with Oral Drugs. <i>ACS Omega</i> , 2021, 6, 6424-6437.	1.6	5
1089	Metalloaminopeptidases of the Protozoan Parasite <i>Plasmodium falciparum</i> as Targets for the Discovery of Novel Antimalarial Drugs. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 1763-1785.	2.9	5
1090	Distribution and Temporal Dynamics of <i>Plasmodium falciparum</i> Chloroquine Resistance Transporter Mutations Associated With Piperaquine Resistance in Northern Cambodia. <i>Journal of Infectious Diseases</i> , 2021, 224, 1077-1085.	1.9	8
1091	Measurement of gene amplifications related to drug resistance in <i>Plasmodium falciparum</i> using droplet digital PCR. <i>Malaria Journal</i> , 2021, 20, 120.	0.8	4
1092	The 100 most-cited articles on malaria: a bibliometric analysis. <i>Collection and Curation</i> , 2021, 40, 58-67.	0.5	1
1093	Molecular surveillance of pfprt, pfmdr1 and pfk13-propeller mutations in <i>Plasmodium falciparum</i> isolates imported from Africa to China. <i>Malaria Journal</i> , 2021, 20, 73.	0.8	12

#	ARTICLE	IF	CITATIONS
1095	A LAMP-SNP Assay Detecting C580Y Mutation in Pfk13 Gene from Clinically Dried Blood Spot Samples. <i>Korean Journal of Parasitology</i> , 2021, 59, 15-22.	0.5	10
1096	An open dataset of <i>Plasmodium falciparum</i> genome variation in 7,000 worldwide samples. <i>Wellcome Open Research</i> , 2021, 6, 42.	0.9	97
1097	Deploying triple artemisinin-based combination therapy (TACT) for malaria treatment in Africa: ethical and practical considerations. <i>Malaria Journal</i> , 2021, 20, 119.	0.8	17
1098	Antimalarial Drug Resistance and Implications for the WHO Global Technical Strategy. <i>Current Epidemiology Reports</i> , 2021, 8, 46-62.	1.1	38
1099	Genomic analysis reveals independent evolution of <i>Plasmodium falciparum</i> populations in Ethiopia. <i>Malaria Journal</i> , 2021, 20, 129.	0.8	8
1100	In vitro growth competition experiments that suggest consequences of the substandard artemisinin epidemic that may be accelerating drug resistance in <i>P. falciparum</i> malaria. <i>PLoS ONE</i> , 2021, 16, e0248057.	1.1	7
1101	The Knockout for G Protein-Coupled Receptor-Like PfSR25 Increases the Susceptibility of Malaria Parasites to the Antimalarials Lumefantrine and Piperaquine but Not to Medicine for Malaria Venture Compounds. <i>Frontiers in Microbiology</i> , 2021, 12, 638869.	1.5	8
1102	Multidrug-Resistant <i>Plasmodium falciparum</i> Parasites in the Central Highlands of Vietnam Jeopardize Malaria Control and Elimination Strategies. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	4
1103	Pharmacoinformatics based elucidation and designing of potential inhibitors against <i>Plasmodium falciparum</i> to target importin β mediated nuclear importation. <i>Infection, Genetics and Evolution</i> , 2021, 88, 104699.	1.0	4
1105	Rolling out the radical cure for vivax malaria in Asia: a qualitative study among policy makers and stakeholders. <i>Malaria Journal</i> , 2021, 20, 164.	0.8	11
1106	An Automated Microscopic Malaria Parasite Detection System Using Digital Image Analysis. <i>Diagnostics</i> , 2021, 11, 527.	1.3	11
1107	Antiplasmodial Compounds from Deep-Water Marine Invertebrates. <i>Marine Drugs</i> , 2021, 19, 179.	2.2	10
1108	Addressing key gaps in implementation of mosquito larviciding to accelerate malaria vector control in southern Tanzania: results of a stakeholder engagement process in local district councils. <i>Malaria Journal</i> , 2021, 20, 123.	0.8	13
1109	Semimechanistic Pharmacokinetic and Pharmacodynamic Modeling of Piperaquine in a Volunteer Infection Study with <i>Plasmodium falciparum</i> Blood-Stage Malaria. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	3
1111	Artemisinin-Based Drugs Target the <i>Plasmodium falciparum</i> Heme Detoxification Pathway. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	13
1112	Targeting Gametocytes of the Malaria Parasite <i>Plasmodium falciparum</i> in a Functional Genomics Era: Next Steps. <i>Pathogens</i> , 2021, 10, 346.	1.2	18
1113	Defining the burden of febrile illness in rural South and Southeast Asia: an open letter to announce the launch of the Rural Febrile Illness project. <i>Wellcome Open Research</i> , 2021, 6, 64.	0.9	11
1114	Assessment of <i>Plasmodium falciparum</i> anti-malarial drug resistance markers in <i>pfk13</i> -propeller, <i>pfprt</i> and <i>pfmdr1</i> genes in isolates from treatment failure patients in Democratic Republic of Congo, 2018–2019. <i>Malaria Journal</i> , 2021, 20, 144.	0.8	6

#	ARTICLE	IF	CITATIONS
1115	Theory of change: Drama and arts-based community engagement for malaria research and elimination in Cambodia. Wellcome Open Research, 2021, 6, 46.	0.9	2
1117	Structure-switching aptamer sensors for the specific detection of piperazine and mefloquine. Science Translational Medicine, 2021, 13, .	5.8	26
1118	Novel Virus-Like Particle Vaccine Encoding the Circumsporozoite Protein of Plasmodium falciparum Is Immunogenic and Induces Functional Antibody Responses in Mice. Frontiers in Immunology, 2021, 12, 641421.	2.2	9
1119	Controlled human malaria infectionâ€”Maker and breaker of dogma. PLoS Medicine, 2021, 18, e1003591.	3.9	3
1120	<i>In Vitro</i> Susceptibility of <i>Plasmodium falciparum</i> Isolates from the China-Myanmar Border Area to Piperazine and Association with Candidate Markers. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	9
1121	Ethical, Regulatory and Market related aspects of Deploying Triple Artemisinin-Based Combination Therapies for Malaria treatment in Africa: A study protocol.. Wellcome Open Research, 2021, 6, 75.	0.9	4
1123	Recrudescence of a high parasitaemia, severe Plasmodium falciparum malaria episode, treated by artesunate monotherapy. International Journal of Infectious Diseases, 2021, 105, 345-348.	1.5	6
1124	Efficacy and safety of dihydroartemisininâ€”piperazine versus artemetherâ€”lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Ugandan children: a systematic review and meta-analysis of randomized control trials. Malaria Journal, 2021, 20, 174.	0.8	11
1125	Absence of Association between Methylene Blue Reduced Susceptibility and Polymorphisms in 12 Genes Involved in Antimalarial Drug Resistance in African Plasmodium falciparum. Pharmaceuticals, 2021, 14, 351.	1.7	2
1126	Green nanoparticles to treat patients with Malaria disease: An overview. Journal of Molecular Structure, 2021, 1229, 129857.	1.8	21
1127	Analytical validation of a real-time hydrolysis probe PCR assay for quantifying Plasmodium falciparum parasites in experimentally infected human adults. Malaria Journal, 2021, 20, 181.	0.8	5
1128	Estimating the programmatic cost of targeted mass drug administration for malaria in Myanmar. BMC Public Health, 2021, 21, 826.	1.2	3
1129	Involvement of 5-Serotonin and Substance p Pathways in Dichroa Alkali Salt-Induced Acute Pica in Rats. Frontiers in Pharmacology, 2021, 12, 588837.	1.6	0
1130	New Acyl Derivatives of 3-Aminofurazanes and Their Antiplasmodial Activities. Pharmaceuticals, 2021, 14, 412.	1.7	2
1131	Zinc oxide nanoparticles using plant Lawsonia inermis and their mosquitocidal, antimicrobial, anticancer applications showing moderate side effects. Scientific Reports, 2021, 11, 8837.	1.6	30
1133	Synthesis of Mono- and Bisperoxide-Bridged Artemisinin Dimers to Elucidate the Contribution of Dimerization to Antimalarial Activity. ACS Infectious Diseases, 2021, 7, 2013-2024.	1.8	5
1134	Novel molecule combinations and corresponding hybrids targeting artemisinin-resistant Plasmodium falciparum parasites. Bioorganic and Medicinal Chemistry Letters, 2021, 39, 127884.	1.0	5
1135	Theory of change: Drama and arts-based community engagement for malaria research and elimination in Cambodia. Wellcome Open Research, 2021, 6, 46.	0.9	5

#	ARTICLE	IF	CITATIONS
1136	Malaria intermittent preventive treatment in Nigeria: a qualitative study to explore barriers. BMC Infectious Diseases, 2021, 21, 438.	1.3	6
1137	A randomized, double-blind, phase 2b study to investigate the efficacy, safety, tolerability and pharmacokinetics of a single-dose regimen of ferroquine with artefenomel in adults and children with uncomplicated Plasmodium falciparum malaria. Malaria Journal, 2021, 20, 222.	0.8	29
1138	Multi-omics approaches to improve malaria therapy. Pharmacological Research, 2021, 167, 105570.	3.1	18
1139	Therapeutic efficacy of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in four malaria endemic states of India. Malaria Journal, 2021, 20, 229.	0.8	6
1140	Development and Validation of an <i>In Silico</i> Decision Tool To Guide Optimization of Intravenous Artesunate Dosing Regimens for Severe Falciparum Malaria Patients. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	1
1141	Malaria in the "Omics Era"™. Genes, 2021, 12, 843.	1.0	4
1142	Molecular surveillance of anti-malarial resistance pfcr, pfmdr1, and pfk13 polymorphisms in African Plasmodium falciparum imported parasites to Wuhan, China. Malaria Journal, 2021, 20, 209.	0.8	11
1143	A Proteasome Mutation Sensitizes <i>P. falciparum</i> Cam3.11 K13 ^{C580Y} Parasites to DHA and OZ439. ACS Infectious Diseases, 2021, 7, 1923-1931.	1.8	6
1144	Artemisinin combination therapy fails even in the absence of Plasmodium falciparum kelch13 gene polymorphism in Central India. Scientific Reports, 2021, 11, 9946.	1.6	14
1145	Therapeutic efficacy of artemether-lumefantrine and artesunate-amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Mali, 2015-2016. Malaria Journal, 2021, 20, 235.	0.8	5
1147	Balanced impacts of fitness and drug pressure on the evolution of PfMDR1 polymorphisms in Plasmodium falciparum. Malaria Journal, 2021, 20, 292.	0.8	5
1148	Therapeutic efficacy of artesunate-amodiaquine and artemether-lumefantrine and polymorphism in Plasmodium falciparum kelch13-propeller gene in Equatorial Guinea. Malaria Journal, 2021, 20, 275.	0.8	7
1149	Mesenchymal Stem Cells: A Novel Therapeutic Approach to Enhance Protective Immunomodulation and Erythropoietic Recovery in Malaria. Stem Cell Reviews and Reports, 2021, 17, 1993-2002.	1.7	5
1150	Antimalarial, Antioxidant, and Toxicological Evaluation of Extracts of Celtis africana, Grosseria vignei, Physalis micrantha, and Stachytarpheta angustifolia. Biochemistry Research International, 2021, 2021, 1-10.	1.5	11
1151	A trio of quinoline-isoniazid-phthalimide with promising antiplasmodial potential: Synthesis, in-vitro evaluation and heme-polymerization inhibition studies. Bioorganic and Medicinal Chemistry, 2021, 39, 116159.	1.4	14
1152	Characterization of pfmdr1, pfcr, pfk13, pfubp1, and pfap2mu in Travelers Returning from Africa with Plasmodium falciparum Infections Reported in China from 2014 to 2018. Antimicrobial Agents and Chemotherapy, 2021, 65, e0271720.	1.4	5
1153	Dynamical Basis of Allosteric Activation for the Plasmodium falciparum Protein Kinase G. Journal of Physical Chemistry B, 2021, 125, 6532-6542.	1.2	3
1154	Mass drug administration for the acceleration of malaria elimination in a region of Myanmar with artemisinin-resistant falciparum malaria: a cluster-randomised trial. Lancet Infectious Diseases, The, 2021, 21, 1579-1589.	4.6	8

#	ARTICLE	IF	CITATIONS
1156	Seeking an optimal dosing regimen for OZ439/DSM265 combination therapy for treating uncomplicated falciparum malaria. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2325-2334.	1.3	8
1157	<i>Plasmodium falciparum</i> phenotypic and genotypic resistance profile during the emergence of Piperazine resistance in Northeastern Thailand. <i>Scientific Reports</i> , 2021, 11, 13419.	1.6	8
1159	<i>Plasmodium</i> Species and Drug Resistance. , 0, , .		2
1160	Targeted deep amplicon sequencing of antimalarial resistance markers in <i>Plasmodium falciparum</i> isolates from Cameroon. <i>International Journal of Infectious Diseases</i> , 2021, 107, 234-241.	1.5	12
1162	Efficient refolding and functional characterization of PfAMA1 (DI+DII) expressed in <i>E. coli</i> . <i>Biochemistry and Biophysics Reports</i> , 2021, 26, 100950.	0.7	2
1163	Molecular Approaches for Malaria Therapy. , 0, , .		0
1164	Survey of ethnobotanical cocktails commonly used in the treatment of malaria in southwestern Nigeria. <i>Future Journal of Pharmaceutical Sciences</i> , 2021, 7, .	1.1	4
1165	Persistent Submicroscopic <i>Plasmodium falciparum</i> Parasitemia 72 Hours after Treatment with Artemether-Lumefantrine Predicts 42-Day Treatment Failure in Mali and Burkina Faso. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0087321.	1.4	7
1166	<i>Plasmodium falciparum</i> K13 mutations in Africa and Asia impact artemisinin resistance and parasite fitness. <i>ELife</i> , 2021, 10, .	2.8	85
1167	Ring Distortion of Vincamine Leads to the Identification of Re-Engineered Antiplasmodial Agents. <i>ACS Omega</i> , 2021, 6, 20455-20470.	1.6	4
1168	Differential Prevalences of Pfmdr1 Polymorphisms in Symptomatic and Asymptomatic <i>Plasmodium falciparum</i> Infections in Lastoursville: A Rural Area in East-Central Gabon. <i>Infection and Drug Resistance</i> , 2021, Volume 14, 2873-2882.	1.1	1
1169	Novel Purine Chemotypes with Activity against <i>Plasmodium falciparum</i> and <i>Trypanosoma cruzi</i> . <i>Pharmaceuticals</i> , 2021, 14, 638.	1.7	5
1170	Screening for antifolate and artemisinin resistance in <i>Plasmodium falciparum</i> clinical isolates from three hospitals of Eritrea. <i>F1000Research</i> , 0, 10, 628.	0.8	0
1171	<i>P. falciparum</i> and Its Molecular Markers of Resistance to Antimalarial Drugs. , 0, , .		4
1172	<i>Plasmodium falciparum</i> kelch13 Mutations, 9 Countries in Africa, 2014–2018. <i>Emerging Infectious Diseases</i> , 2021, 27, 1902-1908.	2.0	8
1173	Pharmacotherapy for artemisinin-resistant malaria. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 2483-2493.	0.9	6
1174	Synthesis of Non-symmetrical Dispiro-1,2,4,5-Tetraoxanes and Dispiro-1,2,4-Trioxanes Catalyzed by Silica Sulfuric Acid. <i>Journal of Organic Chemistry</i> , 2021, 86, 10608-10620.	1.7	11
1176	Artemisinin and multidrug-resistant <i>Plasmodium falciparum</i> – a threat for malaria control and elimination. <i>Current Opinion in Infectious Diseases</i> , 2021, 34, 432-439.	1.3	51

#	ARTICLE	IF	CITATIONS
1177	High Prevalence of <i>Plasmodium falciparum</i> K13 Mutations in Rwanda Is Associated With Slow Parasite Clearance After Treatment With Artemether-Lumefantrine. <i>Journal of Infectious Diseases</i> , 2022, 225, 1411-1414.	1.9	54
1178	New Challenges in Malaria Elimination. <i>Infectious Diseases</i> , 0, , .	4.0	0
1179	The newly discovered role of endocytosis in artemisinin resistance. <i>Medicinal Research Reviews</i> , 2021, 41, 2998-3022.	5.0	16
1180	An open dataset of <i>Plasmodium falciparum</i> genome variation in 7,000 worldwide samples. <i>Wellcome Open Research</i> , 2021, 6, 42.	0.9	51
1181	Artemisinin inspired synthetic endoperoxide drug candidates: Design, synthesis, and mechanism of action studies. <i>Medicinal Research Reviews</i> , 2021, 41, 3062-3095.	5.0	22
1182	<i>Plasmodium falciparum</i> resistance to ACTs: Emergence, mechanisms, and outlook. <i>International Journal for Parasitology: Drugs and Drug Resistance</i> , 2021, 16, 102-118.	1.4	36
1183	A polyphenol, pyrogallol changes the acidic pH of the digestive vacuole of <i>Plasmodium falciparum</i> . <i>Life Sciences Medicine and Biomedicine</i> , 2021, 5, .	0.1	1
1184	Conserved <i>Plasmodium</i> Protein (PF3D7_0406000) of Unknown Function: In-silico Analysis and Cellular Localization. <i>Infection, Genetics and Evolution</i> , 2021, 92, 104848.	1.0	1
1185	Limited polymorphism in k13 gene of <i>Plasmodium falciparum</i> and k12 of <i>Plasmodium vivax</i> isolates imported from African and Asian countries between 2014 and 2019 in Hangzhou city, China. <i>BMC Infectious Diseases</i> , 2021, 21, 853.	1.3	4
1186	Genetic surveillance in the Greater Mekong subregion and South Asia to support malaria control and elimination. <i>ELife</i> , 2021, 10, .	2.8	53
1187	Surveillance of molecular markers of <i>Plasmodium falciparum</i> artemisinin resistance (kelch13) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 347 and Drug Resistance, 2021, 16, 188-193.	1.4	15
1188	Efficacy of dihydroartemisinin-piperaquine versus artemether-lumefantrine for the treatment of uncomplicated <i>Plasmodium falciparum</i> malaria among children in Africa: a systematic review and meta-analysis of randomized control trials. <i>Malaria Journal</i> , 2021, 20, 340.	0.8	6
1189	Combating multi-drug resistant malaria parasite by inhibiting falcipain-2 and heme-polymerization: Artemisinin-peptidyl vinyl phosphonate hybrid molecules as new antimalarials. <i>European Journal of Medicinal Chemistry</i> , 2021, 220, 113454.	2.6	11
1190	Efforts Made to Eliminate Drug-Resistant Malaria and Its Challenges. <i>BioMed Research International</i> , 2021, 2021, 1-12.	0.9	11
1191	Has artemisinin resistance emerged in Africa?. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1056-1057.	4.6	21
1193	Prevalence of Mutations in the pfcoronin Gene and Association with Ex Vivo Susceptibility to Common Quinoline Drugs against <i>Plasmodium falciparum</i> . <i>Pharmaceutics</i> , 2021, 13, 1273.	2.0	3
1194	From Magic Bullet to Magic Bomb: Reductive Bioactivation of Antiparasitic Agents. <i>ACS Infectious Diseases</i> , 2021, 7, 2777-2786.	1.8	14
1195	Emergence of Artemisinin-Resistant <i>Plasmodium falciparum</i> in East Africa. <i>New England Journal of Medicine</i> , 2021, 385, 1231-1232.	13.9	18

#	ARTICLE	IF	CITATIONS
1196	Property activity refinement of 2-anilino 4-amino substituted quinazolines as antimalarials with fast acting asexual parasite activity. <i>Bioorganic Chemistry</i> , 2021, 117, 105359.	2.0	8
1197	Drug susceptibility of <i>Plasmodium falciparum</i> in eastern Uganda: a longitudinal phenotypic and genotypic study. <i>Lancet Microbe</i> , The, 2021, 2, e441-e449.	3.4	34
1198	Antimicrobial Resistance: Is Health Technology Assessment Part of the Solution or Part of the Problem?. <i>Value in Health</i> , 2021, 24, 1828-1834.	0.1	22
1199	Evidence of Artemisinin-Resistant Malaria in Africa. <i>New England Journal of Medicine</i> , 2021, 385, 1163-1171.	13.9	413
1200	Ten-Year Molecular Surveillance of Drug-Resistant <i>Plasmodium</i> spp. Isolated From the China-Myanmar Border. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 733788.	1.8	6
1202	Evolution of Multidrug Resistance in <i>Plasmodium falciparum</i> : a Longitudinal Study of Genetic Resistance Markers in the Greater Mekong Subregion. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0112121.	1.4	21
1203	Preparation, biological & cheminformatics-based assessment of N2,N4-diphenylpyrimidine-2,4-diamine as potential Kinase-targeted antimalarials. <i>Bioorganic and Medicinal Chemistry</i> , 2021, 46, 116348.	1.4	5
1204	8-Amino-6-Methoxyquinoline-Tetrazole Hybrids: Impact of Linkers on Antiplasmodial Activity. <i>Molecules</i> , 2021, 26, 5530.	1.7	3
1205	Are Artemisinin-Based Combination Therapies For Malaria Beginning To Fail in Africa?. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, 105, 857-858.	0.6	10
1206	In vivo antiplasmodial activities and acute toxicity assessment of two plant cocktail extracts commonly used among Southwestern Nigerians. <i>Journal of Parasitic Diseases</i> , 0, , 1.	0.4	1
1208	Selective synthesis of novel quinolones-amino esters as potential antibacterial and antifungal agents: Experimental, mechanistic study, docking and molecular dynamic simulations. <i>Journal of Molecular Structure</i> , 2021, 1241, 130652.	1.8	14
1209	Arterolane-piperaquine-mefloquine versus arterolane-piperaquine and artemether-lumefantrine in the treatment of uncomplicated <i>Plasmodium falciparum</i> malaria in Kenyan children: a single-centre, open-label, randomised, non-inferiority trial. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1395-1406.	4.6	20
1210	REAP (Rapid Elimination of Active Plasmodium): A photodynamic strategy exploiting intrinsic kinetics of the parasite to combat severe malaria. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2021, 223, 112286.	1.7	2
1211	A 30-Year-Old Male Chinese Trader With Fever in Laos. , 2022, , 108-110.		0
1212	Transformative Adaptations for Health Impacts of Climate Change in Burkina Faso and Kenya. , 2021, , 2485-2500.		2
1213	Translation of Research into Action Case Study. , 2021, , 121-145.		0
1214	Kelch13 mutations in <i>Plasmodium falciparum</i> and risk of spreading in Amazon basin countries. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2854-2862.	1.3	7
1215	Artemisinin-resistant K13 mutations rewire <i>Plasmodium falciparum</i> 's intra-erythrocytic metabolic program to enhance survival. <i>Nature Communications</i> , 2021, 12, 530.	5.8	82

#	ARTICLE	IF	CITATIONS
1216	Study towards improving artemisinin-based combination therapies. <i>Natural Product Reports</i> , 2021, 38, 1243-1250.	5.2	16
1217	Water-, Sanitation-, and Hygiene-Related Diseases. , 2021, , 1-31.		0
1218	Plasmodium—a brief introduction to the parasites causing human malaria and their basic biology. <i>Journal of Physiological Anthropology</i> , 2021, 40, 1.	1.0	132
1219	Chemotherapy and Drug Resistance in Schistosomiasis and Other Trematode and Cestode Infections. , 2017, , 705-734.		5
1220	Drug Resistance Assays for Parasitic Diseases. , 2017, , 1409-1463.		7
1221	Enhanced Antimalarial Efficacy Obtained by Targeted Delivery of Artemisinin in Heparin-Coated Magnetic Hollow Mesoporous Nanoparticles. <i>ACS Applied Materials & Interfaces</i> , 2021, 13, 287-297.	4.0	21
1222	OUP accepted manuscript. <i>Journal of Travel Medicine</i> , 2019, 26, .	1.4	16
1239	Modeling and analysis of health-information system of systems for managing transitional complexity using engineering systems multiple-domain matrix. , 2017, , .		4
1240	Plasmodium falciparum Apicomplexan-Specific Glucosamine-6-Phosphate <i>N</i>-Acetyltransferase Is Key for Amino Sugar Metabolism and Asexual Blood Stage Development. <i>MBio</i> , 2020, 11, .	1.8	6
1241	Blood Interferon Signatures Putatively Link Lack of Protection Conferred by the RTS,S Recombinant Malaria Vaccine to an Antigen-specific IgE Response. <i>F1000Research</i> , 2015, 4, 919.	0.8	33
1242	Blood Interferon Signatures Putatively Link Lack of Protection Conferred by the RTS,S Recombinant Malaria Vaccine to an Antigen-specific IgE Response. <i>F1000Research</i> , 2015, 4, 919.	0.8	19
1243	Muddled mechanisms: recent progress towards antimalarial target identification. <i>F1000Research</i> , 2016, 5, 2514.	0.8	6
1244	Community engagement for the rapid elimination of malaria: The case of Kayin State, Myanmar. <i>Wellcome Open Research</i> , 2017, 2, 59.	0.9	45
1245	Safety and effectiveness of mass drug administration to accelerate elimination of artemisinin-resistant falciparum malaria: A pilot trial in four villages of Eastern Myanmar. <i>Wellcome Open Research</i> , 2017, 2, 81.	0.9	71
1246	Drama as a community engagement strategy for malaria in rural Cambodia. <i>Wellcome Open Research</i> , 0, 2, 95.	0.9	20
1247	Drama as a community engagement strategy for malaria in rural Cambodia. <i>Wellcome Open Research</i> , 2017, 2, 95.	0.9	33
1248	Scale up of a Plasmodium falciparum elimination program and surveillance system in Kayin State, Myanmar. <i>Wellcome Open Research</i> , 0, 2, 98.	0.9	11
1249	Scale up of a Plasmodium falciparum elimination program and surveillance system in Kayin State, Myanmar. <i>Wellcome Open Research</i> , 2017, 2, 98.	0.9	27

#	ARTICLE	IF	CITATIONS
1250	Understanding a science-themed puppet theatre performance for public engagement in Thailand. Wellcome Open Research, 0, 3, 7.	0.9	4
1251	Smartphones for community health in rural Cambodia: A feasibility study. Wellcome Open Research, 2018, 3, 69.	0.9	8
1252	“Nine Dimensions”: A multidisciplinary approach for community engagement in a complex postwar border region as part of the targeted malaria elimination in Karen/Kayin State, Myanmar. Wellcome Open Research, 2018, 3, 116.	0.9	14
1253	“Nine Dimensions”: A multidisciplinary approach for community engagement in a complex postwar border region as part of the targeted malaria elimination in Karen/Kayin State, Myanmar. Wellcome Open Research, 2018, 3, 116.	0.9	13
1254	Entomological determinants of malaria transmission in Kayin state, Eastern Myanmar: A 24-month longitudinal study in four villages. Wellcome Open Research, 2018, 3, 109.	0.9	21
1255	An interactive application for malaria elimination transmission and costing in the Asia-Pacific. Wellcome Open Research, 2019, 4, 61.	0.9	7
1256	Synthesis, biological evaluation, QSAR analysis, and molecular docking of chalcone derivatives for antimalarial activity. Asian Pacific Journal of Tropical Disease, 2017, 7, 8-13.	0.5	14
1258	A cautionary note on the use of unsupervised machine learning algorithms to characterise malaria parasite population structure from genetic distance matrices. PLoS Genetics, 2020, 16, e1009037.	1.5	5
1259	Population Pharmacokinetic Properties of Piperaquine in Falciparum Malaria: An Individual Participant Data Meta-Analysis. PLoS Medicine, 2017, 14, e1002212.	3.9	50
1260	malERA: An updated research agenda for basic science and enabling technologies in malaria elimination and eradication. PLoS Medicine, 2017, 14, e1002451.	3.9	29
1261	Implications of Glutathione Levels in the Plasmodium berghei Response to Chloroquine and Artemisinin. PLoS ONE, 2015, 10, e0128212.	1.1	27
1262	Molecular Mechanism for the Thermo-Sensitive Phenotype of CHO-MT58 Cell Line Harboring a Mutant CTP:Phosphocholine Cytidyltransferase. PLoS ONE, 2015, 10, e0129632.	1.1	10
1263	A New Set of Chemical Starting Points with Plasmodium falciparum Transmission-Blocking Potential for Antimalarial Drug Discovery. PLoS ONE, 2015, 10, e0135139.	1.1	51
1264	Picomolar Inhibition of Plasmepsin V, an Essential Malaria Protease, Achieved Exploiting the Prime Region. PLoS ONE, 2015, 10, e0142509.	1.1	27
1265	Artesunate-Amodiaquine and Artemether-Lumefantrine Therapies and Selection of Pfcrt and Pfmdr1 Alleles in Nanoro, Burkina Faso. PLoS ONE, 2016, 11, e0151565.	1.1	37
1266	Single Low Dose Primaquine (0.25mg/kg) Does Not Cause Clinically Significant Haemolysis in G6PD Deficient Subjects. PLoS ONE, 2016, 11, e0151898.	1.1	63
1267	G6PD Deficiency and Antimalarial Efficacy for Uncomplicated Malaria in Bangladesh: A Prospective Observational Study. PLoS ONE, 2016, 11, e0154015.	1.1	28
1268	Evidence of a Mild Mutator Phenotype in Cambodian Plasmodium falciparum Malaria Parasites. PLoS ONE, 2016, 11, e0154166.	1.1	34

#	ARTICLE	IF	CITATIONS
1269	Uncomplicated Clinical Malaria Features, the Efficacy of Artesunate-Amodiaquine and Their Relation with Multiplicity of Infection in the Democratic Republic of Congo. PLoS ONE, 2016, 11, e0157074.	1.1	13
1270	Genetically Determined Response to Artemisinin Treatment in Western Kenyan Plasmodium falciparum Parasites. PLoS ONE, 2016, 11, e0162524.	1.1	4
1271	Therapeutic efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria in a high-transmission area in northwest Ethiopia. PLoS ONE, 2017, 12, e0176004.	1.1	25
1272	Concomitant nevirapine impacts pharmacokinetic exposure to the antimalarial artemether-lumefantrine in African children. PLoS ONE, 2017, 12, e0186589.	1.1	6
1273	Effect of mass dihydroartemisinin-piperazine administration in southern Mozambique on the carriage of molecular markers of antimalarial resistance. PLoS ONE, 2020, 15, e0240174.	1.1	13
1274	Evolution of Fitness Cost-Neutral Mutant PfCRT Conferring P. falciparum 4-Aminoquinoline Drug Resistance Is Accompanied by Altered Parasite Metabolism and Digestive Vacuole Physiology. PLoS Pathogens, 2016, 12, e1005976.	2.1	34
1275	Stage-Specific Changes in Plasmodium Metabolism Required for Differentiation and Adaptation to Different Host and Vector Environments. PLoS Pathogens, 2016, 12, e1006094.	2.1	82
1276	Emergence of artemisinin-resistant Plasmodium falciparum with kelch13 C580Y mutations on the island of New Guinea. PLoS Pathogens, 2020, 16, e1009133.	2.1	81
1277	Preclinical Studies on a New Vaccine Formulation of BK-SE36, a Malaria Vaccine Candidate. Juntendo Medical Journal, 2015, 61, 360-369.	0.1	3
1278	Challenging Malaria Control. Juntendo Medical Journal, 2015, 61, 370-377.	0.1	2
1279	Ocotea porosa: Anatomy and Histochemistry of Leaves and Stems, Chemical Composition, Cytotoxicity and Insecticidal Activities of Essential Oil. Brazilian Archives of Biology and Technology, 0, 63, .	0.5	8
1280	Malaria Elimination and Eradication. , 2017, , 315-346.		23
1281	The potential of synthetic biology for improving environmental quality and human health in developing countries. Revista De La Universidad Industrial De Santander Salud, 2017, 49, 93-101.	0.0	3
1282	Discovery of Anti-Malarial Agents Through Application of In Silico Studies. Combinatorial Chemistry and High Throughput Screening, 2015, 18, 151-187.	0.6	9
1283	„ä,ççç”“äºŽæ£æµæ¶æ§-ÿäŽÿè™«é:è’¿æš-æ£ççç,,æ-ºäž:èj”äžæ£æµæ¶æ-1æ³•-çŽçš¶ä½/2“é~¶æ©µç”ÿä~æµæ¶æ³•(RGA)äšä...¶		
1284	Plasmodium falciparum Genotype Diversity in Artemisinin Derivatives Treatment Failure Patients along the Thai-Myanmar Border. Korean Journal of Parasitology, 2014, 52, 631-637.	0.5	2
1285	Antiplasmodial and Cytotoxic Activities of Toad Venoms from Southern Amazon, Brazil. Korean Journal of Parasitology, 2016, 54, 415-421.	0.5	17
1286	Unraveling Haplotype Diversity of the Apical Membrane Antigen-1 Gene in Plasmodium falciparum Populations in Thailand. Korean Journal of Parasitology, 2018, 56, 153-165.	0.5	8

#	ARTICLE	IF	CITATIONS
1287	Molecular Surveillance of Pfk13 and Pfmdr1 Mutations in Plasmodium falciparum Isolates from Southern Thailand. Korean Journal of Parasitology, 2019, 57, 369-377.	0.5	10
1288	Artemisinin resistance, some facts and opinions. Journal of Infection in Developing Countries, 2015, 9, 597-599.	0.5	5
1289	Antimalarial drug resistance: An overview. Tropical Parasitology, 2016, 6, 30.	0.2	130
1290	Traditional consumption of the fruit pulp of Chrysophyllum albidum (Sapotaceae) in pregnancy may be serving as an intermittent preventive therapy against malaria infection. Ancient Science of Life: Journal of International Institute of Ayurveda, 2017, 36, 191.	0.3	6
1291	Suspected Artesunate Resistant Malaria in South India. Journal of Global Infectious Diseases, 2018, 10, 26.	0.2	5
1292	Pattern of Antimalarial Drug Use in Malaysia. Indian Journal of Pharmaceutical Sciences, 2016, 78, .	1.0	2
1293	Immune evasion by <i>Plasmodium falciparum</i> parasites: converting a host protection mechanism for the parasite's benefit. Advances in Infectious Diseases, 2016, 06, 82-95.	0.0	15
1294	Sustained High Cure Rate of Artemether-Lumefantrine against Uncomplicated Plasmodium falciparum Malaria after 8 Years of Its Wide-Scale Use in Bagamoyo District, Tanzania. American Journal of Tropical Medicine and Hygiene, 2017, 97, 526-532.	0.6	12
1295	Molecular Epidemiology of Malaria in Cameroon and Cote d'Ivoire. XXXI. Kelch 13 Propeller Sequences in Plasmodium falciparum Isolates before and after Implementation of Artemisinin-Based Combination Therapy. American Journal of Tropical Medicine and Hygiene, 2017, 97, 222-224.	0.6	20
1296	Molecular Markers for Sensitive Detection of Plasmodium falciparum Asexual Stage Parasites and their Application in a Malaria Clinical Trial. American Journal of Tropical Medicine and Hygiene, 2017, 97, 188-198.	0.6	19
1297	In Vitro Sensitivity of Pyronaridine in Thai Isolates of Plasmodium falciparum. American Journal of Tropical Medicine and Hygiene, 2018, 98, 51-56.	0.6	3
1298	Reflections on a Community Engagement Strategy for Mass Antimalarial Drug Administration in Cambodia. American Journal of Tropical Medicine and Hygiene, 2018, 98, 100-104.	0.6	30
1299	Polymorphisms in the K13 Gene in Plasmodium falciparum from Different Malaria Transmission Areas of Kenya. American Journal of Tropical Medicine and Hygiene, 2018, 98, 1360-1366.	0.6	30
1300	Efficacy of Artemether-Lumefantrine for Uncomplicated Plasmodium falciparum Malaria in Cruzeiro do Sul, Brazil, 2016. American Journal of Tropical Medicine and Hygiene, 2018, 98, 88-94.	0.6	8
1301	Therapeutic Response to Dihydroartemisinin-Piperaquine for P. falciparum and P. vivax Nine Years after Its Introduction in Southern Papua, Indonesia. American Journal of Tropical Medicine and Hygiene, 2018, 98, 677-682.	0.6	23
1302	Impacts of Antimalarial Drugs on Plasmodium falciparum Drug Resistance Markers, Western Kenya, 2003-2015. American Journal of Tropical Medicine and Hygiene, 2018, 98, 692-699.	0.6	39
1303	Multiple Phenotypic and Genotypic Artemisinin Sensitivity Evaluation of Malian Plasmodium falciparum Isolates. American Journal of Tropical Medicine and Hygiene, 2018, 98, 1123-1131.	0.6	3
1304	Gametocyte Development and Carriage in Ghanaian Individuals with Uncomplicated Plasmodium falciparum Malaria. American Journal of Tropical Medicine and Hygiene, 2018, 99, 57-64.	0.6	7

#	ARTICLE	IF	CITATIONS
1305	Efficacy of Artemisinin-Based Combination Treatments of Uncomplicated Falciparum Malaria in Under-Five-Year-Old Nigerian Children Ten Years Following Adoption as First-Line Antimalarials. <i>American Journal of Tropical Medicine and Hygiene</i> , 2018, 99, 649-664.	0.6	25
1306	Molecular Detection of Residual Parasitemia after Pyronaridine+Artesunate or Artemether+Lumefantrine Treatment of Uncomplicated Plasmodium falciparum Malaria in Kenyan Children. <i>American Journal of Tropical Medicine and Hygiene</i> , 2018, 99, 970-977.	0.6	14
1307	Gametocyte Carriage, Antimalarial Use, and Drug Resistance in Cambodia, 2008+2014. <i>American Journal of Tropical Medicine and Hygiene</i> , 2018, 99, 1145-1149.	0.6	3
1308	Forest Goers and Multidrug-Resistant Malaria in Cambodia: An Ethnographic Study. <i>American Journal of Tropical Medicine and Hygiene</i> , 2019, 100, 1170-1178.	0.6	29
1309	Prevalence of and Risk Factors Associated with Polymerase Chain Reaction-Determined Plasmodium falciparum Positivity on Day 3 after Initiation of Artemether+Lumefantrine Treatment for Uncomplicated Malaria in Bagamoyo District, Tanzania. <i>American Journal of Tropical Medicine and Hygiene</i> , 2019, 100, 1179-1186.	0.6	8
1310	Plasmodium falciparum Gametocyte Enrichment in Peripheral Blood Samples by Magnetic Fractionation: Gametocyte Yields and Possibilities to Reuse Columns. <i>American Journal of Tropical Medicine and Hygiene</i> , 2019, 100, 572-577.	0.6	10
1311	Artemisinin Resistance Outside of Southeast Asia. <i>American Journal of Tropical Medicine and Hygiene</i> , 2018, 99, 1357-1359.	0.6	14
1312	Performance of Ultrasensitive Rapid Diagnostic Tests for Detecting Asymptomatic Plasmodium falciparum. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, 102, 307-309.	0.6	16
1313	Origin and Spread of Evolving Artemisinin-Resistant Plasmodium falciparum Malarial Parasites in Southeast Asia. <i>American Journal of Tropical Medicine and Hygiene</i> , 2019, 101, 1204-1211.	0.6	20
1314	The WorldWide Antimalarial Resistance Network Clinical Trials Publication Library: A Live, Open-Access Database of Plasmodium Treatment Efficacy Trials. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, 103, 359-368.	0.6	10
1315	Molecular Surveillance and in vitro Drug Sensitivity Study of Plasmodium falciparum Isolates from the China+Myanmar Border. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, 103, 1100-1106.	0.6	6
1316	Therapeutic Efficacy of Artemether+Lumefantrine for Uncomplicated Falciparum Malaria in Northern Zambia. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, 103, 2224-2232.	0.6	8
1317	Antimalarial activity of fractions of aqueous extract of Acacia nilotica root. <i>Journal of Intercultural Ethnopharmacology</i> , 2016, 5, 180.	0.9	17
1318	Haematological Changes and Nitric Oxide Levels Accompanying Artemether-Lumefantrine Administration in Male Guinea Pigs: Effect of Unsweetened Natural Cocoa Powder.. <i>Journal of Intercultural Ethnopharmacology</i> , 2016, 5, 350.	0.9	4
1319	Ending Malaria Transmission in the Asia Pacific Malaria Elimination Network (APMEN) Countries: Challenges and the Way Forward. , 0, , .		5
1320	Human and Simian Malaria in the Greater Mekong Subregion and Challenges for Elimination. , 0, , .		3
1321	QSAR based predictive modeling for anti-malarial molecules. <i>Bioinformatics</i> , 2017, 13, 154-159.	0.2	7
1322	Genomic epidemiology of artemisinin resistant malaria. <i>ELife</i> , 2016, 5, .	2.8	242

#	ARTICLE	IF	CITATIONS
1323	Local emergence in Amazonia of Plasmodium falciparum k13 C580Y mutants associated with in vitro artemisinin resistance. <i>ELife</i> , 2020, 9, .	2.8	102
1324	Molecular Determinants of Artemisinin Resistance in k13 Gene of Plasmodium falciparum. <i>British Microbiology Research Journal</i> , 2015, 9, 1-11.	0.2	2
1325	Modular synthesis of antimalarial quinoline-based PGM metallarectangles. <i>Dalton Transactions</i> , 2021, 50, 15274-15286.	1.6	5
1326	Increase in the proportion of Plasmodium falciparum with kelch13 C580Y mutation and decline in pfcr1 and pfmdr1 mutant alleles in Papua New Guinea. <i>Malaria Journal</i> , 2021, 20, 410.	0.8	11
1327	A Computational Study of Molecular Mechanism of Chloroquine Resistance by Chloroquine Resistance Transporter Protein of Plasmodium falciparum via Molecular Modeling and Molecular Simulations. <i>Physchem</i> , 2021, 1, 232-242.	0.5	3
1328	High-Content Phenotypic Screen of a Focused TCAMS Drug Library Identifies Novel Disruptors of the Malaria Parasite Calcium Dynamics. <i>ACS Chemical Biology</i> , 2021, 16, 2348-2372.	1.6	4
1329	First Detection in West Africa of a Mutation That May Contribute to Artemisinin Resistance Plasmodium falciparum. <i>Frontiers in Genetics</i> , 2021, 12, 701750.	1.1	2
1330	Safety monitoring experience of single-low dose primaquine co-administered with artemether+lumefantrine among providers and patients in routine healthcare practice: a qualitative study in Eastern Tanzania. <i>Malaria Journal</i> , 2021, 20, 392.	0.8	3
1331	Lumefantrine attenuates Plasmodium falciparum artemisinin resistance during the early ring stage. <i>International Journal for Parasitology: Drugs and Drug Resistance</i> , 2021, 17, 186-190.	1.4	3
1332	1,2,3-Triazole derivatives: synthesis, docking, cytotoxicity analysis and in vivo antimalarial activity. <i>Chemico-Biological Interactions</i> , 2021, 350, 109688.	1.7	8
1335	South-East Asian strains of Plasmodium falciparum display higher ratio of non-synonymous to synonymous polymorphisms compared to African strains. <i>F1000Research</i> , 2016, 5, 1964.	0.8	0
1336	South-East Asian strains of Plasmodium falciparum display higher ratio of non-synonymous to synonymous polymorphisms compared to African strains. <i>F1000Research</i> , 2016, 5, 1964.	0.8	0
1337	Antimalarial Drug Resistance: Clinical Perspectives. , 2017, , 1245-1275.		0
1341	Capacity Development through the US President's Malaria Initiative's Supported Antimalarial Resistance Monitoring in Africa Network. <i>Emerging Infectious Diseases</i> , 2017, 23, .	2.0	0
1346	Prise en charge du paludisme grave de l'importation de l'adulte. <i>Medecine Intensive Reanimation</i> , 2018, 27, 228-238.	0.1	2
1350	In silico Structural Characterization of Plasmodium falciparum helicase, PfBrr2. <i>Biosciences, Biotechnology Research Asia</i> , 2018, 15, 517-527.	0.2	0
1351	POTENCY OF LUTEOLIN WITH SOLID LIPID NANOPARTICLE (SLN)-POLYETHYLENE GLYCOL (PEG) MODIFICATION FOR ARTEMISININ-RESISTANT PLASMODIUM FALCIPARUM INFECTION. <i>Indonesian Journal of Tropical and Infectious Disease</i> , 2018, 7, 80.	0.1	3
1352	Molecular Mechanisms of Action and Resistance of Antimalarial Drugs. , 2019, , 267-296.		3

#	ARTICLE	IF	CITATIONS
1353	Clinically Relevant Drug Interactions for Malaria. , 2019, , 1-11.		0
1354	The Accuracy and Perception of Test-Based Management of Malaria at Private Licensed Chemical Shops in the Middle Belt of Ghana. American Journal of Tropical Medicine and Hygiene, 2019, 100, 264-274.	0.6	7
1356	An interactive application for malaria elimination transmission and costing in the Asia-Pacific. Wellcome Open Research, 0, 4, 61.	0.9	5
1358	K13 propeller domain mutations and pfmdr1 amplification in isolates of Plasmodium falciparum collected from Thai-Myanmar border area in 2006-2010. Folia Parasitologica, 2019, 66, .	0.7	3
1363	Ensemble machine learning modeling for the prediction of artemisinin resistance in malaria. F1000Research, 0, 9, 62.	0.8	5
1364	Risk Factors For The Presence Of Artemisinin Antibodies Amongst Patients Undergoing Treatment For Malaria In Benin City, Nigeria. European Journal of Medical and Health Sciences, 2020, 2, .	0.1	1
1366	A non-reactive natural product precursor of the duocarmycin family has potent and selective antimalarial activity. Cell Chemical Biology, 2022, 29, 840-853.e6.	2.5	2
1367	Protein abundance and folding rather than the redox state of Kelch13 determine the artemisinin susceptibility of Plasmodium falciparum. Redox Biology, 2021, 48, 102177.	3.9	7
1368	Molecular Surveillance and Ex Vivo Drug Susceptibilities of Plasmodium vivax Isolates From the China-Myanmar Border. Frontiers in Cellular and Infection Microbiology, 2021, 11, 738075.	1.8	5
1371	Antimicrobial Resistance and the Private Sector in Southeast Asia. Public Health Ethics Analysis, 2020, , 75-87.	0.1	3
1372	MALARIA VACCINE DEVELOPMENT: PREVIOUS SUCCESS, CURRENT STATUS AND FUTURE PROSPECTS. , 2019, 04, 74-81.		0
1375	Transformative Adaptations for Health Impacts of Climate Change in Burkina Faso and Kenya. , 2020, , 1-16.		0
1376	Investigational Drugs, Quality, and Drug Formulations for Malaria. , 2020, , 1-16.		0
1377	Mechanisms of CaaX Protein Processing: Protein Prenylation by FTase and GGTase-I. , 2020, , 497-527.		0
1378	Ethics and Antimalarial Drug Resistance. Public Health Ethics Analysis, 2020, , 55-73.	0.1	4
1382	Immediate pools of malaria infections at diagnosis combined with targeted deep sequencing accurately quantifies frequency of drug resistance mutations. PeerJ, 2021, 9, e11794.	0.9	0
1384	Expansion Microscopy Reveals Plasmodium falciparum Blood-Stage Parasites Undergo Anaphase with A Chromatin Bridge in the Absence of Mini-Chromosome Maintenance Complex Binding Protein. Microorganisms, 2021, 9, 2306.	1.6	42
1389	Combination therapy--a way to forestall artemisinin resistance and optimize uncomplicated malaria treatment. Journal of Medicine and Life, 2015, 8, 326-8.	0.4	3

#	ARTICLE	IF	CITATIONS
1390	Cerebral Malaria Treated with Artemisinin in the Intensive Care Unit: A Case Report. Iranian Journal of Parasitology, 2016, 11, 116-20.	0.6	0
1391	Pediatric Malaria. Pediatric Clinics of North America, 2022, 69, 47-64.	0.9	0
1392	Synthesis and in silico ADME/Tox profiling studies of heterocyclic hybrids based on chloroquine scaffolds with potential antimalarial activity. Parasitology Research, 2022, 121, 441-451.	0.6	5
1393	Discovery of Imidazole-Based Inhibitors of <i>Plasmodium falciparum</i> cGMP-Dependent Protein Kinase. ACS Medicinal Chemistry Letters, 2021, 12, 1962-1967.	1.3	2
1394	Scoping Review of Antimalarial Drug Candidates in Phase I and II Drug Development. Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0165921.	1.4	8
1395	Artemisinin Binds and Inhibits the Activity of Plasmodium falciparum Ddi1, a Retroviral Aspartyl Protease. Pathogens, 2021, 10, 1465.	1.2	5
1396	A Validated HPLC-PDA-HRMS Method to Investigate the Biological Stability and Metabolism of Antiparasitic Triterpenic Esters. Molecules, 2021, 26, 7154.	1.7	0
1397	Absence of Plasmodium falciparum artemisinin resistance gene mutations eleven years after the adoption of artemisinin-based combination therapy in Nigeria. Malaria Journal, 2021, 20, 434.	0.8	3
1398	Antimalarial Drug Predictions Using Molecular Descriptors and Machine Learning against Plasmodium Falciparum. Biomolecules, 2021, 11, 1750.	1.8	8
1399	Distance matters: barriers to antenatal care and safe childbirth in a migrant population on the Thailand-Myanmar border from 2007 to 2015, a pregnancy cohort study. BMC Pregnancy and Childbirth, 2021, 21, 802.	0.9	9
1400	Prevalence of potential mediators of artemisinin resistance in African isolates of Plasmodium falciparum. Malaria Journal, 2021, 20, 451.	0.8	15
1401	Allelic Frequencies of Mutants of the <i>Plasmodium Falciparum</i> , Quinoline and Folate Metabolizing Genes in the West Region of Cameroon. SSRN Electronic Journal, 0, , .	0.4	0
1402	Molecular Investigation of Genetic Signatures of Selection in <i>Plasmodium falciparum</i> ; Actin-Binding Protein Coronin, Cysteine Desulfurase, and Plasmepsin 2 Gene in Mbita Field Isolates, Western Kenya. Open Journal of Genetics, 2021, 11, 120-144.	0.1	4
1403	FIT-PNAs as RNA-Sensing Probes for Drug-Resistant <i>Plasmodium falciparum</i> . ACS Sensors, 2022, 7, 50-59.	4.0	4
1404	Peroxide Antimalarial Drugs Target Redox Homeostasis in <i>Plasmodium falciparum</i> Infected Red Blood Cells. ACS Infectious Diseases, 2022, 8, 210-226.	1.8	23
1405	Time for African youth in science. Acta Tropica, 2022, 226, 106270.	0.9	0
1406	Specific sub fractions from Terminalia mantaly (H. Perrier) extracts potently inhibit Plasmodium falciparum rings, merozoite egress and invasion. Journal of Ethnopharmacology, 2022, 285, 114909.	2.0	1
1407	Design, Synthesis and Biological Evaluation of Aminoalkylated Chalcones as Antimalarial Agent. Sains Malaysiana, 2020, 49, 2667-2677.	0.3	3

#	ARTICLE	IF	CITATIONS
1408	Methods Used to Investigate the Plasmodium falciparum Digestive Vacuole. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 829823.	1.8	4
1409	Future directions for the discovery of natural product-derived immunomodulating drugs: an IUPHAR positional review. <i>Pharmacological Research</i> , 2022, 177, 106076.	3.1	23
1410	Assessment <i>In Vitro</i> of the Antimalarial and Transmission-Blocking Activities of Cipargamin and Ganaplacide in Artemisinin-Resistant <i>Plasmodium falciparum</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0148121.	1.4	4
1411	Improving anthelmintic treatment for schistosomiasis and soil-transmitted helminthiases through sharing and reuse of individual participant data. <i>Wellcome Open Research</i> , 2022, 7, 5.	0.9	5
1412	Assessment of Plasmodium falciparum Artemisinin Resistance Independent of <i>kelch13</i> Polymorphisms and with Escalating Malaria in Bangladesh. <i>MBio</i> , 2022, 13, e0344421.	1.8	7
1413	Decoquinate liposomes: highly effective clearance of Plasmodium parasites causing severe malaria. <i>Malaria Journal</i> , 2022, 21, 24.	0.8	3
1414	Insecticide, Acaricide, Repellent and Antimicrobial Development. <i>Molecules</i> , 2022, 27, 386.	1.7	3
1415	A Phosphoinositide-Binding Protein Acts in the Trafficking Pathway of Hemoglobin in the Malaria Parasite Plasmodium falciparum. <i>MBio</i> , 2022, 13, e0323921.	1.8	10
1416	Repurposing the Pathogen Box compounds for identification of potent anti-malarials against blood stages of Plasmodium falciparum with PfUCLH3 inhibitory activity. <i>Scientific Reports</i> , 2022, 12, 918.	1.6	4
1417	<i>Plasmodium falciparum</i> Kelch13 and its artemisinin-resistant mutants assemble as hexamers in solution: a SAXS data-driven modelling study. <i>FEBS Journal</i> , 2022, 289, 4935-4962.	2.2	4
1418	Compounds targeting GPI biosynthesis or N-glycosylation are active against Plasmodium falciparum. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 850-863.	1.9	6
1419	Long-term effects of increased adoption of artemisinin combination therapies in Burkina Faso. <i>PLOS Global Public Health</i> , 2022, 2, e0000111.	0.5	13
1420	Identification of polymorphisms in genes associated with drug resistance in Plasmodium falciparum isolates from school-age children in Kinshasa, Democratic Republic of Congo. <i>Parasitology International</i> , 2022, 88, 102541.	0.6	4
1421	Biennial surveillance of Plasmodium falciparum anti-malarial drug resistance markers in Democratic Republic of Congo, 2017 and 2019. <i>BMC Infectious Diseases</i> , 2022, 22, 145.	1.3	5
1423	Spatio-temporal distribution of antimalarial drug resistant gene mutations in a Plasmodium falciparum parasite population from Kilifi, Kenya: A 25-year retrospective study. <i>Wellcome Open Research</i> , 0, 7, 45.	0.9	8
1424	Machine learning for artemisinin resistance in malaria treatment across <i>in vivo</i> - <i>in vitro</i> platforms. <i>IScience</i> , 2022, 25, 103910.	1.9	4
1425	Identification of an Inhibitory Pocket in Falcylisin Bound by Chloroquine Provides a New Avenue for Malaria Drug Development. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1427	Evaluation of the antimalarial activity and toxicity of Mahanil-Tang-Thong formulation and its plant ingredients. <i>BMC Complementary Medicine and Therapies</i> , 2022, 22, 51.	1.2	6

#	ARTICLE	IF	CITATIONS
1429	Is it time for Africa to adopt primaquine in the era of malaria control and elimination?. <i>Tropical Medicine and Health</i> , 2022, 50, 17.	1.0	3
1430	Circulation of an Artemisinin-Resistant Malaria Lineage in a Traveler Returning from East Africa to France. <i>Clinical Infectious Diseases</i> , 2022, 75, 1242-1244.	2.9	5
1431	GeneTargeter: Automated <i>In Silico</i> Design for Genome Editing in the Malaria Parasite, <i>Plasmodium falciparum</i> . <i>CRISPR Journal</i> , 2022, 5, 155-164.	1.4	3
1432	The Antagonizing Role of Heme in the Antimalarial Function of Artemisinin: Elevating Intracellular Free Heme Negatively Impacts Artemisinin Activity in <i>Plasmodium falciparum</i> . <i>Molecules</i> , 2022, 27, 1755.	1.7	7
1433	Synthesis, Antiplasmodial, and Antileukemia Activity of Dihydroartemisinin-HDAC Inhibitor Hybrids as Multitarget Drugs. <i>Pharmaceuticals</i> , 2022, 15, 333.	1.7	4
1434	Synthesis and antimalarial activity of amide and ester conjugates of siderophores and ozonides. <i>BioMetals</i> , 2022, , 1.	1.8	2
1435	Biotransformation of artemisinin to a novel derivative via ring rearrangement by <i>Aspergillus niger</i> . <i>Applied Microbiology and Biotechnology</i> , 2022, 106, 2433-2444.	1.7	5
1436	Defining the burden of febrile illness in rural South and Southeast Asia: an open letter to announce the launch of the Rural Febrile Illness project. <i>Wellcome Open Research</i> , 0, 6, 64.	0.9	11
1437	Reduction in <i>Plasmodium falciparum</i> Pfk13 and pfg377 allele diversity through time in southern Vietnam. <i>Tropical Medicine and Health</i> , 2022, 50, 19.	1.0	0
1438	Targeted Amplicon Deep Sequencing for Monitoring Antimalarial Resistance Markers in Western Kenya. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, e0194521.	1.4	4
1439	Efficacy and safety of dihydroartemisinin-piperazine for the treatment of uncomplicated <i>Plasmodium falciparum</i> and <i>Plasmodium vivax</i> malaria in Papua and Sumatra, Indonesia. <i>Malaria Journal</i> , 2022, 21, 95.	0.8	5
1440	Molecular surveillance for operationally relevant genetic polymorphisms in <i>Plasmodium falciparum</i> in Southern Chad, 2016-2017. <i>Malaria Journal</i> , 2022, 21, 83.	0.8	5
1441	The Changing Global Landscape in the Development of Artemisinin-Based Treatments: A Clinical Trial Perspective. <i>The American Journal of Chinese Medicine</i> , 2022, 50, 733-748.	1.5	1
1442	Triple therapy with artemether-lumefantrine plus amodiaquine versus artemether-lumefantrine alone for artemisinin-resistant, uncomplicated <i>falciparum</i> malaria: an open-label, randomised, multicentre trial. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 867-878.	4.6	27
1443	Targeted Amplicon deep sequencing of <i>ama1</i> and <i>mdr1</i> to track within-host <i>P. falciparum</i> diversity throughout treatment in a clinical drug trial. <i>Wellcome Open Research</i> , 0, 7, 95.	0.9	0
1444	A single low dose of primaquine is safe and sufficient to reduce transmission of <i>Plasmodium falciparum</i> gametocytes regardless of cytochrome P450 2D6 enzyme activity in Bagamoyo district, Tanzania. <i>Malaria Journal</i> , 2022, 21, 84.	0.8	7
1445	Artemisinin resistance in the malaria parasite, <i>Plasmodium falciparum</i> , originates from its initial transcriptional response. <i>Communications Biology</i> , 2022, 5, 274.	2.0	33
1446	Adherence to Dihydroartemisinin+Piperazine Treatment Regimen in Low and High Endemic Areas in Indonesia. <i>Journal of Tropical Medicine</i> , 2022, 2022, 1-11.	0.6	0

#	ARTICLE	IF	CITATIONS
1447	Molecular Surveillance for Imported Antimicrobial Resistant <i>Plasmodium falciparum</i> , Ontario, Canada. <i>Emerging Infectious Diseases</i> , 2022, 28, 812-819.	2.0	1
1448	Spiral molecules with antimalarial activities: A review. <i>European Journal of Medicinal Chemistry</i> , 2022, 237, 114361.	2.6	8
1449	Anti-Gametocyte Antigen Humoral Immunity and Gametocytemia During Treatment of Uncomplicated <i>Falciparum</i> Malaria: A Multi-National Study. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, 804470.	1.8	1
1450	Glycosylphosphatidylinositol-anchored micronemal antigen (GAMA) interacts with the band 3 receptor to promote erythrocyte invasion by malaria parasites. <i>Journal of Biological Chemistry</i> , 2022, 298, 101765.	1.6	11
1451	Malaria eradication revisited. <i>International Journal of Epidemiology</i> , 2022, 51, 382-392.	0.9	3
1452	Combined Transcriptome and Proteome Profiling for Role of pfEMP1 in Antimalarial Mechanism of Action of Dihydroartemisinin. <i>Microbiology Spectrum</i> , 2021, 9, e0127821.	1.2	4
1454	Temporal evolution of the resistance genotypes of <i>Plasmodium falciparum</i> in isolates from Equatorial Guinea during 20 years (1999 to 2019). <i>Malaria Journal</i> , 2021, 20, 463.	0.8	4
1455	Multipurpose Drugs Active Against Both <i>Plasmodium</i> spp. and Microorganisms: Potential Application for New Drug Development. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 797509.	1.8	1
1456	Dynamic changes in genetic diversity, drug resistance mutations, and treatment outcomes of <i>falciparum</i> malaria from the low-transmission to the pre-elimination phase on the islands of São Tomé and Príncipe. <i>Malaria Journal</i> , 2021, 20, 467.	0.8	2
1457	Limited Polymorphism in <i>Plasmodium falciparum</i> Artemisinin Resistance Kelch13-Propeller Gene Among Clinical Isolates from Bushenyi District, Uganda. <i>Infection and Drug Resistance</i> , 2021, Volume 14, 5153-5163.	1.1	1
1458	Malaria in 2022: Challenges and Progress. <i>American Journal of Tropical Medicine and Hygiene</i> , 2022, 106, 1565-1567.	0.6	11
1459	Discovery, Biosynthetic Origin, and Heterologous Production of Massinidine, an Antiplasmodial Alkaloid. <i>Organic Letters</i> , 2022, 24, 2935-2939.	2.4	6
1460	Evaluations of candidate markers of dihydroartemisinin-piperaquine resistance in <i>Plasmodium falciparum</i> isolates from the China-Myanmar, Thailand-Myanmar, and Thailand-Cambodia borders. <i>Parasites and Vectors</i> , 2022, 15, 130.	1.0	7
1461	Is triple artemisinin-based combination therapy necessary for uncomplicated malaria?. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 585-586.	4.6	4
1481	Population Pharmacokinetics of Antimalarial Naphthoquine in Combination with Artemisinin in Tanzanian Children and Adults: Dose Optimization. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, , e0169621.	1.4	0
1482	Polymorphisms of potential drug resistant molecular markers in <i>Plasmodium vivax</i> from China-Myanmar border during 2008-2017. <i>Infectious Diseases of Poverty</i> , 2022, 11, 43.	1.5	6
1483	Mosquirixâ€¢ RTS, S/AS01 Vaccine Development, Immunogenicity, and Efficacy. <i>Vaccines</i> , 2022, 10, 713.	2.1	23
1484	Artesunateâ€¢ amodiaquine and artemetherâ€¢ lumefantrine for the treatment of uncomplicated <i>falciparum</i> malaria in Liberia: in vivo efficacy and frequency of molecular markers. <i>Malaria Journal</i> , 2022, 21, 134.	0.8	7

#	ARTICLE	IF	CITATIONS
1486	Worldwide Research Trends on Artemisinin: A Bibliometric Analysis From 2000 to 2021. <i>Frontiers in Medicine</i> , 2022, 9, .	1.2	11
1487	Antimalarial Drug Strategies to Target Plasmodium Gametocytes. <i>Parasitologia</i> , 2022, 2, 101-124.	0.6	5
1488	Novel pfk13 polymorphisms in Plasmodium falciparum population in Ghana. <i>Scientific Reports</i> , 2022, 12, 7797.	1.6	6
1489	Malaria in 2022: Increasing challenges, cautious optimism. <i>Nature Communications</i> , 2022, 13, 2678.	5.8	37
1490	Learnings from Thailand in building strong surveillance for malaria elimination. <i>Nature Communications</i> , 2022, 13, 2677.	5.8	5
1491	Assessing the Roles of Molecular Markers of Antimalarial Drug Resistance and the Host Pharmacogenetics in Drug-Resistant Malaria. <i>Journal of Tropical Medicine</i> , 2022, 2022, 1-9.	0.6	5
1493	Age-Dosed Single Low Dose Primaquine in Falciparum-Infected African Children with G6pd Deficiency is Well Tolerated and Safe. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1494	On the Contribution of the Rodent Model Plasmodium Chabaudi for Understanding the Genetics of Drug Resistance in Malaria. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1495	A brief history of malaria. <i>Presse Medicale</i> , 2022, 51, 104130.	0.8	12
1496	Low Complexity of Infection Is Associated With Molecular Persistence of Plasmodium falciparum in Kenya and Tanzania. , 2022, 2, .		3
1499	Comparison of antibody responses and parasite clearance in artemisinin therapeutic efficacy studies in Democratic Republic of Congo and Asia. <i>Journal of Infectious Diseases</i> , 0, , .	1.9	1
1500	Synthesis, Anti-Plasmodial Activities, and Mechanistic Insights of 4-Aminoquinoline-Triazolopyrimidine Hybrids. <i>ACS Medicinal Chemistry Letters</i> , 2022, 13, 1068-1076.	1.3	9
1501	Swertiamarin-mediated immune modulation/adaptation confers protection against <i>Plasmodium berghei</i> . <i>Future Microbiology</i> , 0, , .	1.0	1
1502	Parasite Viability as a Measure of <i>In Vivo</i> Drug Activity in Preclinical and Early Clinical Antimalarial Drug Assessment. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, .	1.4	3
1503	Plasmodium knowlesi Cytoadhesion Involves SICA Variant Proteins. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	4
1504	Molecular Surveillance of Artemisinin-Based Combination Therapies Resistance in Plasmodium falciparum Parasites from Bioko Island, Equatorial Guinea. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	3
1505	Genetics of cerebral malaria: pathogenesis, biomarkers and emerging therapeutic interventions. <i>Cell and Bioscience</i> , 2022, 12, .	2.1	3
1506	Using an antimalarial in mosquitoes overcomes Anopheles and Plasmodium resistance to malaria control strategies. <i>PLoS Pathogens</i> , 2022, 18, e1010609.	2.1	10

#	ARTICLE	IF	CITATIONS
1507	Designing and development of phthalimides as potent anti-tubulin hybrid molecules against malaria. <i>European Journal of Medicinal Chemistry</i> , 2022, 239, 114534.	2.6	7
1508	Environmental impacts of mass drug administration programs: exposures, risks, and mitigation of antimicrobial resistance. <i>Infectious Diseases of Poverty</i> , 2022, 11, .	1.5	6
1509	Making data map-worthyâ€”enhancing routine malaria data to support surveillance and mapping of <i>Plasmodium falciparum</i> anti-malarial resistance in a pre-elimination sub-Saharan African setting: a molecular and spatiotemporal epidemiology study. <i>Malaria Journal</i> , 2022, 21, .	0.8	0
1510	The influence of biological, epidemiological, and treatment factors on the establishment and spread of drug-resistant <i>Plasmodium falciparum</i> . <i>ELife</i> , 0, 11, .	2.8	14
1511	Evaluation of the Effect of Gene Duplication by Genome Editing on Drug Resistance in <i>Plasmodium falciparum</i> . <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	3
1512	4-Substituted Thieno[3,2-d]pyrimidines as Dual-Stage Antiplasmodial Derivatives. <i>Pharmaceuticals</i> , 2022, 15, 820.	1.7	4
1513	Genomic epidemiological models describe pathogen evolution across fitness valleys. <i>Science Advances</i> , 2022, 8, .	4.7	2
1514	Translational Research on Chagas Disease: Focusing on Drug Combination and Repositioning. , 0, , .		0
1515	Antimalarial Activity of Crude Extract and Solvent Fractions of Leaves of <i>Solanum nigrum</i> L. (Solanaceae) against <i>Plasmodium berghei</i> in Mice. <i>Evidence-based Complementary and Alternative Medicine</i> , 2022, 2022, 1-10.	0.5	2
1516	On the contribution of the rodent model <i>Plasmodium chabaudi</i> for understanding the genetics of drug resistance in malaria. <i>Parasitology International</i> , 2022, 91, 102623.	0.6	3
1517	The assessment of antimalarial drug efficacy in vivo. <i>Trends in Parasitology</i> , 2022, 38, 660-672.	1.5	7
1518	Phytochemical profiling, in vitro biological activities, and in-silico molecular docking studies of <i>Typha domingensis</i> . <i>Arabian Journal of Chemistry</i> , 2022, 15, 104133.	2.3	25
1519	Prevalence of Mutations in the <i>Pf dhfr</i> , <i>Pf dhps</i> , and <i>Pf mdr1</i> Genes of Malarial Parasites Isolated from Symptomatic Patients in Dogondoutchi, Niger. <i>Tropical Medicine and Infectious Disease</i> , 2022, 7, 155.	0.9	4
1520	Spatiotemporal spread of <i>Plasmodium falciparum</i> mutations for resistance to sulfadoxine-pyrimethamine across Africa, 1990â€”2020. <i>PLoS Computational Biology</i> , 2022, 18, e1010317.	1.5	16
1521	Functional inactivation of <i>Plasmodium falciparum</i> glycogen synthase kinase GSK3 modulates erythrocyte invasion and blocks gametocyte maturation. <i>Journal of Biological Chemistry</i> , 2022, 298, 102360.	1.6	1
1524	Diagnosis, Treatment, and Prevention of Malaria in the US. <i>JAMA - Journal of the American Medical Association</i> , 2022, 328, 460.	3.8	25
1525	Substrate Peptidomimetic Inhibitors of <i>P. falciparum</i> Plasmeprin X with Potent Antimalarial Activity. <i>ChemMedChem</i> , 2022, 17, .	1.6	5
1527	The first case of artemisinin treatment failure of <i>Plasmodium falciparum</i> imported to Oman from Tanzania. <i>Journal of Travel Medicine</i> , 2023, 30, .	1.4	2

#	ARTICLE	IF	CITATIONS
1529	Persistently high proportions of plasmodium-infected Anopheles funestus mosquitoes in two villages in the Kilombero valley, South-Eastern Tanzania. <i>Parasite Epidemiology and Control</i> , 2022, 18, e00264.	0.6	15
1532	Epidemiology and clinical features of imported malaria: a 14-year retrospective single-centre descriptive study in Prague, Czech Republic. <i>Malaria Journal</i> , 2022, 21, .	0.8	1
1533	Naturally Acquired Kelch13 Mutations in Plasmodium falciparum Strains Modulate <i>In Vitro</i> Ring-Stage Artemisinin-Based Drug Tolerance and Parasite Survival in Response to Hyperoxia. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	4
1534	Anti-folate quintuple mutations in Plasmodium falciparum asymptomatic infections in Yaoundé, Cameroon. <i>Parasitology International</i> , 2023, 92, 102657.	0.6	0
1535	A song for the unsung: The relevance of Plasmodium vinckei as a laboratory rodent malaria system. <i>Parasitology International</i> , 2023, 92, 102680.	0.6	0
1536	Biomarkers of the Toxic Effects of Chemotherapeutic Agents: A Focus on Antimalarials. <i>Biomarkers in Disease</i> , 2022, , 1-27.	0.0	1
1537	Nanovesicles for drug codelivery. , 2022, , 21-37.		0
1538	Australian chemistry and drug discovery towards the development of antimalarials. <i>Australian Journal of Chemistry</i> , 2022, , .	0.5	1
1539	Semi-field evaluation of human landing catches versus human double net trap for estimating human biting rate of Anopheles minimus and Anopheles harrisoni in Thailand. <i>PeerJ</i> , 0, 10, e13865.	0.9	2
1540	Antiprotozoal Activity of Azabicyclo-Nonanes Linked to Tetrazole or Sulfonamide Cores. <i>Molecules</i> , 2022, 27, 6217.	1.7	4
1541	How do the mutations in PfK13 protein promote anti-malarial drug resistance?. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 7329-7338.	2.0	0
1542	GAPDH mediates drug resistance and metabolism in Plasmodium falciparum malaria parasites. <i>PLoS Pathogens</i> , 2022, 18, e1010803.	2.1	2
1543	Temporal trends in molecular markers of drug resistance in Plasmodium falciparum in human blood and profiles of corresponding resistant markers in mosquito oocysts in Asembo, western Kenya. <i>Malaria Journal</i> , 2022, 21, .	0.8	2
1544	Artemisinin resistance and malaria elimination: Where are we now?. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	22
1545	Exploring a Tetrahydroquinoline Antimalarial Hit from the Medicines for Malaria Pathogen Box and Identification of its Mode of Resistance as Pf-eEF2. <i>ChemMedChem</i> , 2022, 17, .	1.6	5
1546	Methylene Blue-Based Combination Therapy with Amodiaquine Prevents Severe Malaria in an Experimental Rodent Model. <i>Pharmaceutics</i> , 2022, 14, 2031.	2.0	2
1547	Efficacy of three anti-malarial regimens for uncomplicated Plasmodium falciparum malaria in Cambodia, 2009–2011: a randomized controlled trial and brief review. <i>Malaria Journal</i> , 2022, 21, .	0.8	3
1548	Experience and confidence in health technologies: evidence from malaria testing and treatment in Western Kenya. <i>BMC Public Health</i> , 2022, 22, .	1.2	0

#	ARTICLE	IF	CITATIONS
1549	Efficacy of Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Plasmodium falciparum Malaria among Children in Western Kenya, 2016 to 2017. Antimicrobial Agents and Chemotherapy, 2022, 66, .	1.4	5
1551	Pfmdr 1 and kelch 13 genes distribution among children that are 5 years and below in Akure, Nigeria. Journal of Parasitic Diseases, 0, , .	0.4	0
1553	Structural Modelling Prediction of Recombinant Plasmodium falciparum K13-F446I and K13-C580Y Gene by AlphaFold Method and Heterologous Expression in Spodoptera frugiperda 9 Cells. Pathogens, 2022, 11, 1271.	1.2	0
1554	In vitro susceptibility profile of Plasmodium falciparum clinical isolates from Ghana to antimalarial drugs and polymorphisms in resistance markers. Frontiers in Cellular and Infection Microbiology, 0, 12, .	1.8	3
1555	Multidisciplinary Investigations of Sustained Malaria Transmission in the Greater Mekong Subregion. American Journal of Tropical Medicine and Hygiene, 2022, 107, 138-151.	0.6	5
1556	Molecular Profiles of Multiple Antimalarial Drug Resistance Markers in Plasmodium falciparum and Plasmodium vivax in the Mandalay Region, Myanmar. Microorganisms, 2022, 10, 2021.	1.6	5
1557	The Impact of Human Activities on River Pollution and Health-Related Quality of Life: Evidence from Ghana. Sustainability, 2022, 14, 13120.	1.6	6
1558	Asia-Pacific ICEMR: Understanding Malaria Transmission to Accelerate Malaria Elimination in the Asia Pacific Region. American Journal of Tropical Medicine and Hygiene, 2022, 107, 131-137.	0.6	2
1559	Genome-wide functional screening of drug-resistance genes in Plasmodium falciparum. Nature Communications, 2022, 13, .	5.8	4
1560	Parasite clearance dynamics in children hospitalised with severe malaria in the Ho Teaching Hospital, Volta Region, Ghana. Parasite Epidemiology and Control, 2022, 19, e00276.	0.6	0
1562	Bioactive compounds, anti-inflammatory, anti-nociceptive and antioxidant potentials of ethanolic leaf fraction of Sida linifolia L. (Malvaceae). Arabian Journal of Chemistry, 2023, 16, 104398.	2.3	3
1563	A community based study on haemoglobinopathies and G6PD deficiency among particularly vulnerable tribal groups in hard-to-reach malaria endemic areas of Odisha, India: implications on malaria control. Malaria Journal, 2022, 21, .	0.8	1
1564	Biomarkers of the Toxic Effects of Chemotherapeutic Agents: A Focus on Antimalarials. Biomarkers in Disease, 2023, , 1-27.	0.0	1
1565	Analogues of Oxamate, Pyruvate, and Lactate as Potential Inhibitors of Plasmodium knowlesi Lactate Dehydrogenase Identified Using Virtual Screening and Verified via Inhibition Assays. Processes, 2022, 10, 2443.	1.3	2
1566	Ring-stage growth arrest: Metabolic basis of artemisinin tolerance in Plasmodium falciparum. IScience, 2023, 26, 105725.	1.9	8
1567	Village malaria workers for the community-based management of vivax malaria. , 2023, 9, 100128.		10
1568	Targeting malaria parasites with novel derivatives of azithromycin. Frontiers in Cellular and Infection Microbiology, 0, 12, .	1.8	2
1569	Malaria outbreak in Laos driven by a selective sweep for Plasmodium falciparum kelch13 R539T mutants: a genetic epidemiology analysis. Lancet Infectious Diseases, The, 2023, 23, 568-577.	4.6	10

#	ARTICLE	IF	CITATIONS
1570	Malaria outbreak in Laos caused by formerly rare artemisinin resistant strains of Plasmodium falciparum. <i>Lancet Infectious Diseases</i> , The, 2023, 23, 513-514.	4.6	0
1571	Safety of age-dosed, single low-dose primaquine in children with glucose-6-phosphate dehydrogenase deficiency who are infected with Plasmodium falciparum in Uganda and the Democratic Republic of the Congo: a randomised, double-blind, placebo-controlled, non-inferiority trial. <i>Lancet Infectious Diseases</i> , The, 2023, 23, 471-483.	4.6	6
1572	Drug resistance of Plasmodium falciparum and Plasmodium vivax isolates in Indonesia. <i>Malaria Journal</i> , 2022, 21, .	0.8	9
1573	Zebras in the Era of COVID. <i>Cureus</i> , 2022, , .	0.2	0
1575	Molecular markers of dihydroartemisinin-piperaquine resistance in northwestern Thailand. <i>Malaria Journal</i> , 2022, 21, .	0.8	0
1576	Phytochemical, Antimalarial, and Acute Oral Toxicity Properties of Selected Crude Extracts of Prabchompoothawweep Remedy in Plasmodium berghei-Infected Mice. <i>Tropical Medicine and Infectious Disease</i> , 2022, 7, 395.	0.9	6
1577	Allelic frequencies of mutants of the Plasmodium falciparum, quinoline and folate metabolizing genes in the west region of Cameroon. <i>Heliyon</i> , 2022, 8, e11861.	1.4	1
1579	Urinary Metabolic Profiling in Volunteers Undergoing Malaria Challenge in Gabon. <i>Metabolites</i> , 2022, 12, 1224.	1.3	1
1580	Quinolone: a versatile therapeutic compound class. <i>Molecular Diversity</i> , 2023, 27, 1501-1526.	2.1	11
1581	Blood-stage antiplasmodial activity and oocyst formation-blockage of metallo copper-cinchonine complex. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	0
1582	Different In Vitro Drug Susceptibility Profile of Plasmodium falciparum Isolates from Two Adjacent Areas of Northeast Myanmar and Molecular Markers for Drug Resistance. <i>Tropical Medicine and Infectious Disease</i> , 2022, 7, 442.	0.9	1
1583	Molecular surveillance of artemisinin resistance-related Pfk13 and pfcr1 polymorphisms in imported Plasmodium falciparum isolates reported in eastern China from 2015 to 2019. <i>Malaria Journal</i> , 2022, 21, .	0.8	0
1584	Targeted amplicon deep sequencing of ama1 and mdr1 to track within-host P. falciparum diversity throughout treatment in a clinical drug trial. <i>Wellcome Open Research</i> , 0, 7, 95.	0.9	0
1585	How do malaria testing and treatment subsidies affect drug shop client expenditures? A cross-sectional analysis in Western Kenya. <i>BMJ Open</i> , 2022, 12, e066814.	0.8	0
1586	Editorial: Antimalarial chemotherapy in the XXIst century. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	0
1587	Prevalence of malaria resistance-associated mutations in Plasmodium falciparum circulating in 2017-2018, Bo, Sierra Leone. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	0
1588	The impact of sequestration on artemisinin-induced parasite clearance in Plasmodium falciparum malaria in Africa. <i>Clinical Infectious Diseases</i> , 0, , .	2.9	1
1592	Development of Potent and Highly Selective Epoxyketone-Based Plasmodium Proteasome Inhibitors. <i>Chemistry - A European Journal</i> , 2023, 29, .	1.7	4

#	ARTICLE	IF	CITATIONS
1593	New antiplasmodial 4-amino-thieno[3,2-d]pyrimidines with improved intestinal permeability and microsomal stability. <i>European Journal of Medicinal Chemistry</i> , 2023, 249, 115115.	2.6	2
1594	Structure-Activity Relationship Studies of Antimalarial Plasmodium Proteasome Inhibitors-Part II. <i>Journal of Medicinal Chemistry</i> , 2023, 66, 1484-1508.	2.9	1
1595	The microbiota, the malarial parasite, and the mosquito [MMM] - A three-sided relationship. <i>Molecular and Biochemical Parasitology</i> , 2023, 253, 111543.	0.5	4
1597	Structure-based development of potent Plasmodium falciparum M1 and M17 aminopeptidase selective and dual inhibitors via S1 ² -region optimisation. <i>European Journal of Medicinal Chemistry</i> , 2023, 248, 115051.	2.6	2
1598	Synthesis and Antiprotozoal Activity of Azabicyclo-Nonane Pyrimidine Hybrids. <i>Molecules</i> , 2023, 28, 307.	1.7	0
1599	In vitro and ex vivo antiplasmodial activity of Plasmodium spp. in the state of Rondônia, Brazil. <i>Brazilian Journal of Pharmaceutical Sciences</i> , 0, 58, .	1.2	0
1600	Biomarkers of the Toxic Effects of Chemotherapeutic Agents: A Focus on Antimalarials. <i>Biomarkers in Disease</i> , 2023, , 1035-1061.	0.0	0
1601	Short tandem repeat polymorphism in the promoter region of cyclophilin 19B drives its transcriptional upregulation and contributes to drug resistance in the malaria parasite Plasmodium falciparum. <i>PLoS Pathogens</i> , 2023, 19, e1011118.	2.1	2
1603	Water-, Sanitation-, and Hygiene-Related Diseases. , 2023, , 189-219.		1
1604	Mapping emerging trends and South-South cooperation in regional knowledge networks: A bibliometric analysis of avian influenza research in Southeast Asia. <i>Journal of International Development</i> , 0, , .	0.9	2
1605	A Water-Soluble Polymer-Lumefantrine Conjugate for the Intravenous Treatment of Severe Malaria. <i>Macromolecular Bioscience</i> , 2023, 23, .	2.1	1
1606	Integrating Pharmacokinetic-Pharmacodynamic Modeling and Physiologically Based Pharmacokinetic Modeling to Optimize Human Dose Predictions for Plasmodium falciparum Malaria: a Chloroquine Case Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2023, 67, .	1.4	1
1607	Insight into molecular diagnosis for antimalarial drug resistance of Plasmodium falciparum parasites: A review. <i>Acta Tropica</i> , 2023, 241, 106870.	0.9	1
1608	The effect of transfluthrin-treated jute and cotton emanator vests on human landing and fecundity of Anopheles minimus in Thailand. <i>Acta Tropica</i> , 2023, 242, 106904.	0.9	1
1609	Incorporation of Trifluoromethyltriazoline in the Side Chain of 4-Aminoquinolines: Synthesis and Evaluation as Antiplasmodial Agents. <i>ChemMedChem</i> , 2023, 18, .	1.6	0
1610	Screening for antifolate and artemisinin resistance in Plasmodium falciparum clinical isolates from three hospitals of Eritrea. <i>F1000Research</i> , 0, 10, 628.	0.8	0
1611	Molecular surveillance of Kelch-13 gene in Plasmodium falciparum field isolates from Mayurbhanj District, Odisha, India, and in silico artemisinin-Kelch-13 protein interaction study. <i>Parasitology Research</i> , 2023, 122, 717-727.	0.6	1
1612	Characterizing the Blood-Stage Antimalarial Activity of Tafenoquine in Healthy Volunteers Experimentally Infected With Plasmodium falciparum. <i>Clinical Infectious Diseases</i> , 2023, 76, 1919-1927.	2.9	4

#	ARTICLE	IF	CITATIONS
1614	Optimization of 2,3-Dihydroquinazolinone-3-carboxamides as Antimalarials Targeting PfATP4. <i>Journal of Medicinal Chemistry</i> , 2023, 66, 3540-3565.	2.9	4
1615	7- <i>N</i> -Substituted-3-oxadiazole Quinolones with Potent Antimalarial Activity Target the Cytochrome <i>bc₁</i> Complex. <i>ACS Infectious Diseases</i> , 2023, 9, 668-691.	1.8	4
1616	Chemical proteomic profiling with photoaffinity labeling strategy identifies antimalarial targets of artemisinin. <i>Chinese Chemical Letters</i> , 2023, 34, 108296.	4.8	2
1617	Ferrocene Derivatives as New Generation of Antimalarial Agents: Opportunity or Illusion?. <i>Current Topics in Medicinal Chemistry</i> , 2023, 23, .	1.0	0
1618	Antimalarial Drug Resistance: Trends, Mechanisms, and Strategies to Combat Antimalarial Resistance. , 2023, , 43-69.		2
1620	Antimalarial Endoperoxides: from Natural Sesquiterpene Drugs to a Rising Generation of Synthetic Congeners. , 2023, , 158-227.		0
1623	Examining the Early Distribution of the Artemisinin-Resistant <i>Plasmodium falciparum</i> kelch13 R561H Mutation in Areas of Higher Transmission in Rwanda. <i>Open Forum Infectious Diseases</i> , 2023, 10, .	0.4	9
1624	In vitro activity of rhinacanthin analogues against drug resistant <i>Plasmodium falciparum</i> isolates from Northeast Thailand. <i>Malaria Journal</i> , 2023, 22, .	0.8	0
1626	Structural basis of the substrate recognition and inhibition mechanism of <i>Plasmodium falciparum</i> nucleoside transporter PfENT1. <i>Nature Communications</i> , 2023, 14, .	5.8	3
1627	Safe drugs with high potential to block malaria transmission revealed by a spleen-mimetic screening. <i>Nature Communications</i> , 2023, 14, .	5.8	1
1628	Designing a multi-epitope chimeric protein from different potential targets: A potential vaccine candidate against <i>Plasmodium</i> . <i>Molecular and Biochemical Parasitology</i> , 2023, , 111560.	0.5	0
1646	Basic Nitrogen (BaN) Is a Key Property of Antimalarial Chemical Space. <i>Journal of Medicinal Chemistry</i> , 2023, 66, 8382-8406.	2.9	4
1671	Antimalarial drug discovery: progress and approaches. <i>Nature Reviews Drug Discovery</i> , 2023, 22, 807-826.	21.5	12
1679	The uncertain role of substandard and falsified medicines in the emergence and spread of antimicrobial resistance. <i>Nature Communications</i> , 2023, 14, .	5.8	1
1689	Artemisinin Resistance in <i>Plasmodium falciparum</i> Malaria. <i>Parasitology Research Monographs</i> , 2023, , 267-278.	0.4	0
1703	Protozoan diseases: Malaria clinical features, management, and prevention. , 2023, , .		0
1709	Malaria Treatment Landscape: Current Trends and Future Directions. <i>Infectious Diseases</i> , 0, , .	4.0	0
1732	The future of antiparasitic therapy. , 2024, , 391-405.		0

#	ARTICLE	IF	CITATIONS
1736	Emergence, transmission dynamics and mechanisms of artemisinin partial resistance in malaria parasites in Africa. Nature Reviews Microbiology, 0, , .	13.6	0